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The N-terminal BRCA1 C61G mutation is clinically important in the development of breast 
cancer but the aetiology of this pathogenic BRCA1 mutation is not clear. Brca1 C61G 
homozygote mice are embryonic lethal and tissue-specific Brca1 C61G leads to 
tumourigenesis.  
This thesis shows the removal of 53bp1 rescues the mouse embryonic lethality of Brca1 
C61G homozygote mutation. 53bp1-/-Brca1C61G/C61G mice have an increased rate of tumour 
development compared to 53bp1-null mice and show male-specific sterility. The Brca1 C61G 
mutation causes a reduced level of Brca1 protein suggesting this missense mutation causes 
protein-wide affects. This mutation causes defects in DSB and DNA crosslink repair foci and 
defects in the response of 53bp1-/-Brca1C61G/C61G cells to chemotherapy agents, particularly IR 
and Cisplatin. Brca1 C61G appears to cause deficient DSB repair despite displaying normal 
Rad51 foci levels, which is an indication of functional homologous recombination, and a 
previously undescribed increase in FANCD2 foci upon induction of DNA crosslinks. 53bp1-
null cells that are heterozygote for the Brca1 C61G mutation display phenotypes that are 
suggestive of haploinsufficiency caused by Brca1 C61G protein.  
Overall, the Brca1 C61G missense mutation can cause cells that affect DNA repair and 
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Chapter 1 – Introduction 
1.1 Introduction 
The Breast Cancer 1, early onset, (BRCA1) gene has been a topic of media attention due to 
high profile cases of celebrities with hereditary breast and ovarian cancer syndrome (such as 
Angelina Jolie). The treatments for breast cancer have developed vastly from DNA-damage-
directed chemotherapies to the use of hormone-directed therapies (non-DNA-damaging), 
but there are still tumours in which current therapies are not effective and DNA-damaging 
chemotherapy must be used. Tumours can become resistant to both of these types of 
therapy. A better understanding of BRCA1 using basic science could provide more clinical 
avenues for prevention and treatment of cancer by investigating the cellular pathways in 
which BRCA1 has a function which can be clinically manipulated. This research would help all 
tumours, not just BRCA1 mutation carrier tumours or breast and ovarian cancer, because 
unpicking tumour suppressing mechanisms can provide new targets for cancer therapy. 
Although there is still a great deal of research needed to understand why mutations in 
BRCA1 lead to such a high risk (almost inevitable) of developing breast cancer. 
1.2 Clinical BRCA1 
1.2.1 Hereditary breast and ovarian cancer syndrome and BRCA1 
The BRCA1 gene was mapped to chromosome 17q21 through linkage analysis of families 
with hereditary breast and ovarian cancer syndrome (Hall et al., 1990; Miki et al., 1994; 
Narod et al., 1997). The presence of a heterozygote BRCA1 or BRCA2 mutation in the general 
population is between 1 in 400-800 people (Claus et al., 1996; Ford et al., 1994; Whittemore 
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et al., 1997) but many communities such as Ashkenazi Jews and those of African ancestry 
have a higher frequency of BRCA1 mutations (Haffty et al., 2006; John et al., 2007; Liede and 
Narod, 2002; Olopade et al., 2003; Szabo and King, 1997). It is possible for mutations to 
occur along the entire BRCA1 gene but clinically important cancer mutations are most 
commonly in the RING (Really Interesting New Gene) domains or the BRCT (BRCA1 C-
Terminus) domains (Figure 1.1 taken from (Clark et al., 2012)).  
 
Figure 1.1 – Mutations rate across BRCA1 exons 
This figure was taken from Clark et al (Clark et al., 2012). It shows the BRCA1 mutation rate 
found in patients with breast and ovarian cancer, pinpointing the mutations to where they lie 
on the gene and which protein domains these cover.  
The BRCA1 C61G mutation is the most common missense (239 cases) mutation found in 
BRCA1 in all cases reported on the Breast Cancer Information Core (BIC) database and fifth 
most common clinically important mutation (Szabo et al., 2000). The majority of disease-
causing mutation are truncations. The BRCA1 C61G mutation accounts for 20% of Polish 
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families with breast and ovarian hereditary cancer syndrome in a study by Gorski et al 
(Gorski et al., 2000).  
There have been only two reported cases of humans born with a mutation in both BRCA1 
alleles (Domchek et al., 2013; Sawyer et al., 2015). One patient developed ovarian cancer at 
28 years old and had developmental abnormalities (Domchek et al., 2013). She had a 
truncating mutation (p.Asp821Ilefs*25) and a missense mutation (p.Val1736Ala) that 
affected the BRCT domain binding to BACH1 (Domchek et al., 2013). The second patient also 
had developmental anomalies that produce a Fanconi Anaemia-like syndrome and she 
developed breast cancer at 23 years old (Sawyer et al., 2015). She also has a truncating 
mutation (p.Ser198Argfs*35) and a missense mutation (p.Arg1699Trp) that affect the BRCT 
domains of BRCA1, but this single amino acid change is thought to affect the structure of 
BRCA1 (Sawyer et al., 2015). These biallelic mutations would allow for some BRCA1 protein 
to be made (although mutated) and this is likely to be partially functional as the 
developmental defects did not cause embryonic lethality, as seen in the majority of 
homozygote Brca1-mutated mice (Section 1.5.1). 
It has been thought that the loss of the wild-type allele in BRCA1 mutant carriers is the driver 
behind tumour development (Esteller et al., 2000; Neuhausen and Marshall, 1994; Smith et 
al., 1992), but this is disputed because some tumours maintain a wild-type BRCA1 allele 
(Clark et al., 2012; Smith et al., 1992; Wei et al., 2005). It is also known that BRCA1 is altered 
(mutated or altered expression) in many cases of sporadic cancer to give a clinically BRCA-
like phenotype to the cancer (Neuhausen and Marshall, 1994; Smith et al., 1992).  
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1.2.2 BRCA1 mutation carriers and cancer development 
The risk of getting breast cancer by the age of 70 in a carrier of a BRCA1 mutation is 
estimated to be approximately 40-90%, although this depends on the mutation that has 
been inherited (Antoniou et al., 2003; Easton et al., 1995; Hopper et al., 1999; Risch et al., 
2006). The risk of getting ovarian cancer was shown to be approximately 24-39% by the age 
of 70 (Risch et al., 2006). Male BRCA1 mutation carriers are at an increased risk of 1.2% of 
getting breast cancer by the age of 70 (Fentiman et al., 2006; Tai et al., 2007) compared to 
the 1 in 100,000 risk in the general male population of Europe (Sasco et al., 1993). Being a 
carrier of a BRCA1 mutation also increases a person’s risk to other cancers such as fallopian 
tube carcinoma (Medeiros et al., 2006), prostate cancer (Cybulski et al., 2008; Thompson et 
al., 2002), cervical cancer (Thompson et al., 2002), and pancreatic cancer (Lynch et al., 2005; 
Thompson et al., 2002).  
Breast and ovarian cancer in patients with a BRCA1 mutation occur at an earlier age and the 
increased risk is mostly seen in their 20-30’s (Burke et al., 1997) compared to cases of 
sporadic breast cancer. The breast cancers in BRCA1 mutation carriers tend to be triple-
negative (TN) in type and the ovarian cancers are frequently serous ovarian cancers (Foulkes 
et al., 2003; Lacroix and Leclercg, 2005; Lakhani et al., 2005; Rakha et al., 2008).  
The triple-negative phrase relates to these cancers being dysfunctional for three receptors; 
estrogen receptor (ER), progesterone receptor (PR) and HER-2/neu (Dent et al., 2007). TN 
breast cancers are associated with higher grades (typically III) of cancer, at an earlier age 
with signs of a more advanced cancer such as higher occurrence of metastasis and high 
proliferation rate of cells (Diaz et al., 2007; Irvin and Carey, 2008; Reis-Filho and Tutt, 2008; 
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Stockmans et al., 2008; Thike et al., 2010). TN cancer equates to 10-20% of the total number 
of breast cancer cases (Papa et al., 2015) and these cancers include both sporadic breast 
cancer and those in patients carrying a BRCA mutation. However the incidence of a BRCA 
mutation in TN cancers is reported to be from 16-42% which is higher than the rate of BRCA 
mutation in other types of breast cancer (Atchley et al., 2008; Gonzalez-Angulo et al., 2011). 
Although the percentage of inherited BRCA mutations is variable in TN breast cancers, a 
large number of TN breast cancer have dysfunctional BRCA1 protein which gives a BRCA-like 
phenotype, i.e. TN, in non-BRCA1 mutation carriers (Lakhani et al., 2005; Turner et al., 2004; 
Turner et al., 2007).  
1.2.3 BRCA1 carrier cancer patient outcomes 
Studies have looked at the outcomes of the patients with a BRCA1 mutation who develop 
breast cancer compared to women who develop breast cancer and do not have an inherited 
BRCA1 mutation, and they are inconclusive; the outcomes have been reported as better 
(Marcus et al., 1996; Porter et al., 1994), worse (Ansquer et al., 1998; Brekelmans et al., 
2006; Foulkes et al., 1997; Stoppa-Lyonnet et al., 2000), or the same prognosis as non-BRCA 
carriers patients (Gaffney et al., 1998; Johannsson et al., 1998; Lee et al., 1999; Rennert et 
al., 2007; Verhoog et al., 1998; Verhoog et al., 1999). The outcomes for TN breast cancer is 
clearer in the literature than BRCA breast cancers. TN breast cancers are associated with a 
higher rate of cancer recurrence (Metcalfe et al., 2004) leading to a reduced survival rate 
within 5 years (Patil et al., 2011), especially if the cancer has metastasised (Mersin et al., 
2008; Rodriguez-Pinilla et al., 2006).  
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TN breast cancer phenotype refers to the three receptors that are the target of hormone-
targeted therapies (Tamoxifen, Herceptin and Onapristone) in breast cancer treatment and 
TN cancers are less responsive to these therapies than those who are positive for these 
receptors (Kassam et al., 2009; Liedtke et al., 2008; Rouzier et al., 2005). These hormone-
targeted therapies have less side effects than the traditional DNA-damaging chemotherapy 
or radiation but these more aggressive chemotherapy options are used when tumours are 
unresponsive or resistant to the hormone-targeted therapies, as in TN breast cancer. A 
BRCA1 mutation or an ill-functioning BRCA1 does sensitize cells to DNA-damaging agents, 
especially Platinum-based agents (Cass et al., 2003; Lafarge et al., 2001; Quinn et al., 2003; 
Tassone et al., 2003; Tassone et al., 2009) and PARP inhibitors (PARPi)(Farmer et al., 2005; 
Fong et al., 2009; Turner et al., 2008), due to BRCA1’s role in DNA double-strand break (DSB) 
repair (further discussion in 5.1). However, BRCA1-driven tumours can develop resistance to 
these DNA-damaging agents and this may explain the variation seen in prognosis in BRCA1-
related breast cancers.  
Of all ovarian cancer cases in America in a 2005 study, 9.4% of women had a known BRCA1 
mutation (8.2% have a BRCA mutation of unknown significance) (Pal et al., 2005). The 
majority of BRCA1-related ovarian cancer cases were serous ovarian tumours (90%) which is 
higher than non-mutation carriers (50%) (Aida et al., 1998; Berchuck et al., 1998; Lu et al., 
1999; Pal et al., 2005; Rubin et al., 1996). BRCA1 mutation carriers have an onset age for 
ovarian cancer that is 8 years earlier than for patients with no underlying BRCA1 mutation 
(Boyd et al., 2000). However, the survival outcomes for ovarian cancer patients with or 
without a BRCA1 mutation has been described as the same (Brunet et al., 1997; Buller et al., 
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2002; Johannsson et al., 1998; Zweemer et al., 2001) or improved (Aida et al., 1998; Cass et 
al., 2003; Chetrit et al., 2008; Tan et al., 2008) despite the earlier onset of ovarian cancer. 
1.2.4 BRCA1 mutation carrier: clinical intervention 
A BRCA1 mutation carrier has many options of how to manage their risk of developing 
cancer. There are surveillance programmes for women that are effective at identifying 
breast cancer by MRI (Magnetic Resonance Imaging) scan (Kriege et al., 2004; Kuhl et al., 
2005; Leach et al., 2005; Lehman et al., 2005; Warner et al., 2004; Warner and Causer, 2005) 
or mammography (although less effective (Saslow et al., 2007)), identifying ovarian cancer 
women by transvaginal ultrasounds and CA-125 serum screening (Clarke-Pearson, 2009) and 
identifying prostate cancer in men with a BRCA1 mutation by frequent prostate screening 
from the age of 40 (Burke et al., 1997; Mettlin et al., 1993). However, surveillance does not 
prevent cancer; it identifies it earlier. 
Oral contraceptives have a protective role against ovarian cancer in BRCA1 mutation 
patients of up to 33% risk reduction after 5 years of treatment (Narod et al., 1998; 
Whittemore et al., 2004). Breast feeding for over a year has shown a reduction in the risk of 
breast and ovarian cancer in BRCA1 mutation carriers (Jernstrom et al., 2004), although this 
is disputed (Andrieu et al., 2006; Antoniou et al., 2009). Tamoxifen has also been used as a 
preventative agent to reduce the occurrence of cancers in BRCA1 patients (Fisher et al., 
1998; King et al., 2001; Metcalfe et al., 2005; Narod et al., 2000), although the majority of 
breast tumours in BRCA1 mutation carriers develop ER-negative tumours and it was most 
effective at preventing ER-negative tumours (Gail et al., 1999).  
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The most effective way of preventing the development of cancer in BRCA1 mutation carriers 
is by surgically removing the mostly likely tissue to develop cancer; the ovaries and the 
breast tissue. Bilateral prophylactic mastectomies have shown to be highly effective 
reducing the rate of breast cancer in BRCA1/2 mutation carriers from 48.7% down to 1.9% or 
up to 90% reduction in similar studies, bringing their risk to the approximately the same as a 
non-carrier (Hartmann et al., 2001; Hartmann et al., 1999; Olopade and Artioli, 2004; 
Rebbeck et al., 2004). Whilst oophorectomies reduce the risk of ovarian cancer by 
approximately 80-96% (Kauff et al., 2002; Rebbeck et al., 2004; Rutter et al., 2003), they 
have also been shown to reduce the breast cancer incidence to 53% (Olopade and Artioli, 
2004; Rebbeck et al., 2004). Surgical options have enormous benefit but do come at the cost 
of cosmetic appearance, an early menopause and can significantly affect mental health.  
BRCA1 variants that are found in patients are always not known to be clinically significant 
and this makes it difficult to give BRCA1 variant carrier an accurate prediction of cancer risk. 
This makes the decision for the patient of what or if any preventative measures should be 
taken to reduce this risk.  
The BIC database does accumulate the known mutations and variants found in BRCA1 and 
BRCA2 in the attempt to provide more information about each mutation (Szabo et al., 2000). 
There are studies that attempt to look at specific mutations in BRCA1 or specific regions of 
BRCA1 to also provide evidence of how a variant may affect the BRCA1 protein’s tumour 
suppressor activity (Section 1.3.1) (Loke et al., 2015; Starita et al., 2015). Despite this, many 
functions of BRCA1 and whether variants in BRCA1 affect these functions still remain elusive.  
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The prognosis of TN BRCA1-related tumours remains poor and the hormone-based therapies 
are ineffective, leaving DNA-damaging chemotherapy as the best treatment of these 
tumours. Whilst poly (ADP)-ribose polymerase (PARP) inhibitors (PARPi) and platinum-based 
agents are proving effective in many cases, the level of resistance and recurrence is high and 
more therapy options are needed (Section 5.1).  
1.3 BRCA1 gene and protein 
1.3.1 Protein domains 
BRCA1 is a gene that translates into an 1863 amino acid protein. The main regions of BRCA1 
are the N-terminal RING domain, the nuclear localisation/export sequences (NLS/NES), 
coiled-coil domain, a SQ cluster domain and two tandem BRCT domains at the C-terminal 
(Figure 1.2). BRCA1 is a tumour suppressor and has multiple roles in maintaining genome 
integrity. The part of BRCA1 that is responsible for each role has been investigated through 
its interacting proteins, but many proteins interact with several of BRCA1’s domains. 
The N-terminal RING domain of BRCA1 is the only part of BRCA1 that possesses a catalytic 
activity. It is an E3 ubiquitin ligase that predominantly assembles lysine 6-linked (K6) 
polyubiquitin chains which is an unconventional linkage associated with efficient DNA repair 
(Morris and Solomon, 2004; Wu-Baer et al., 2003). The most crucial protein that the RING 
domain interacts with is BARD1 (BRCA1 Associated RING domain 1) (Joukov et al., 2001; Wu 
et al., 1996) because it is needed for the stability and catalytic function of the BRCA1 RING 




Figure 1.2 – BRCA1 domains and protein interactions 
This diagram is a representation of the protein domain locations in BRCA1 and the some of the proteins that are reported to interact with 
these regions. The RING domain structure is from Brzovic et al (Brzovic et al., 2001b) derived through NMR and the BRCT domains 
structure comes from a crystal structure in Williams et al (Williams et al., 2001).  
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The RING domains of BRCA1 and BARD1 bind to create heterodimer (Joukov et al., 2001; Wu 
et al., 1996), of which there is a NMR (Nuclear magnetic resonance) structure (Brzovic et al., 
2001b) (Figure 1.2).  
A definitive list of BRCA1 substrates that influence genome stability is still not complete but 
multiple targets that have been reported for ubiquitination by the BRCA1:BARD1 
heterodimer, and they include H2AX (Yu et al., 2003), Cyclin B/Cdc25C (Shabbeer et al., 
2013), CtIP (Yu et al., 2006), SAFB2 (Song et al., 2011), progesterone receptor (Calvo and 
Beato, 2011) and RNA polymerase subunits (Starita et al., 2005; Wu et al., 2007).  
BRCA1 has nuclear localisation sequences that are located at amino acid 501-508 (NLS1) and 
606-615 (NLS2) (Chen et al., 1995; Fabbro et al., 2002; Thakur et al., 1997; Wilson et al., 
1997), although deletion of NLS2 doesn’t appear to affect BRCA1 localisation (Thakur et al., 
1997). BRCA1’s nuclear export sequences are recognised by the CRM1-nuclear exporter 
(Fabbro et al., 2002) and are located within the RING domain of BRCA1 (Fabbro et al., 2002; 
Rodriguez and Henderson, 2000; Rodriguez et al., 2003a; Rodriguez et al., 2004). 
Interruption of nuclear localisation sequences could affect BRCA1 localisation in the nucleus 
where most of its actions are located and therefore these localisation sequences may be 
important for regulation of BRCA1 roles.  
The SWI/SNF complex is a chromatin remodelling complex that interacts with BRCA1 in the 
region spanning amino acids 260-553 (Figure 1.2) (Bochar et al., 2000). A subunit of this 
complex, BRD7, does directly bind BRCA1 and has the potential to influence BRCA1 as a 
transcriptional regulator (Harte et al., 2010).  
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Members of the MRN (Mre11/Rad50/Nbs1) complex, a DSB repair complex, bind around 
341-748 amino acids into BRCA1 (Figure 1.2) (Wang et al., 2000) although this interaction 
relies on the BRCA1 BRCT domains binding CtIP (Yu et al., 1998; Yuan and Chen, 2010; Zhong 
et al., 1999).   
The SQ cluster region (phosphorylation region) is a patch that includes the coiled-coil 
domain of BRCA1 that is phosphorylated upon DNA damage to activate BRCA1 (Figure 1.2). 
One such phosphorylation of BRCA1 is by Chk2 on the serine at amino acid 988 (Lee et al., 
2000), but other proteins have the ability to phosphorylate BRCA1 such as ATR (Yoo et al., 
2007).  
The BRCA1-B complex binds through BRCA1 coiled-coil domains directly to PALB2 (Figure 
1.2) (Sy et al., 2009; Zhang et al., 2009b), and this links BRCA1 and BRCA2 (Sy et al., 2009; Xia 
et al., 2006; Zhang et al., 2009a; Zhang et al., 2009b). It is thought that Rad51 may directly 
bind to BRCA1 at amino acid 758-1064, but this interaction could be indirect through the 
MRN complex (Garcia-Higuera et al., 2001).  
The BRCT domains at the C-terminus of BRCA1 (aa1650-1863) (Figure 1.2) were identified by 
Koonin (Koonin et al., 1996) and the crystal structure has been solved (Williams et al., 2001) 
(Figure 1.2). Mutation in the BRCT domains, whether truncating or missense mutations, have 
been reported to destabilise the BRCA1 protein due to structural changes (Lee et al., 2010; 
Williams and Glover, 2003; Williams et al., 2003). The BRCT domains bind the sequence 
pSXXF (Manke et al., 2003; Rodriguez et al., 2003b; Yu et al., 2003) on ATM/ATR 
phosphorylated proteins such as BACH1/FANCJ/BRIP1 (Yu et al., 2003), CtIP (Buis et al., 
2012; Yu et al., 2003; Yu and Chen, 2004; Yun and Hiom, 2009), and CCDC98/Abraxas (Kim et 
13 
 
al., 2007a; Wang et al., 2007). These proteins, when bound to BRCA1, are important for DNA 
repair. These complexes have the ability to recruit other DNA repair proteins and therefore 
whether it is a direct or indirect interaction to bind BRCA1 is unclear, for example TopBP1 
which is associated with BACH1 but also thought to have a direct BRCA1 interaction 
(Greenberg et al., 2006; Karppinen et al., 2006). The BRCT domains are also known to bind 
proteins that are not phosphorylated and to bind DNA (Yamane et al., 2000). 
BRCA1 has a role in chromatin remodelling through its interaction with BACH1 through the 
BRCT domains (Cantor and Andreassen, 2006) (Figure 1.2). Remodelling DNA is important to 
allow repair proteins to access the damaged DNA (Cantor and Andreassen, 2006). BACH1 
also has a role in resolving DNA restructures during replication (Cantor et al., 2004; London 
et al., 2008; Wu et al., 2008) and BACH1-BRCA1 interaction aids the BRCA1-B complex in 
activating the S phase checkpoint (Cantor et al., 2001; Greenberg et al., 2006; Litman et al., 
2005).  
The BRCT domain also binds to phosphorylate cell cycle checkpoint proteins, such as Chk1 
(Joughin et al., 2005). This interaction is needed to active the G2/M checkpoint (Yarden et 
al., 2002) to ensure DNA is repaired before mitosis.  
The BRCA1-A complex involves Abraxas directly binding to the BRCT domains of BRCA1 
(Figure 1.2) to recruit RAP80 (Wang et al., 2007) which also binds the BRCT domains 
(Sobhian et al., 2007). BRCC36 is also important for the localisation of the BRCA1-A complex 
to sites of DSBs (Chen et al., 2006). MERIT40 is needed for the stability of the BRCA1-A 
complex because it stabilises Abraxas (Shao et al., 2009a), the scaffold of the BRCA1-A 
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complex (Liu et al., 2007b), and this reduced the localisation of the whole complex to sites of 
DNA damage (Feng et al., 2009; Shao et al., 2009a).  
CtIP binds to BRCA1’s BRCT domains but may also interact with the RING domain as it is 
reported to be ubiquitinated by BRCA1:BARD1 heterodimer (Figure 1.2) (Yu and Chen, 2004; 
Yu et al., 2006). The BRCA1-CtIP interaction is considered to be required to promote efficient 
DNA end resection in homologous recombination (HR) (Buis et al., 2012; Chen et al., 2008; 
Sartori et al., 2007; Wong et al., 1998; Yu et al., 1998; Yun and Hiom, 2009; Zhong et al., 
1999), but there are papers that suggest that CtIP enhances DNA end resection-
independently of BRCA1 (Nakamura et al., 2010; Polato et al., 2014; Reczek et al., 2013). 
UHRF1, an E3 ubiquitin ligase, was recently reported to interact with the BRCT domains of 
BRCA1 when phosphorylated (Zhang et al., 2016). This interaction and the ubiquitin ligase 
function of UHRF1 was reported to orchestrate the pathway choice between DSBs being 
repaired through homologous recombination (HR) or non-homologous end-joining (NHEJ) 
(Zhang et al., 2016).  
The BRCA1 BRCT domain interaction to UBXN1 may be involved in the inhibition of the 
ubiquitin ligase activity of the BRCA1:BARD1 heterodimer (Wu-Baer et al., 2010).  
These interactions described here are not all of the reported or putative interactions that are 
in the literature and it is clear from the multiple BRCA1 complexes through to the multiple 
E3 ubiquitin ligase substrates, that BRCA1 is involved in a great many important cellular 
functions that require its multiple domains. It is also important to note that a mutation in 
BRCA1 could lead to a change that affects multiple domains or whole protein stability which 
could affect all of its functions. 
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1.3.2 Evolution of BRCA1, BARD1 and the BRCA1:BARD1 heterodimer 
The evolutionary past of BRCA1 and BARD1 can help us estimate the degree of conservation 
of the protein and its domains as an indicator of these proteins necessity in cellular 
functions. The conservation of the BRCA1:BARD1 heterodimer between mammals can help 
to understand the differences in phenotype we may see between humans and mice with the 
same genetic alteration. However, it does not convey the larger degree of conservation that 
may help us understand why the RING domain in BRCA1 is essential for cellular function 
through evolution.  
The most distantly divergent genus with a BRCA1 gene orthologue (BRC-1) is C.elegans 
(nematode) (Boulton et al., 2004). It was identified using the yeast-two-hybrid system 
through BARD1 orthologue (BRD-1), because the Genefinder used by Boulton et al failed to 
predict certain exons of BRCA1 (Boulton et al., 2004). This is likely due to these exons lacking 
similarity to the equivalent human BRCA1 exons. BRC-1 has more similarity to the BRCA1 
isoform that lacks exon 11 than the full-length human BRCA1, although it does contain a 
RING domain, two BRCT domains and a nuclear localisation domain (Boulton et al., 2004).  
The ENSEMBL orthologue tree for BRCA1 (Appendices figure I) does not identify BRCA1 in 
species older than Ciona genus (sea squirts) (C. intestinalis and C. savignyi) (Cunningham et 
al., 2015), which diverges after C.elegans, and this could be due to a similar reason as stated 
in Boulton et al (Boulton et al., 2004) (lack of conservation in multiple exons). Ciona have 
two orthologues of BRCA1 and yet nematodes and ancient fish (coelacanth) have one 
orthologue suggesting BRCA1 has either become a single gene or diverged into two genes 




Figure 1.3 – N-terminal RING domain alignment of human BRCA1 with the RING domain 
containing BRCA1 orthologues. 
Using CLUSTALW2 multiple sequence alignment tool and ENSEMBL, the protein sequences of 
the RING domain-containing BRCA1 orthologues from species with two orthologues of BRCA1 
(O. anatinus_30158 =platypus, C. savignyi_10887 and C. intestinalis_20173 =sea worms 
identified from Appendices figure I) were aligned with human BRCA1 RING domain and its 
oldest common ancestor (Coelacanth= ancient fish). 
Site I and Site II show the residues that contact the zinc ions that maintain the RING domain 
structure. The conservation of each residue and its properties is shown by the characters 
underneath the alignment. The characters depict the consensus between the residues in the 
alignment. The asterisk ‘*’ indicates a fully conserved or identical residue, the colon ‘:’ 
indicates residues with highly similar properties, the period ‘.’ indicates residues with weakly 





On closer inspection of the protein sequences in species with two BRCA1 orthologues, it 
appears that one orthologue has lost one or both of the BRCT domains and kept the N-
terminal RING domain, and the other orthologue does not have a RING domain and has an 
intact BRCT domain (Appendices figure I) (Schreiber et al., 2014) (refer to figure of BRCA1 
domains; Figure 1.2). The presence of a RING domain containing BRCA1 orthologue separate 
from the BRCT domain orthologue may suggest that the RING domain and BRCT domains 
may have roles that are independent of each other.  
When the RING domain-containing BRCA1 orthologues from C. intestinalis, C. savignyi and O. 
anatinus (platypus) are aligned with humans and coelacanth, it is evident that the RING 
domain is highly conserved as a whole and the important residues needed for holding the 
two structurally important zinc ions are conserved (Figure 1.3) (McWilliam et al., 2013). 
These highly conserved residues were also conserved in human BRCA1 to the C.elegans 
orthologue (Boulton et al., 2004).  
As BARD1 and BRCA1 form a heterodimer which is important for heterodimer stability, it is 
essential to assess whether BARD1 has evolved alongside BRCA1 because this would support 
a conserved protein interaction. However, unlike BRCA1, the ENSEMBL orthologue tree 
identifies BARD1’s oldest orthologue in yeast (Appendices figure II) (Cunningham et al., 
2015). On closer inspection, the oldest BARD1 orthologues have homology of their ankyrin 
domain and not the RING domain. The presence of the ankyrin domain may make the 
evolutionary age of BARD1 more speculative because it one of the most common domains in 
nature (Schreiber et al., 2014). BARD1 in C.elegans contains three Ankyrin domains, a BRCT 
domain and a RING domain, which is important for binding to BRCA1, and the RING domain 
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shows sequence similarity and conservation of functionally and structurally important 
residues (Boulton et al., 2004).  
Boulton et al show that C.elegans BRC-1 and BRD-1 form a heterodimer suggesting that the 
relationship between the BRCA1:BARD1 heterodimer is highly conserved (Boulton et al., 
2004). The BRC-1/BRD-1 complex was also shown to have the ability to ubiquitinate 
chromatin after irradiation using the UbcH5 orthologue (Polanowska et al., 2006). Disruption 
of BRC-1 or BRD-1 cause IR-sensitivity and chromosome abnormalities that are similar to the 
phenotype seen in human BRCA1 and BARD1 mutations (Boulton et al., 2004). This suggests 
that heterodimer function and E3 ubiquitin ligase activity function is highly conserved 
(Boulton et al., 2004; Polanowska et al., 2006). 
1.3.3 RING domain function in BRCA1 roles (C61G debate) 
Many papers have tried to allocate BRCA1 roles to the RING domain to better understand 
why mutations in the RING domain are associated with increased tumour risk in humans. As 
discussed previously (Section 1.3.1), BRCA1 is functionally active as an E3 ubiquitin ligase 
when it is in heterodimer formation with BARD1 (Figure 1.4) (Chen et al., 2002; Hashizume 
et al., 2001). Mutations in this area can affect one or several of the following: the structure 
of the RING domain, the binding of BRCA1 and BARD1 and the binding of BRCA1 to other 
proteins (Brzovic et al., 2003; Chen et al., 2002; Hashizume et al., 2001; Joukov et al., 2001). 
The C61G mutation is thought to influence all of these BRCA1 properties which dramatically 
reduces the ubiquitin ligase activity (Figure 1.4 Black side chain) (Brzovic et al., 2001a; 
Brzovic et al., 2003; Hashizume et al., 2001; Joukov et al., 2001; Mallery et al., 2002; Morris 




Figure 1.4 – Structure of BRCA1:BARD1 heterodimer and E2 binding 
This figure shows the structure of the BRCA1:BARD1 heterodimer (red:pink) with the 
mutations C61G and I26A. It also shows the predictive interaction of the E2, UbcH5a (purple), 
with the heterodimer. Zinc ions are in grey.  
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There is evidence that the C61G mutation in BRCA1 can affect the stability of the BRCA1 
C61G protein, whether through destabilisation of the RING domain or reduced binding to 
BARD1, targeting BRCA1 for degradation assessed using both biochemical and cellular 
techniques (Brzovic et al., 1998; Brzovic et al., 2001b; Choudhury et al., 2004; Wang et al., 
2014b). Other papers, using similar cell-based methods, suggest that the BRCA1 C61G 
protein is stable and at equivalent levels to wild-type BRCA1 (Campbell et al., 2001; Lu et al., 
2007; Nelson and Holt, 2010).  
The I26A mutation is reported to only affect the E2 conjugating enzyme (Figure 1.4 Purple 
structure) (UbcH5a (Dodd et al., 2004)) binding interface and this disrupts ubiquitin ligase 
activity (Figure 1.4 Blue side chain) (Brzovic et al., 2003), although it may not abolished 
(Metzger et al., 2014). These mutations have been used to isolate the roles of the BRCA1 N-
terminal RING domain and the need of functional BRCA1 E3 ubiquitin ligase activity. 
Human and mouse cell line models have shown that the BRCA1 C61G mutation causes cell 
lethality (Chang et al., 2009; Drost et al., 2011), spontaneous DNA damage (Nelson and Holt, 
2010), reduced HR repair (Li and Yu, 2013; Nelson and Holt, 2010; Ransburgh et al., 2010), 
centrosome amplification (Parvin and Sankaran, 2006; Sankaran et al., 2006) and sensitivity 
to ionising radiation (IR) (Li and Yu, 2013; Ruffner et al., 2001; Shabbeer et al., 2013). The 
Brca1 C61G mouse model made by Drost et al, was embryonic lethal when homozygote, and 
when Brca1 C61G was conditionally expressed alongside a Brca1-null allele and two p53-null 
alleles in mammary epithelial cells, tumours developed at an elevated rate (Drost et al., 
2011). These results suggest that the C61G mutation is important for genomic stability and 
tumour suppression. However, it is unclear if these phenotypes are due to a defect in the E3 
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ubiquitin ligase activity function of BRCA1 as the C61G mutation also causes instability in the 
BRCA1 RING domain.  
To address whether the BRCA1 E3 ubiquitin ligase activity is required for tumour suppression 
and genome stability, the mutation I26A is used because it is less disruptive to the RING 
domain structure than C61G. Cells with BRCA1 I26A (or equivalent for species) have 
spontaneous γH2AX foci (Zhu et al., 2011) and are sensitive to DNA-damaging agents, such 
as Camptothecin (CPT; DNA topoisomerase I inhibitor) (Sato et al., 2012), Neocarzinostatin 
(NCS; radiomimetic drug) (Shabbeer et al., 2013) and Mitomycin C (MMC; DNA crosslinking 
agent) (Tian et al., 2013). Although Sato et al, used DT40 chicken cells with V26A (equivalent 
to I26A) and they were not sensitive to MMC (Sato et al., 2012).  
Reid et al created isogenic I26A stem cells that do not appear to produce have a defect in 
spontaneous DNA repair (no chromosome abnormalities) or reduction in HR levels compared 
to wild-type cells (Reid et al., 2008). Unlike C61G mice (Drost et al., 2011), homozygote 
Brca1 I26A mice are not embryonic lethal and do not develop tumours (Shakya et al., 2011). 
These contradictory phenotypes between Brca1 C61G and I26A N-terminal mutations, leaves 
the role of BRCA1’s E3 ubiquitin ligase activity in genomic instability and tumour suppression 
as ambiguous.  
Further research is needed to separate the functional role of the N-terminal RING domain of 
BRCA1 and BRCA1’s E3 ubiquitin ligase activity and to understand why mutations in this 
region correlate with an increased cancer risk. 
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1.4 BRCA1 functions 
BRCA1 has a multitude of functions across many cellular functions and many of them could 
share the tumour suppressing role of BRCA1 (Figure 1.5). The results of this thesis primarily 
investigate BRCA1’s role in DNA repair.  
1.4.1 DNA repair 
BRCA1 has roles in the repair of multiple type of DNA damage which can be caused by 
natural cellular processes (such as replication or respiration), outside radiation or 
therapeutic drugs. Table 1.1 shows several types of DNA lesion, their repair pathway and 
examples of radiation or therapies that produce these types of DNA lesions.  
1.4.1.1 DNA double-strand break repair 
DSBs are one of the most severe types of DNA damage as they can lead to rearranged 
chromosomes, large scale deletions and insertions and, if the cells continue though the cell 
cycle with DSBs, they leads to apoptosis. There are tightly regulated pathways that control 
the sensing of a DSB, the choice of repair pathways and the repair of the break. These 
pathways are all involved in the cell cycle checkpoint response as continuing the cell cycle, 
i.e. into mitosis and division, with DSBs leads to daughter cells inheriting mutations.  
The first responders to a DSB are the Ku70/80 heterodimer complex (Soutoglou et al., 2007) 
and the MRN complex (Lavin, 2007). The Ku70/80 complex binds directly to the end of the 
DNA break point and protects the ends from being resected by nucleases (Soutoglou et al., 
2007). The MRN complex is made up of Mre11, Rad50 and Nbs1 (Lavin, 2007). Part of its 
function is to activate ATM (Berkovich et al., 2007) which phosphorylates H2AX histones 





Figure 1.5 – Functions of BRCA1 




Table 1.1 – Table of DNA damage, repair and inducing agents 








Other NHEJ variations 
Ionising radiation (IR) 
[predominantly DSB but also 
other DNA damage], 





Mismatch repair (MMR), 
Nucleotide excision repair 
(NER) 
Poly (ADP-ribose) polymerase 
inhibitors (PARPi) - 
Olaparib/4AN/Veliparib, 
Ultraviolet light (UV), 
Topoisomerase I inihbitors - 
Camptothecin 
(CPT)/Topotecan 
DNA crosslinking repair 
(FANC pathway) 
ICL repair (uses HR) Mitomycin C (MMC), Nitrogen 
Mustard,  
Platinum agents - Cisplatin 
Replication stress 
Replication restart,  
Dissolution of DNA 
structures, 
DSB repair (after long 
period of replication stress) 
Hydroxyurea (HU),  
Gemcitabine (Gemca), 
Fluorouracil (5-FU) 
γH2AX acts as a beacon for further DSB repair proteins to accumulate. The first of these is 
MDC1 (Fau et al., 2003), which interacts with Nbs1, of the MRN complex (Lukas et al., 2004). 
MDC1 accumulation leads to the recruitment of RNF8 (Huen et al., 2007) which is an E3 
ubiquitin ligase that can monoubiquitinate histones (Mailand et al., 2007). The signal from 
the monoubiquitination of histones is amplified by the creation of polyubiquitin chains 
(Bekker-Jensen et al., 2010). Histone H1 is monoubiquitinated by RNF8/Ubc13 complex 
(Hodge et al., 2016), and RNF168 or RNF8 can extend Histone H1 modifications into Lysine 
63 (K63)-linked polyubiquitin chains (Hodge et al., 2016) that are needed for recruitment of 
BRCA1 (Bekker-Jensen et al., 2010; Hodge et al., 2016; Thorslund et al., 2015) and the 
Abraxas complex (Wang et al., 2007). RNF168 monoubiquitinates histone H2A on lysine 15 
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with K63-linked polyubiquitin chains, which recruits 53BP1 (Doil et al., 2009; Fradet-Turcotte 
et al., 2013; Gatti et al., 2012; Mattiroli et al., 2012; Stewart et al., 2009). Although it was 
previous shown that histones modified with K48 polyubiquitin chains may be required for 
recruitment of 53BP1 (Huen et al., 2007) and a recent paper suggested 53BP1 was recruited 
due to chromatin modification, but this could be independent of RNF8 and RNF168 
(Kocylowski et al., 2015). L3MBTL1 binds to dimethyl-histone H4 Lysine 20 (H4K20me2) with 
a similar interaction site as 53BP1 (Min et al., 2007). In contrasting papers, the recruitment 
of 53BP1 has been reported to promote both NHEJ (Noon et al., 2010) and HR (Kakarougkas 
et al., 2013a), through promoting Kap1 phosphorylation of Serine 824 (pS824). RNF4 was 
recently described to be the controlling factor that degrades and localises phosphorylated 
Kap1 in a cell cycle-dependent manner and that pS824-Kap1 and 53BP1 colocalise after IR 
(Kuo et al., 2016). This paper suggests that pS824-Kap1 presence is a promoter of NHEJ and 
the accumulation of RNF4 in S/G2 phase relieves this NHEJ promotion through the 
degradation of Kap1 (Kuo et al., 2016). 
Chromatin rearrangement is needed for both DSB repair pathways but 53BP1 binding to 
H4K20me2 (Botuyan et al., 2006) leads to the restriction of HR nucleases to access to the 
DSB (Xie et al., 2007). The ubiquitination of 53BP1 by Rad6-Rad18, allows 53BP1 to stably 
bind and be retained at chromatin, and this is specific to G1 phase of the cell cycle 
(Watanabe et al., 2009). SUMOylation of BRCA1 and 53BP1 are needed for their retention on 
chromatin (Galanty et al., 2009), and for BRCA1 E3 ubiquitin ligase activity (Morris et al., 
2009).  
Ku70/Ku80 heterodimer binds almost immediately to DSB DNA ends and forms the DNA-PK 
complex with DNA-PKcs (Gottlieb and Jackson, 1993). DNA-PKcs is a kinase that is activated 
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by the binding to DNA of Ku70/Ku80 and autophosphorylation (Hammarsten and Chu, 1998). 
It phosphorylates surrounding histones such as H2AX along with ATM and ATR (Kysela et al., 
2005).  
1.4.1.1.1 Homologous recombination 
In S phase the DNA-PK complex is removed by VCP (Jiang et al., 2013b) as are K48 
polyubiquitin chains on the histone (Meerang et al., 2011), and the DNA ends are ready for 
resection. K63 polyubiquitin chains, made by RNF168 and Ubc13 (Doil et al., 2009; Plans et 
al., 2006; Stewart et al., 2009; VanDemark et al., 2001), recruit the BRCA1-A complex (Wang 
and Elledge, 2007). Abraxas is the platform that holds the BRCA1-A complex together (Wang 
and Elledge, 2007), which is made up of Cdc98 (Liu et al., 2007b), BRE, MERIT40 (Wang and 
Elledge, 2007) and BRCC63 (Dong et al., 2003), a deubiuqinating enzyme (DUB). BRCC63 
removed K63 polyubiquitin chains once the BRCA1-A complex is recruited allowing K6 
polyubiquitin chains to be formed by BRCA1 (Shao et al., 2009b). The function of these K6-
linked polyubiquitin chains is not clear.  
End resection nucleases Mre11 (Taylor et al., 2010), from the MRN complex, and CtIP, in the 
BRCA1-C complex, resect DNA (Buis et al., 2012). CtIP is responsible for the majority of the 
resection and this activity is dependent on CtIP being phosphorylated by ATM (Yu and Chen, 
2004). During end resection, the DNA is unwound by BLM helicase to elongate the 3’ ssDNA 
(single-stranded DNA) end (Nimonkar et al., 2008). Phosphorylated RPA coats ssDNA to 
protect it from nucleases (Erdile et al., 1991), until it is replaced by Rad51 (Wang and Haber, 
2004). The 9-1-1 clamp complex is phosphorylated in response to DNA damage signals and, 
alongside Rad17, is loaded onto RPA-coated ssDNA to sense DNA damage and start the 
recruitment of DNA damage proteins (Zou et al., 2002; Zou et al., 2003). TopBP1 is also 
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recruited (Kim et al., 2005) to ensure correct DNA repair. Rad51 is recruited by RNF8’s K48 
polyubiquitin chains (Ramadan, 2012) and is loaded onto ssDNA with the aid of BRCA2 (Dong 
et al., 2003) and DSS1 (Gudmundsdottir et al., 2004). BRCA1-B complex is made up of BRCA1, 
BRCA2 and PALB2. The BRCA1 and BRCA2 interaction is through BRCA1 coiled-coil domain 
binding to PALB2, and this recruits DSS1 (Zhang et al., 2009b). C-Abl phosphorylates Rad51 
and this allows loading into the DNA (Yuan et al., 1998). Once bound to ssDNA, Rad51 forms 
filaments between the broken DNA strand and the sister chromatid template (Sung and 
Robberson, 1995; Yu et al., 2001) to allow the repair to be synthesised by a DNA polymerase 
such as Polζ-REV1 (Sharma et al., 2012). Once the DNA strand has been replicated and Rad51 
filaments are displaced from the DNA, the template and new strand re-anneal and this can 
form a Holliday Junction (HJ) (Jones Petermann , 2012). HJ’s are cut using Mus81/Mms4, 
which resolves the DNA strand structure and this can lead to sister chromatid crossover 
depending on the strand cut by Mus80/Mms4 (Boddy et al., 2001; Hanada et al., 2007). The 
cuts in the DNA backbones are ligated together by Lig1 or Lig3 (Liang et al., 2008).  
1.4.1.1.2 Non-Homologous End-Joining 
If 53bp1/DNA-PKcs/Ku complex is not removed from the DSB, DNA-PKcs is 
autophosphorylated (Hammarsten and Chu, 1998) and NHEJ repair is activated. DNA-PKcs 
also phosphorylates Artemis and RPA (Drouet et al., 2006). The conformational changes that 
occur in DNA-PKcs allow NHEJ proteins to access the DSB, such Artemis (Drouet et al., 2006), 
PNKP (Weinfeld et al., 2011), Tdt and pol λ and pol μ (Ramsden, 2011). Artemis is a ssDNA 5’ 
exonuclease and has been shown, with DNA-PKcs, to have ssDNA 5’ and 3’ endonuclease 
activity (Drouet et al., 2006). PNKP is a 5’ kinase and a 3’ phosphatase and has been shown 
to require XRCC4 and DNA-PKcs to be active as phosphatases (Weinfeld et al., 2011). Artemis 
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is suggested to process the DNA ends for PNKP to chemically prepare the backbone of the 
DNA strands, and Tdt, pol λ and pol μ can replace any missing nucleotides that have created 
ssDNA overhang at the DSB (Ramsden, 2011). This is in preparation for Lig4, bound to XRCC4, 
to ligate the backbones together and fix the DSB (Kysela et al., 2005). NHEJ is considered to 
be error-prone because the DNA ends are processed before they are ligated back together 
and no DNA template is used to ensure there are no deletions. 
1.4.1.1.3 DSB repair pathway choice 
The mechanism that controls the choice of repair pathway is still being deciphered, but 
BRCA1 and 53BP1 remain the upstream effector proteins that orchestrate the choice of NHEJ 
or HR through prevention of DNA end resection and its antagonism (Figure 1.6). 53BP1 
protects DSB ends from resection (Botuyan et al., 2006), a prerequisite for HR, and BRCA1 
promotes resection (Schlegel et al., 2006), antagonising 53BP1’s role to prevent DNA end-
resection. 53bp1’s prevention of end resection is orchestrated through phosphorylation-
dependent interactions with RIF1 and PTIP (Callen et al., 2013). RIF1’s role in preventing HR 
is less defined (Chapman et al., 2013; Escribano-Diaz et al., 2013; Zimmermann et al., 2013) 
than PTIP’s but it may have a role in chromatin regulation (Dan et al., 2014) and RIF1 
thought to act through the end-resection-inhibiting effects of REV7 (Boersma et al., 2015). 
PTIP binds 53bp1 through S/QT phosphorylation sites (Callen et al., 2013) and promotes end 
resection through recruitment of the nuclease Artemis which prepares DNA ends 
subsequently promoting NHEJ (Wang et al., 2014a). It is this that promotes the errors in 
NHEJ (Callen et al., 2013). In S phase BRCA1 BRCT domains can bind to the E3 ubiquitin 
ligase, UHRF1, which ubiquitinates RIF1 with K63-linked polyubiquitin chains which in turn 




Figure 1.6 – The DSB repair pathway choice and BRCA1 roles 
This simplifies NHEJ and HR, and the choice between which DSB repair pathway is used for 
repair. It identifies where BRCA1 has a role.   
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limits the presence of K63-linked polyubiquitin chains at a DSB (Butler et al., 2012) and this 
affects the accumulation of 53bp1 at the ends of the DSB (but not from the surrounding DSB 
area) (Kakarougkas et al., 2013b). The outward movement of 53BP1 from the centre of the 
DSB creates an increase in the 53BP1 foci size (Butler et al., 2012) and forms a core devoid of 
53BP1 (Kakarougkas et al., 2013b). This devoid core is also devoid of RAP80 (Kakarougkas et 
al., 2013b). The polyubiquitin chains created by RNF8/RNF168 are removed (Butler et al., 
2012) by USP26 and USP37 (Typas et al., 2015). These processes allows DNA to be nicked 
and resected by Mre11 and EXO1/BLM nucleases (Shibata et al., 2014), and allows RPA foci 
to form (Kakarougkas et al., 2013b). Shibata et al, suggest that it is the resection by Mre11 
and EXO/BLM endonuclease activity that commits a DSB to be repair via HR (Shibata et al., 
2014). USP26 and USP37 were also shown to promote the BRCA1 interaction with PALB2 
(Typas et al., 2015), which is needed alongside BRCA2 to load Rad51 foci onto chromatin 
(Dong et al., 2003; Zhang et al., 2009b).  
This removal of 53BP1 and its downstream effectors allows HR to progress although this is 
cell cycle-dependent (Chapman et al., 2012; Feng et al., 2013). Zhang et al, suggested the 
recruitment and phosphorylation of UHRF1 by CDK2/CyclinA, allow UHRF1 to 
polyubiquitinate RIF1 which leads to the disassociation of 53BP1 from sites of DSB, 
promoting HR (Zhang et al., 2016) in S/G2 phases of the cell cycle. The Ku complex has been 
reported to be removed from DSB ends in S/G2 phase by phosphorylation (Lee et al., 2016) 
and ubiquitination (Ismail et al., 2015). Many of the DSB repair proteins have 
phosphorylation sites that are provide control over their localisation or actions dependent 
on the cell cycle and as described above, these must in part contribute to the choice of 
repair pathway utilised at a DSB break. 
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1.4.1.1.4 BRCA1 roles in HR 
BRCA1 has several roles in the HR repair and its functions can be seen when looking at the 
properties of each BRCA1 complex that is formed and localised to DSBs.  
The first complex is called BRCA1-A, and contains RAP80 (Wang and Elledge, 2007), Abraxas 
(Wang and Elledge, 2007), ABRA1, CCDC98 (Liu et al., 2007b), NBA1/MERIT40 (Wang and 
Elledge, 2007), BRE and BRCC36 (Dong et al., 2003). Abraxas has coiled-coil domain which 
allows it to act as binding platform for proteins and its C-terminal phospho-Ser406 in its 
pSXXF motif interacts with the BRCT domains in BRCA1 (Wu et al., 2016). It also binds to 
RAP80, which is localised as a prerequisite for BRCA1 localisation. NBA1 has been shown to 
enhance the localisation of BRCA1-A complex to sites of DSB but only when ubiquitin is 
present (Wang and Elledge, 2007). In fact, many of the proteins in this complex are required 
for the localisation of BRCA1 because when they are knocked down or absent from cells, 
BRCA1 foci are greatly altered or decreased (Chen et al., 2006; Dong et al., 2003; Kim et al., 
2007b; Liu et al., 2007b; Shao et al., 2009b; Sobhian et al., 2007; Wang et al., 2007). The 
localisation has also been shown to be influenced by ubiquitination of histones by RNF8 
(Wang and Elledge, 2007) and RNF168 (Doil et al., 2009). However, BRCC36 is a DUB that 
hydrolyses K63 polyubiquitin chains, and it also is needed for BRCA1 recruitment in response 
to damage (Dong et al., 2003). This suggests that this role of BRCA1 is highly regulated by the 
presence and absence of ubiquitin chains. It has been suggested that the BRCA1-A complex 
has the ability to limit end resection at DSBs (Coleman and Greenberg, 2011) and a RAP80 
knockdown in BRCA1 mutated cells leads to increased levels of RPA in S/G2 phase cells and 
G1 cells are unaffected (Dong et al., 2003). This is interesting as BRCA1-C complex is 
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considered to promote HR by enhancing end resection, whilst the BRCA1-A complex limits 
end resection.  
The BRCA1-C complex involved BRCA1/BARD1 heterodimer and CtIP. CtIP interacts with 
BRCA1 through its BRCT domains at its C-terminal end (Williams et al., 2009). CtIP, like 
BRCA1, is also phosphorylated by ATM and phosphorylates Chk2 (Yu and Chen, 2004; Yun 
and Hiom, 2009). CtIP is polyubiquitinated by BRCA1 in cells without damage, but 
ubiquitinated CtIP binding to chromatin in response to damage is BRCA1-dependent (Yu et 
al., 2006). Localisation of CtIP is also S and G2 phase-dependent as it is Cyclin A-dependent 
(Chen et al., 2008). CtIP is shown to resect DNA ends at a DSB, but also has been shown to 
promote MRE11 of the MRN complex and EXO1/BLM to complete bidirectional resection of 
the DSB ends (Buis et al., 2012; Shibata et al., 2014). 
BRCA1 E3 ubiquitin ligase activity is needed to polyubiquitinate CtIP but the type of ubiquitin 
chain BRCA1 ligates onto CtIP is not known (Barber and Boulton, 2006). Unlike RNF8 or 
RNF168, BRCA1 predominantly ubiquitinates with K6 polyubiquitin chains (Morris and 
Solomon, 2004; Wu-Baer et al., 2003). These K6 polyubiquitin chains could provide a self-
enhancement for the BRCA1/BARD1 complex ubiquitin ligase activity (Mallery et al., 2002) 
but the exact function of these K6 polyubiquitin chains is not clear and it is possible that they 
are placed on an unknown substrate. 
BRCA1-B complex is characterised by the interaction of BRCA1 and BRCA2 through 
PALB2/FANCN (Sy et al., 2009; Zhang et al., 2009b). The main function of the BRCA1-B 
complex is to load Rad51 onto ssDNA, replacing RPA (Yu et al., 2001), and allowing RAD51 
filaments to bring in the sister chromatid as a template for repair of the DSB via HR (Sung 
and Robberson, 1995). Truncated BRCA1 proteins have shown that BRCA1 C-terminus is 
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needed for recruitment of the BRCA1-B complex and Rad51 foci formation (Zhang et al., 
2009b). The specific interaction of BRCA1 and PALB2 is around aa1400 (amino acid 1400) in 
BRCA1 at the coiled-coil domain, next to the BRCT domains and several phosphorylation 
sites, and between PALB2’s WT40 domains. Deletion of either of these regions stops the 
BRCA1-BRCA2 interaction and RAD51 loading. Although it has been seen that overexpression 
of RAD51 can overcome BRCA1 (Martin et al., 2007) or BRCA2 defects (Lee et al., 2009). 
BACH1/BRIP1/FANCJ helicase (Dohrn et al., 2012; Kumaraswamy and Shiekhattar, 2007) also 
associates with the BRCA1-B complex in a BACH1-phosphorylation G2 phase cell cycle-
dependent manner (Yu et al., 2003) and is associated with TopBP1 which is involved in the 9-
1-1 complex at the polymerase step of HR DSB repair (Cotta-Ramusino et al., 2011).  
1.4.1.1.5 BRCA1 in NHEJ 
Although BRCA1 is involved in favouring HR over NHEJ DBS repair in S/G2 phase of the cell 
cycle, it has been shown to have a role in NHEJ in G1 (Baldeyron et al., 2002; Iliakis et al., 
2004; Thompson et al., 2012; Wang et al., 2006; Zhong et al., 2002a; Zhong et al., 2002b; 
Zhuang et al., 2006). BRCA1 binds to Ku80 with its N-terminus (Jiang et al., 2013a), and this 
interaction aids rapid BRCA1 recruitment to DSBs (Wei et al., 2008). This interaction is 
independent of BARD1 and Ku80 binds to a similar region of BRCA1 suggesting competition 
for binding (Wei et al., 2008). The C-terminus of BRCA1 does not appear to be needed for 
this interaction or role in NHEJ (Wei et al., 2008). BRCA1 improves the stability of Ku80 
binding to DSB ends (Jiang et al., 2013a). BRCA1 was reported to need active ATM/Chk2 cell 
checkpoint responses and kinase activity to be effect in aiding NHEJ (Wang et al., 2006; 
Zhuang et al., 2006). BRCA1 appears to be involved in c-NHEJ (canonical-NHEJ) (Dohrn et al., 
2012) which provides an error-free method of repair in G1, and cells lacking BRCA1 show an 
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increased error-prone NHEJ repairs DNA causing more sequence deletion and chromosome 
aberrations in G1 cells treated with DSB-inducing agents (Jiang et al., 2013a).  
1.4.1.2 DNA crosslink repair 
1.4.1.2.1 The FANC repair pathway 
The Fanconi anaemia pathway orchestrates the repair of DNA crosslinks repair and without 
this repair cells develop genomic instability and patients can develop cancer (Alter et al., 
2003; Fanconi, 1964; Matthew, 2006; Tischkowitz and Hodgson, 2003). The cells from these 
patients are sensitive to MMC and Cisplatin, interstrand DNA crosslinking (ICL) damaging 
agents, and have chromosomal rearrangements (Matthew, 2006). These genetic mutations 
underlying Fanconi anaemia have been mapped to at least 15 genes that make up the 
Fanconi anaemia (FA) DNA repair pathway (de Winter et al., 1998; de Winter et al., 2000a; 
de Winter et al., 2000b; Howlett et al., 2002; Levitus et al., 2004; Levitus et al., 2005; Lo Ten 
Foe et al., 1996; Meetei et al., 2003; Meetei et al., 2004; Meetei et al., 2005; Strathdee et al., 
1992; Timmers et al., 2001; Tischkowitz et al., 2007).  
The FA pathway is activated during DNA replication where ICLs are recognised by FANCM-
FAAP24 (Kim et al., 2008) and starts the repair by signalling the S phase checkpoint pathway 
via ATR (Collis et al., 2008) and recruiting the FA E3 ubiquitin ligase complex (Garcia-Higuera 
et al., 2001). The FA E3 ubiquitin ligase complex is made up of FANCA, FANCB, FANCC, 
FANCE, FANCF, FANCG, FANCL and FANCM (de Winter et al., 1998; de Winter et al., 2000a; 
de Winter et al., 2000b; Lo Ten Foe et al., 1996; Meetei et al., 2003; Meetei et al., 2004; 
Meetei et al., 2005; Strathdee et al., 1992). Once phosphorylated, FANCM is stabilised onto 
chromatin in association with MHF1 and MHF2 (Singh et al., 2010; Yan et al., 2010). Chk1, 
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from the ATR-checkpoint pathway, phosphorylates several of the FANC proteins in the 
complex to aid activation of the repair (Cohn and D'Andrea, 2008). 
FANCL, the E3 ubiquitin ligase of the FA complex (Cole et al., 2010), monoubiquitinates 
FANCD2 and FANCI with the E2 conjugating enzyme, UBE2T, during S phase (Garner and 
Smogorzewska, 2011). Once FANCD2 and FANCI are ubiquitinated they are recruited, 
alongside FANCM/MHF complex, to the DNA lesion with the aid of BRCA1 (Bouwman et al., 
2010; Bunting et al., 2012; Garcia-Higuera et al., 2001; Vandenberg et al., 2003; Zhang et al., 
2010) to co-ordinate repair (Garner and Smogorzewska, 2011). Rad18 has also been seen to 
ubiquitinate FANCD2 as part of its activity in regulating translesion synthesis (TLS) (Williams 
et al., 2011). Ubiquitinated FANCD2 recruits the ubiquitin binding nucleases, FAN1 and 
P/SLX4, to start excision of the replicated DNA surrounding the DNA crosslink (Crossan and 
Patel, 2012). MUS81-EME and XPF-ERCC1 nucleases are recruited to cut the specific ‘chicken 
foot’ structure that replicated DNA has formed around the DNA crosslink (Ciccia et al., 2008). 
These nucleases lead to DSB formation that allows the cross between the two strands in the 
interstrand crosslink to stay attached to one strand of the DNA whilst the other is replicated 
via TLS (Long et al., 2011). The TLS of the DNA is polymerised by REV1 and pol ζ (Acharya et 
al., 2006; Hara et al., 2010). The remaining lesion is repair by nucleotide excision repair (NES) 
and DNA replication (Muniandy et al., 2010).  
The DSBs are repaired through HR utilising BRCA1 (Bhattacharyya et al., 2000; Sawyer et al., 
2015), Rad18 (Huang et al., 2009), BRCA2/FANCD1 (Howlett et al., 2002; Moynahan et al., 
2001b), BRIP1/FANCJ (Litman et al., 2005; Sommers et al., 2009), PALB2/FANCN (Zhang et 
al., 2009b) and RAD51C/FANCO (Vaz et al., 2010) to promote Rad51 loading. FANCJ may 
have a role with BLM, as helicases for unwinding DNA to be resected by the endonucleases 
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(Suhasini et al., 2011). The inhibition of USP1 and UAF1 decreases the efficiency to HR at 
ICLs, suggesting that the removal of ubiquitin from FANCD2 may be needed to facilitate HR 
(Murai et al., 2011). Once USP1 and UAF1 have deubiquitinated FANCD2 and FANCI (Cohn et 
al., 2007; Cohn et al., 2009; Kim et al., 2009a; Murai et al., 2011; Nijman et al., 2005), DNA 
replication and the cell cycle can continue.  
HR is used to repair the DSBs created in the resolution of ICLs because there is a second copy 
of the DNA to use a template in the form of the TLS product. The FA pathway does show a 
promotion of HR, over NHEJ, favouring error-free repair (Adamo et al., 2010; Pace et al., 
2010). FANCD2, as a purified protein, has been suggested to be an antagonist for Ku70 
activity through modifying DNA surrounding the ICL DSB (Pace et al., 2010).  
This was shown by the successful attempts to rescue NHEJ repair in cells with defective FA 
repair by inhibiting NHEJ factors, such as DNA-PKcs, Lig4 and Ku70, (Adamo et al., 2010; Pace 
et al., 2010). However, not all NHEJ protein depletions rescue the FA pathway suggesting 
that the removal of NHEJ pathway is not sufficient, but there is a need for the removal of the 
mechanism by which FA pathway promotes NHEJ (Adamo et al., 2010).  
1.4.1.2.2 BRCA1 roles in the FANC repair pathway 
BRCA1 aids in the localisation of PALB2 and BRCA2 for Rad51 loading onto ssDNA for 
template repair in ICL repair. BRCA1’s role with PALB2 and BRCA2 in Rad51 loading is an 
important component of HR, and it has been shown that in 53bp1-null Brca1-defective cells, 
the loading of Rad51 foci at DSBs is independent of wild-type Brca1 (Bunting et al., 2012; 
Nakada et al., 2012). This redundancy of BRCA1 in the loading of Rad51 would suggest that it 
is a 53bp1-independent role of BRCA1 that can lead to DNA crosslink sensitivity in BRCA1-







Figure 1.7 – DNA crosslink repair 
This figure shows a simplified depiction of DNA crosslink repair and the involvement of 
BRCA1.   
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BRCA1 is important for the localisation of ubiquitinated FANCD2 to DNA crosslink repair foci 
(Figure 1.7) (Bouwman et al., 2010; Bunting et al., 2012; Garcia-Higuera et al., 2001; 
Vandenberg et al., 2003; Zhang et al., 2010) and FANCD2-FANCDI ubiquitination is essential 
for bringing in nucleases to start resection at ICLs (Klein Douwel et al., 2014; Knipscheer et 
al., 2009). In vitro, BRCA1/BARD1 E3 ubiquitin ligase activity has the ability to 
monoubiquinate FANCD2, but in vivo assays have shown that BRCA1 presence or E3 
ubiquitin ligase activity (Exons 3&5 deleted) are not required for monoubiquitination but do 
lead to chromosome abnormalities (Vandenberg et al., 2003). FANCD2 and BRCA1 colocalize 
at sites of DNA damage (Garcia-Higuera et al., 2001; Taniguchi et al., 2002) and cells treated 
with BRCA1 siRNA or that have a BRCA1 mutation show reduced localization of FANCD2 foci 
(Garcia-Higuera et al., 2001; Vandenberg et al., 2003).  
A paper recently described BRCA1 in promoting the unloading of a helicase, called CMG, 
from replication structures (which include DNA crosslink repair structures) (Long et al., 
2014). Long et al suggest that BRCA1 is localised to DNA crosslinks through ubiquitin signals 
and then unloads the CMG helicase which is upstream of FANCD2 recruitment or nucleases 
creating a DSB (Long et al., 2014). The BRCA1-CtIP interaction may also be important for 
DNA crosslink repair, as Yeo et al suggested that BRCA1 is essential for CtIP and FANCD2 
being localised to chromatin (Yeo et al., 2014). It has also been shown that BRCA1 binds to 
FANCJ and its localisation is dependent on functioning BRCA1 ((Zhang et al., 2010).  
These papers suggest that BRCA1 has at least one role in the DNA crosslink pathway that is 
upstream of Rad51 loading onto resected DNA. This upstream function supports that BRCA1 
has a 53bp1-independent role in DNA crosslink repair and may explain why 53bp1-/-
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Brca1Δ11/Δ11 cells are sensitive to DNA crosslinking-agents but are functional in repairing DSBs 
through HR when caused by PARP inhibitors or IR (Bunting et al., 2010; Bunting et al., 2012).  
1.4.1.3 Other DNA repair pathways 
BRCA1’s has DNA repair functions outside of the described roles in DSB and DNA crosslinks 
repair. The base excision repair (BER) pathway repairs lesions caused by oxidized DNA (Aiub 
et al., 2004; Evans et al., 2010) and BRCA1-deficient cells are sensitive to oxidative stress 
agents (Fridlich et al., 2015). NER involves the BASC complex (BRCA1-associated genome 
surveillance complex) of which BRCA1 is key (Wang et al., 2000). Both NER and BER can be 
repaired due to collisions with transcription machinery and BRCA1/BARD1 is involved in the 
degradation of RNA Pol II which removes proteins to allow DNA repair to proceed (Kleiman 
et al., 2005; Le Page et al., 2000; Starita et al., 2005) and is required for the transactivation 
of repair proteins (Hartman and Ford, 2002). UV radiation causes lesions that are repaired 
through TLS which is regulated by BRCA1’s interaction with REV1 (Tian et al., 2013). It is 
important to note that if any of these repair mechanisms or DNA/protein structures are 
faulty, they can become DSBs in replication and need BRCA1-dependent HR for accurate 
repair.  
1.4.2 Other Brca1 functions 
DNA repair by BRCA1 is needed for genome stability but other cellular functions that are 
BRCA1-dependent are also important for the suppression of tumours.  
1.4.2.1 Chromatin regulation 
Loss of BRCA1 causes chromatin de-condensation on a genome-wide scale (Ye et al., 2001) 
and dysregulation of repetitive-satellite-containing heterochromatin (Zhu et al., 2011). This 
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has been reported to be through BRCA1 and BARD1’s ability to ubiquitinate H2A (Zhu et al., 
2011), but BRCA1 also interacts with chromatin remodelling proteins that could contribute 
to BRCA1-dependent chromatin regulation.  
BRCA1 binds to histone deacetylases and the SWI/SNF chromatin remodelling complex 
(Chen et al., 2001; Harte et al., 2010; Yarden and Brody, 1999). It has also been reported to 
recruit DNA methyltransferases and interact with HP1 (a heterochromatin packaging 
protein) (Choi et al., 2012; Filipponi et al., 2013), which gives BRCA1 the ability to influence 
gene expression, as it does of Wip1 (Filipponi et al., 2013) and FOXA1 (Gong et al., 2015). 
Zhu et al suggested that the dysregulation of satellite DNA, due to BRCA1 mutation, is 
enough to cause tumour development (Zhu et al., 2011).  
1.4.2.2 Transcription regulation 
BRCA1 has a role in active transcription which includes regulating mRNA splicing (Savage et 
al., 2014). Phosphorylated BRCA1 is recruited to the BRCA1 mRNA splicing complex through 
its subunit BCLAF1 in response to DNA damage (Savage et al., 2014). BRCA1 can inhibit 
polyadenylation of 3’ mRNA through ubiquitinating RNA Pol II and this affects the stability of 
mRNA (Kleiman et al., 2005).  
BRCA1 also has the ability to resolve R-loops and aid transcription restart without the 
formation of DSBs (Hatchi et al., 2015; Hill et al., 2014). BRCA1-PALB2 complex is seen to be 
locating to actively transcribed regions of chromatin, and specifically DNA damage sites that 
are being transcribed (Aymard et al., 2014; Gardini et al., 2014; Tang et al., 2013). BRCA1 can 
interact with complexes containing RNA and hnRNP proteins that are formed after the DNA 
is damaged (Chiba and Parvin, 2001).  
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BRCA1 has a patch of acidic amino acid residues in the C-terminus and Miki et al predicted 
BRCA1 to be involved in transcription (Miki et al., 1994). It was then shown that the C-
terminus fragment of BRCA1 alongside the GAL4 DNA binding domain, did have 
transcriptional activity (Monterio et al., 1996). C-terminal mutations found in patients with 
cancer showed that this region was essential for BRCA1 transcriptional activity (Humphrey et 
al., 1997; Monterio et al., 1996). BRCA1 has roles in both transcriptional regulation that 
promotes and inhibits gene transcription. The BRCA1 transcriptome showed that the 
majority of BRCA1 gene regulation is DNA damage-induced (Gorski et al., 2011).  
ATM/ATR-phosphorylated BRCA1 promotes the transcription of p21-dependent DNA repair 
and cell cycle checkpoint genes through p53 (Andrews et al., 2002; Fabbro et al., 2004a; 
MacLachlan et al., 2002). Through Oct-1 interaction, BRCA1 aids the transactivation of 
GADD45 which stalls the cell cycle and promotes apoptosis (Fan et al., 2002; Harkin et al., 
1999) in DNA damage cells, but in undamaged cells CtIP/Zrbk-1 aids BRCA1-Oct-1 in GADD45 
repression (Li et al., 1999; Yu et al., 1998; Zheng et al., 2000). Oct-1/BRCA1 also activated the 
expression of BER pathway proteins, such as NTH1, REF1/Ape1 and OGG1 (Saha et al., 2010). 
Stat-1 was found to co-activate pro-apoptotic genes with BRCA1 after interferon-γ 
stimulation (Buckley et al., 2007; Ouchi et al., 2000). BRCA1 also inhibits apoptosis by 
activating anti-apoptotic genes regulated by NF-κB pathway by recruiting p50 to promoters 
where BRCA1/p60 are bound (Harte et al., 2014). 
BRCA1 can repress genes when in complex with c-Myc and Nmi, which stops hTERT and 
other tumour-related genes, from being expressed (Kennedy et al., 2005; Li et al., 2002). 
BRCA1’s influence on p53-regulated genes does promote one set of genes to be expressed 
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but it also causes the repression of p53-regulated pro-apoptotic genes (Andrews et al., 2002; 
MacLachlan et al., 2002). The estrogen receptor alpha (ERα) is repressed when it binds to 
BRCA1 (Fan et al., 2001a; Zheng et al., 2001) and this stops the transcription of proteins that 
promote angiogenesis and tumour proliferation (Kawai et al., 2002). COBRA1 is a co-factor of 
BRCA1 that aids the inhibition of ERα by stalling RNA Pol II mRNA elongation (Aiyar et al., 
2004). Oct-1 is also involved in recruiting BRCA1 to ERα (Hosey et al., 2007). The 
BRCA1/CtIP/Zbrk1 complex is known to repress genes such as RFC1, which is a DNA repair 
protein (Furuta et al., 2006). 
These studies collectively show that BRCA1 has transcriptional roles that influence a great 
number of tumour suppressing and oncogenes that are known to aid tumour development 
when dysregulated.  
1.4.2.3 Cell cycle checkpoint regulation 
Many DSB repair proteins aid cell cycle checkpoint activation to allow the cell cycle to halt 
for the time it takes to repair the DNA. BRCA1 is needed to activate cell cycle checkpoint 
proteins but cell cycle proteins regulate its own activation.  
BRCA1 mediates the ATM/ATR-dependent phosphorylation of p53 at Serine 15 after IR 
(Fabbro et al., 2004a). But to do this BRCA1 must be phosphorylated by ATM or ATR at 
Serine 1423 or 1524 (Fabbro et al., 2004a; Xu et al., 2001a). The phosphorylation of p53 
orchestrates the G1/S phase checkpoint by transcribing p21 (Fabbro et al., 2004a). The 
phosphorylation of BRCA1 is transient and is removed once the DNA is repaired (Chen et al., 
1996; Ruffner and Verma, 1997).  
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BRCA1’s interaction with TopBP1 is required for the ATR activation that activates the S phase 
checkpoint (Xie et al., 2012). The BRCA1-ATRIP complex is thought to aid pRPA-coated ssDNA 
to activate an ATR checkpoint response (Venere et al., 2007; Zou and Elledge, 2003). hCds1 
and Chk2 are also involved in the BRCA1-mediated replication arrest (Yarden et al., 2002).  
The BRCA1 interacting protein ATRIP is also important for an efficient G2/M checkpoint and 
can be disrupted by altering the interaction between the BRCT domains of BRCA1 and 
phosphorylated Serine 239 in ATRIP (Venere et al., 2007). It has been reported that BRCA1 
ubiquitinates Cyclin B/Cdc25C which is degraded (Shabbeer et al., 2013), and this stops their 
accumulation and the entry into mitosis (Kostyrko et al., 2015; Yarden et al., 2002).  
The G2/M checkpoint requires both ATM and BRCA1 to be fully functional (Draga et al., 
2015; Yarden et al., 2002). BRCA1 S1423 is phosphorylated by ATM and prolongs the 
phosphorylation of Chk1 which when activated arrests the cells in G2 phase (Draga et al., 
2015; Yarden et al., 2002). BRCA1 requires ABRAXAS to achieve this G2 arrest (Draga et al., 
2015).  
The presence of a functional checkpoint response is important for correct DNA repair. In the 
case of BRCA1’s role in DSBS repair end resection, if Chk2 is not phosphorylated in response 
to DNA damage, there is a delay in DSB end resection and BRCA1 foci are retained for longer 
at DSBs (Parameswaran et al., 2015).  
BRCA1 mutated cells have different cell cycle defects dependent on the mutation. Cells that 
only express the BRCA1 Exon 11 (Δ11) isoform have a defective G2/M checkpoint but have a 
functional G1/S phase checkpoint (Larson et al., 1997; Xu et al., 1999b). Mutation of Serine 
1423 on BRCA1 abolishes ATM phosphorylation and this causes a G2/M checkpoint defect, 
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but does not affect the S phase checkpoint arrest (Xu et al., 2001a). Shabbeer et al suggest 
that the ubiquitin ligase activity of BRCA1 is also important for a G2/M cell cycle arrest 
(Shabbeer et al., 2013). Overexpressing BRCA1 has also been seen to arrest cells in G0/1 
(Campbell et al., 2001) and G1/2 (Somasundaram et al., 1997).  
Without functional BRCA1 (or a BRCA1 that cannot be phosphorylated correctly), cells 
display the signs of DNA damage being present throughout the cell cycle and through mitosis 
and this leads to sensitivity to DNA-damaging agents (Cortez et al., 1999; Wiltshire et al., 
2007). This also leads to mitotic problems and daughter cells that can inherited mutations or 
loose/gain chromosome arms. Therefore BRCA1 cell cycle roles are important for 
maintaining genomic stability.  
1.4.2.4 Centrosome 
Centrosomes are the main microtubule organising centres during mitosis and they are 
important for the correct segregation of chromosomes to ensure genome integrity. In 
normal cells BRCA1 colocalises with centrosomes (Di Paolo et al., 2014; Hsu and White, 
1998; Sankaran et al., 2005) and BRCA1-deficient cells show an amplification of 
centrosomes, abnormal chromosome segregation and aneuploidy (Di Paolo et al., 2014; 
Starita et al., 2004; Xu et al., 1999b). BRCA1 interacts with proteins that are involved in the 
spindle assembly checkpoint (Bae et al., 2005; Chabalier et al., 2006; Wang et al., 2004a) and 
spindle pole proteins (Jin et al., 2009; Joukov et al., 2006). The loss of BRCA1 protein causes 
an increased distance between interkinetochores and less centromeric cohesion (Di Paolo et 
al., 2014). This may be due to BRCA1 being important for the full accumulation of Aurora B 
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kinase at centromeres, through its role in hypomethylation by recruiting DNMT2b, a DNA 
methyltransferase (Di Paolo et al., 2014).  
1.5 Brca1 mouse models 
Due to the clinical nature of BRCA1 mutations, mouse models with Brca1 mutation have 
been explored to help provide more information about the human BRCA1 mutation and how 
they could leave to cancer development. Mice are used as a model organism from human 
disease because they are a mammal, therefore are closely related in evolution, and because 
they can be genetically altered to mimic genetic disorders and their progression. Brca1 in 
mice is 75.22% (Clustal 2.1) similar to human BRCA1 and important residues and domains 
are conserved (Intro 1.3.2 and Chapter 3.2).  
1.5.1 Brca1 mouse mutations and embryonic lethality  
The various mouse models that have been made encompass several different mutations in 
Brca1 and the defects and phenotypes of the mice vary. This variety is likely to be due to the 
disruption of a region of Brca1 altering a function of Brca1 that is actioned by that region. 
Figure 1.8 maps out previously studied mouse mutations and their positions in Brca1 
domains to indicate the possible impact each mutation has on the protein structure of Brca1 
and some of the phenotypes seen in these mice.  
Some Brca1 mouse models have used a flox system that encompasses Exon 11 (Δ11) of 
Brca1 creating a large deletion of the gene (Cressman et al., 1999b; Gowen et al., 1996; Liu 
et al., 1996; Shen et al., 1998; Xu et al., 1999a). The Flox system consists of flanking a region 






Figure 1.8 – Brca1 mouse mutations and phenotype 
This figure shows Brca1 mutation mouse models and their position in the Brca1 protein. It also comments on the embryonic lethality, 
fertility and tumour risk phenotype of these mice. The red line depicts the approximate location of the point mutation. Domains are 








Protein Fertility Tumours Reference 
Exon 11 (Δ11) Yes Δ11 isoform - - 
(Cressman et al., 1999b; 
Gowen et al., 1996; Liu et 
al., 1996; Xu et al., 1999) 
Full-length only (FL) No 
FL only, no 
Δ11 isoform 
Normal Yes (Kim et al., 2006) 
Exon 5-6 (Δ5-6) Yes 
No protein, 
frameshift 
- - (Hakem et al., 1997) 
Exon 2 (Δ2) Yes Unstable - - (Ludwig et al., 1997) 
Truncation at amino 
acid 1700 (Tr aa1700) 
Yes Truncated - - (Hohenstein et al., 2001) 
Truncation at amino 






Yes (Ludwig et al., 2001) 
Ile26Ala (I26A) No Normal 
Male 
infertile 
No (Shakya et al., 2011) 
Cys64Gly (C64G) Yes 
aa22 
frameshift 
- - (Yang et al., 2003) 
Cys61Gly (C61G) Yes 
Normal in 
tumours 
- - (Drost et al., 2011) 
Ser971Ala (S971A) No Normal Normal Yes (Kim et al., 2004) 
Ser1152Ala (S1152A) No Normal Normal Yes (Kim et al., 2009) 
Ser1598Phe (S1598F) No Normal 
Male 
infertile 












                 Embryonic day 
Reference Brca1 mutation E4 E5 E6 E7 E8 E9 E10 E11 E12 E13   
(Gowen et al., 1996) Exon 11                 
(Hakem et al., 1996) Exon 5&6               
(Liu et al., 1996) Exon 11 aa300-361                  
(Hakem et al., 1997) Exon 5&6               
(Ludwig et al., 1997) Exon 2                   
(Shen et al., 1998) Exon 10-11                 
(Cressman et al., 1999a) aa223-763 exon 11                
(Lane et al., 2000) neo into Exon 11              
(Xu et al., 2001b) Exon 11 neo insert               
(Xu et al., 2001c) exon 11                
(Hohenstein et al., 2001) aa1700 truncation                 
(Yang et al., 2003) C64G human BAC              defects  
(Drost et al., 2011) C61G                dead  
Figure 1.9 – Mouse Brca1 mutations and the embryonic lethality timing 
This figure shows the Brca1 mutations that caused embryonic lethality in mice and the embryonic day at which defects (orange) and death 
(red) was identified.  
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flox vectors do not include the Brca1 has a splice acceptor site and therefore the isoform of 
Brca1 created by alternative splicing is not affected in these Exon 11 mutations (Gowen et 
al., 1996; Liu et al., 1996). The isoforms function was separated from full-length Brca1 by 
blocking the acceptor site (Kim et al., 2006). Mice that only express full-length Brca1 (no 
Exon 11 deletion isoform) were born healthy but showed altered mammary gland 
development and increased proliferation and tumourigenesis of the uterus (Kim et al., 
2006). This suggests that the Exon 11 isoform of Brca1 is involved in genome stability and 
hormonal driven development in mice. Interestingly, the tumours from Exon-11-isoform-
deleted mice did not have full-length Brca1 protein suggesting that full-length Brca1 is still 
needed to prevent cancer development (Kim et al., 2006).  
Other mutations to in Brca1 mouse have included the deletion of Exons 5 and 6 (Δ5-6) 
(Hakem et al., 1996; Hakem et al., 1997), Exon 2 (Δ2) (Ludwig et al., 1997), Exon 21-24 (Δ21-
24) (McCarthy et al., 2007) and truncation at aa1700 (tr1700) (Chandler et al., 2001; 
Hohenstein et al., 2001) and they have all been embryonic lethal like Exon 11 (aa300-361 
(Liu et al., 1996) and aa233-763 (Cressman et al., 1999a)). The phenotypes in these embryos 
are all similar, but they do have some variability between them in the morphological defects 
and in the embryonic day they are reabsorbed (Figure 1.9).  
One truncation mutation of Brca1 (aa924) was not embryonic lethal but were born at 
reduced Mendelian rations (4% instead of 25%) (Ludwig et al., 2001). The mutation in Brca1 
was caused by a knock-in of 50bp insert into Exon 11 which causes a stop codon due to the 
frameshift (Ludwig et al., 2001). In cells of this genotype full-length Brca1 is not detected 
and there is a reduction in the truncated Brca1 mRNA (Ludwig et al., 2001). However, the 
splicing variant of Brca1 was detected at wild-type levels (Ludwig et al., 2001). The mice that 
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were born had defects in skin pigmentation, growth rate, tail formation and male 
spermatogenesis (Ludwig et al., 2001). At the time of death, 26% of control mice had 
developed tumours compare to the 85% of homozygous mutant mice that developed a 
range of tumours, including lymphomas, sarcomas, ovarian teratoma and carcinomas of the 
breast, lung, liver, uterus and colon (Ludwig et al., 2001). The non-lethal phenotype of the 
truncation could suggest that the C-terminal of Brca1 is not the cause of the embryonic 
lethality in other Brca1 mutants however there still is a presence of the Brca1 Exon 11 
isoform. Isoform protein levels are approximately a fifth of full-length Brca1 protein levels, 
but could have a functional C-terminus. This would mean that the functional absent region 
of Brca1 in these mice is from aa924 to Exon 10 (aa1365).  
To divide the functions of BRCA1, mutations can be made that alter a region-associated 
function. I26A, C64G, C61G, S971A, S1152A and S1598F are all missense mutations in 
important residue that are targeted to affect a specific activity of BRCA1. S1598F changes a 
serine residue to a proline, which disrupts the BRCT domain binding to BACH and FANCJ 
(Shakya et al., 2011). This mutation, when homozygote, was also not embryonic lethal but 
the mice did develop tumours and the male mice were sterile (Shakya et al., 2011). This 
suggests that the BRCT domain interaction with BACH and FANCJ are not important in 
embryonic lethality, but may be for tumour development (Shakya et al., 2011).  
S971A and S1152A both change a serine to an alanine. S971 relates to S988 in human BRCA1 
and it known to be a Chk2 phosphorylation site. The mice were born at expected ratios but 
still developed uterus and ovarian tumours by 2 years of age showing underlying genomic 
instability (Kim et al., 2004). This mouse can be compared to the Chk2-deficient Brca1-
deficient mice (Cao et al., 2006), as S971A functions the same as the removal of Chk2 in the 
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ATM-p53-Chk2 checkpoint pathways. The mutation does not cause embryonic lethality 
which suggests that it is not responsible for the developmental defects, but still causes 
checkpoint defects that lead to tumourigenesis (Kim et al., 2004). S1152, which is S1189 in 
humans, is phosphorylated by ATM in response to DSBs. Like the S971A mice, S1155A mice 
were born at the expected ratio and at 18 months old, developed tumours, however S1152A 
mice has a severe phenotype with higher levels of apoptosis and growth retardation (Kim et 
al., 2009b). The lack of ATM-BRCA1 interaction is also not responsible for the embryonic 
lethality in Brca1-deficient mice, but shows control in growth and genome stability. Both of 
these mutations target the ATM-p53-Chk2 cell cycle checkpoint, which has been shown to 
allow the rescue of embryonic lethality in Brca1-deficient mice (Cao et al., 2003; Cao et al., 
2006; Cao et al., 2007; Cressman et al., 1999a; Mak et al., 2000; Xu et al., 1999a; Xu et al., 
2001c), but the lack of embryonic lethality suggests that neither missense mutation solely 
controls the checkpoint or the checkpoint defect is not enough to cause the developmental 
defects.  
C61G and C64G missense mutations both change cysteines into glycines in Site II of the zinc 
ligating region and I26A mutation changes an isoleucine to an alanine in Site I of the zinc 
ligating region, of the RING domain in BRCA1. The BRCA1 RING domain is highly conserved 
and these missense mutations have been shown to reduce the BRCA1 E3 ubiquitin ligase 
activity using an in vivo ubiquitination assay (Brzovic et al., 2003). C61G and C64G mutations 
alter zinc ligation and BARD1 binding and this is what causes the reduction in ubiquitin ligase 
activity (Brzovic et al., 2003; Hashizume et al., 2001; Mallery et al., 2002; Ruffner et al., 2001; 
Wu et al., 1996). I26A does not alter zinc ligation but does alter the binding of an E2 
conjugating enzyme which causes the reduced ubiquitin ligase activity (Brzovic et al., 2003). 
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Brca1I26A/Δ2 embryonic stem (ES) cells show differentiation and colony formation showing 
that I26A ES cells are viable, but do show male sterility and a decreased body weight (Shakya 
et al., 2011). The Brca1I26A/Δ2 mice were viable and did not develop tumours (Shakya et al., 
2011). C61G (Drost et al., 2011) and C64G mice (Yang et al., 2003) were both embryonic 
lethal. C64G mutation of a G-T at nucleotide 309 has been shown to produce a 22-nucleotide 
deletion from Brca1 mRNA transcript due to the interruption of splicing site (Yang et al., 
2003). C61G mice are also embryonic lethal but showed Brca1 C61G protein levels similar to 
wild-type Brca1 protein levels in tumour cells (Drost et al., 2011). This could suggest that the 
C61G mutation lethality is caused by the single amino acid change affecting the E3 ubiquitin 
ligase activity (Drost et al., 2011) rather than affecting the amount of Brca1 protein. There is 
other evidence, mostly cell-based, that suggests Brca1 C61G protein is stable (Campbell et 
al., 2001; Lu et al., 2007; Nelson and Holt, 2010) and evidence that disagrees with this 
(Brzovic et al., 1998; Brzovic et al., 2001b; Choudhury et al., 2004; Wang et al., 2014b) which 
is both biochemical and cell-based research. The difference in phenotypes produced by 
these three N-terminal RING domain mutations suggests more research is needed to explain 
why specific mutations lead to specific phenotypes, and how this relates to the function of 
the RING domain.  
1.5.2 Tissue-specific Brca1 mutations in mice 
A tissue-specific Brca1 mutation can be used to study Brca1 homozygote mutations in mice 
without the problem of embryonic lethality. This uses a tissue-specific genome editing 
system that will create a Brca1 homozygote mutation using a promoter that is only 
expressed in the specific cell type. A T cell-specific Lck promoter with Cre recombinase ability 
was bred with Brca1fl5-6 to investigate Brca1 function in T cell-lineage development (Mak et 
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al., 2000). There was 90% less thymocytes in the Brca1-defective mice compared to WT mice 
showing Brca1 to be essential for T cell lineage development. p53-rescued Brca1-deficient 
mice have some levels of T cell lineage depletion but not to the extent of the conditional 
LckCre Brca1-defective mice, suggesting that a p53-dependent Brca1 pathway causes the cell 
death in T cells (Mak et al., 2000).  
Ovarian cancer occurs at high prevalence in hereditary BRCA1 mutation families. A Fshr-Cre 
Exon 11 deletion in Brca1 was made which creates a Brca1 homozygous mutation in 
granulosa cells (Chodankar et al., 2005). 68% of these mice develop ovarian and uterine cysts 
between 12-20 months and the majority of cysts were cancerous (Chodankar et al., 2005). 
The tumours in these mice show similar histology and genomic rearrangements that are 
seen in human ovarian serous carcinoma and cells were of non-granulosa, epithelial origin 
(Chodankar et al., 2005). This paper suggests that it may not be the DSB repair defect caused 
by Brca1 deficiency that starts the tumour development, but faulty or lack control of the 
ovarian and uterine growth via Brca1, possibly through the oestrus cycle (Chodankar et al., 
2005).   
Brca1 is expressed in highly proliferative epithelial tissue the several conditional Cre 
recombinase mouse models have been made to remove Brca1 specifically from epithelial 
tissues. Whey acidic protein (Wap), mouse mammary tumour virus-long terminal repeat 
(MMTV-LTR), β-lactoglobulin (BLG), keratin 5 (K5) and keratin 14 (K14) are all promoters 
expressed in mammary epithelial cells, but some are not exclusive to mammary tissue. K5 
promoter is found in the oral and sinus cavity, esophagus, bladder, prostate, vagina, skin 
basal layer and mammary gland epithelial cells (Ramirez et al., 1994). K14 is specific to 
squamous epithelia and epidermal keratinocytes mainly involving breast tissue and skin 
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(Vassar et al., 1989). MMTV-LTR is expressed in mammary epithelial cells and ductal cells of 
the salivary gland (Wagner et al., 1997). Wap promoter is specific to the alveolar epithelial 
mammary cells (Wagner et al., 1997). BLG is expressed in secretory epithelial cells in the 
mammary glands and at low levels in salivary glands (Whitelaw et al., 1992). 
Brca1Δ11K5-Cre mice showed apoptotic skin epithelial from 6 weeks old and at 88 weeks 
mice developed a variety of cancers such as lymphoma, ear, oral cavity, stomach, skin and 
vagina (Berton et al., 2003). Brca1Δ21-24BLG-Cre (McCarthy et al., 2007), Brca1Δ5-13K14-Cre 
(Liu et al., 2007a) and Brca1F/C61G K14-Cre (Drost et al., 2011) mice developed breast tumours 
when combined with one or two mutations in p53. Brca1Δ11Wap-Cre and Brca1Δ11MMTV-
LTR-Cre mice showed abnormal mammary and fat pad development and mammary tumours 
around 1 year of age, but the tumour development was be sped up by a p53 heterozygous 
mutation (Brodie et al., 2001). The Wap-Brca1 and K14-Brca1 mouse mammary tumours 
resembled human BRCA1 breast cancer histology (Brodie et al., 2001; Drost et al., 2011). 
1.5.3 Brca1 mutant mice with a second gene mutation 
A second method of evading the homozygote Brca1 mutation embryonic lethality is by 
removing a second gene (or one allele of another gene) to compensate for the defects that 
cause developmental problems.  
Chk2 and p53 mutated rescue of Brca1-deficient mice leads to the development of various 
types of cancer (Cao et al., 2003; Cao et al., 2006; Cao et al., 2007; Hakem et al., 1997; Xu et 
al., 1999a). p53 rescue leads to lymphoma (Cressman et al., 1999a), breast (Xu et al., 1999a), 
oesophageal and stomach cancer (Cao et al., 2007), but the mice have other phenotypes 
such as premature aging and high levels of senescence (Cao et al., 2003). Chk2 rescued mice 
produce mainly breast and ovarian tumours and show a reduced, but not normal, level of 
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apoptosis and senescence (Cao et al., 2006) compared to p53 rescued mice (Cao et al., 
2007). Cells from both rescued Brca1-deficient mice still show premature aging and genomic 
instability (Cao et al., 2003; Cao et al., 2006). Chk2 and p53 are part of the ATM-Chk2-p53 
cell cycle checkpoint signalling pathway that is activated in response to DNA damage to stop 
cells from replicating with unresolved DNA damage (Iliakis et al., 2003). Brca1 deficiency 
leads to unrepaired damage due to a HR defect and this triggers the ATM-Chk2-p53 
checkpoint and cells senescence or become apoptotic (Xu et al., 2001c). Without a second 
mutation in this checkpoint pathway cells cannot proliferate and this could be why Brca1-
deficient embryos stop growth and show very high levels of senescence (Xu et al., 2001c). 
With a mutation in p53 or Chk2, Brca1-deficient cells still show some senescence and a DNA 
damage repair defect with chromosomal abnormalities leading to tumourigenesis, but cells 
do manage to proliferate allowing development past embryogenesis (Bachelier et al., 2003; 
Cao et al., 2003; Cao et al., 2006; Cao et al., 2007; Cressman et al., 1999a; Xu et al., 2001c).  
Mutations in genes with similar functions have been made to attempt to rescue Brca1-
deficient mice. p21 is a downstream regulator of the p53-dependent cell cycle checkpoint 
that controls G1-S transition in the cell cycle, therefore if p21 were mutated this could 
overcome the checkpoint and allow proliferation (Mak et al., 2000). Brca1;p21-deficient 
embryos do show reduced levels of senescence and survive until birth, however they die 
within 24 hours (Hakem et al., 1997; Mak et al., 2000). This suggests that p21 is part of the 
pathway is involved in the Brca1-deficient embryonic lethality but p53 is upstream of p21 




Chk1, is part of a cell cycle checkpoint response called ATR-Chk1-p53 signalling pathway and 
it control the DNA replication checkpoint (Cao et al., 2006). Chk1-null homozygote mice are 
embryonic lethal at day E4.5, therefore a heterozygous mutation of Chk1 was bred to 
produce a Brca1-deficient mouse (Cao et al., 2006). There was a partial rescue as 80% of 
Brca1-deficient Chk1-null heterozygous mice survived until birth, but they died within 24 
hours (Cao et al., 2006). This suggests, similarly to p21, that there is a postnatal 
development defect that is not rescued by mutated Chk1, because of Chk1-independent 
Chk2-dependent pathway.  
Other proteins that are involved in p53 cell cycle regulation and DNA damage repair 
pathways have be used to attempt to rescue embryo development in the Brca1 homozygote 
mice but they have not succeeded; proteins such as PTEN (Cao et al., 2006), Gadd45a (Wang 
et al., 2004b), APC, Msh-2 (Hohenstein et al., 2001) and PARP1 (Cao et al., 2006). 
DNA repair genes have also been mutated in attempt to rescue the development of Brca1-
deficient mice. The most successful was a null mutation in the NHEJ promoting protein 
53bp1 which alleviated the embryonic lethality of Brca1Δ11/Δ11 mice (Bunting et al., 2010; 
Bunting et al., 2012; Cao et al., 2009). 53bp1-null mice are born at normal Mendelian ratios, 
but have a suppressed immune system, IR sensitivity, chromosome abnormalities, thymic 
lymphoma and slowed growth (Morales et al., 2003; Ward et al., 2003b). The suppressed 
immunity is caused by faulty end-joining in V(D)J recombination which affects CSR (class 
switch recombination). CSR utilises NHEJ in AID (Activation-Induced Deaminase) during G1 to 
create variety in switch regions in immunoglobulin heavy-chains and this allows Ig’s to have 
more diversity producing a more effective immune system, and therefore 53bp1-deficient 
mice have the phenotype of weakened immunity (mice die from unknown causes, 
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suggestive of succumbing to infection) (Morales et al., 2003). Chromosome abnormalities 
are a phenotype evident of errors in DSB repair and having dysfunctional telomeres and 
chromosome segregation that is seen in 53bp1-/- mice (Ward et al., 2003b). 53BP1 acts to 
protect DSB and telomere ends by binding to dimethyl-histone 4 (H4K20me2) which 
prevents the relaxation of the histones, stopping the endonucleases from access to the DNA 
ends (Botuyan et al., 2006; Xie et al., 2007). This protects chromosome ends from being 
degraded which leads to DNA and, possibly, gene loss and stops end resection at DSB breaks 
from promoting HR (Xie et al., 2007).  
In Brca1-deficient mice, the 53bp1 knockout rescues the embryonic lethality and the 53bp1-/-
Brca1Δ11/Δ11 mice are born at Mendelian ratios and have a normal lifespan without elevated 
tumour incidence (Bunting et al., 2010; Bunting et al., 2012; Cao et al., 2009). Chromosome 
exchanges and radial chromosomes were reduced in 53bp1-/-Brca1Δ11/Δ11 cells in comparison 
to Brca1Δ11/Δ11p53-/- cells (Bunting et al., 2010). Brca1-deficient cells with a p53 mutation 
show sensitivity to DSB and DNA crosslinking damaging agents (Bunting et al., 2012) but 
53bp1-/-Brca1Δ11/Δ11 MEFs show a rescue of the Brca1-dependent sensitivity to PARPi, CPT, 
and IR which all cause DSBs (Bunting et al., 2010). PARPi inhibit PARP, a single-strand DNA 
break (SSB) repair protein (Altmeyer et al., 2009), and CPT inhibits topoisomerase I, a ssDNA 
exonuclease, causing an accumulation of single-stranded breaks (Hsiang et al., 1985). These 
ssDNA breaks are converted into DSB during DNA replication (Liu et al., 2008; Satoh and 
Lindahl, 1992). IR causes multiple types of DNA damage but the majority are DSBs (Painter, 
1974; Yamamoto et al., 1985). The rescue of sensitivity in 53bp1-/-Brca1Δ11/Δ11 MEFs suggests 
that DSB repair is possible in these cells.  
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53bp1-/-Brca1Δ11/Δ11 MEFs show sensitivity to crosslinking agents such as Cisplatin and MMC 
(Bunting et al., 2012) suggesting that although DSB repair is possible, DNA crosslink repair is 
defective (Bunting et al., 2012). Brca1 has a 53bp1-independent role of the crosslinking 
repair pathway (Section 1.4.1) and therefore the deletion of 53bp1 does not rescue the ICL 
repair pathway. 
The deletion of other HR proteins, such as Brca2 and Xrcc2 (Bunting et al., 2010), do not 
replicate the HR rescue phenotype with the removal of 53bp1, and the deletion of NHEJ 
proteins, such as Ku70, DNA-PKcs (Bunting et al., 2012) and Lig4 (Bunting et al., 2010), show 
no or only partial rescue of the Brca1-deficient phenotype. Deletion of proteins in multiple 
DNA repair pathways often leads to synthetic lethality due to the cells being unable to repair 
DNA damage leading to cell death (Mohni et al., 2015; Somyajit et al., 2015; Turner et al., 
2008). Synthetic viability is the alleviation of a mutated genes’ lethal phenotype due to the 
deletion of a second protein. This is true for 53bp1-null homozygote Brca1 Δ11 mice which 
develop to maturity (Bunting et al., 2010; Bunting et al., 2012; Cao et al., 2009).  
1.5.4 Male infertility 
DNA repair proteins have been known to be involved in the resolution and control of meiotic 
crossover involving DSB repair (Boateng et al., 2013; Cressman et al., 1999a; Kopanja et al., 
2011; Lou et al., 2006; Santos et al., 2010; Schaetzlein et al., 2013; Simhadri et al., 2014; Xu 
et al., 2003; Xu et al., 1996) and chromatin control, including meiotic sex chromosome 
inactivation and sex body control (Adamo et al., 2008; Fernandez-Capetillo et al., 2003; 
Santos et al., 2010). Mutations in DNA damage repair proteins have been shown to cause 
male infertility in humans (Ji et al., 2013) and this is replicated in mouse models mutated in 
DSB repair genes such as MDC1 (Lou et al., 2006), RNF8 (Li et al., 2010; Lu et al., 2010; 
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Santos et al., 2010), PALB2 (Simhadri et al., 2014) and CUL4 (Kopanja et al., 2011). Although 
these gene mutations cause male infertility, some DNA repair proteins cause male and 
female sterility such as mutations in BRCA2 (Friedman et al., 1998), ATM (Xu et al., 1996) 
and Exo1 (Schaetzlein et al., 2013). Other DSB repair proteins show no effect on fertility 
(Chapman et al., 2013; de Murcia et al., 1997; Gu et al., 1997; Ward et al., 2003b; Zhu et al., 
1996), and 53bp1 is one of these proteins (Ward et al., 2003b). Mus81 is an exonuclease 
needed to resolve collapsed replication forks (Boddy et al., 2001; Hanada et al., 2007) and 
mice with homozygote null mutations in Mus81 are fertile (Dendouga et al., 2005; Holloway 
et al., 2008; McPherson et al., 2004) but do show dysregulated crossovers in meiosis 
(Holloway et al., 2008). These results suggest that mutations in DNA repair proteins may 
cause different effects on fertility depending on the functional change they have on meiosis. 
The reasons behind the sex-specific infertility is not completely understood but one theory is 
that it is the inactivation of the meiotic XY sex chromosomes that affects spermatogenesis 
(Royo et al., 2010).  
Brca1 mice with mutations affecting the BRCT domains or the RING domain ubiquitin ligase 
function cause male-specific infertility (Brca1 null mutation lacking 53bp1 (Bunting et al., 
2012), truncating mutation (Ludwig et al., 2001), I26A (Shakya et al., 2011), Δ223-763 
(Cressman et al., 1999a) and Δ11 with either p53+/- (Xu et al., 2003) or Chk2-/- (Cao et al., 
2006)). However Brca1 point mutations not affecting these domains (S1152A (Kim et al., 
2009b) and S971A (Kim et al., 2006)) and Brca1 mice which only express full-length Brca1 
(Kim et al., 2004) do not show any infertility. This suggests that the function of Brca1 in 




BRCA1 is important for resolution of meiosis crossovers in which DSBs are created and 
repaired (Cressman et al., 1999a; Simhadri et al., 2014; Xu et al., 2003), and is involved in the 
chromatin regulation and sex body inactivation since BRCA1 binds to unsynapsed meiotic 
chromosomes and inactivated sex chromosomes (Adamo et al., 2008; Ganesan et al., 2002; 
Turner et al., 2004; Turner et al., 2005; Xu et al., 2003). Xu et al suggest that the meiotic 
defects associated with BRCA1 occur in Prophase I when there is a high level of DSBs created 
for crossovers to occur (Xu et al., 2003). Specifically, BRCA1-defective cells arrest in 
pachytene stage and maintain a prolonged γH2AX signal (a DNA damage sensor) and 
prolonged GCNA protein presence which does not allow for the continuation of meiosis (Xu 
et al., 2003). Spo11 is the exonuclease that creates DSBs during meiotic crossover (Bellani et 
al., 2010; Boateng et al., 2013; Romanienko and Camerini-Otero, 2000) and Spo11/Brca1 
double mutant in C.elegans shows infertility even though DSBs are not created in meiosis 
(Adamo et al., 2008). Adamo et al suggests that the Brca1 defect in meiosis is not caused by 
faulty DSB repair (Adamo et al., 2008) and therefore it may be BRCA1’s role in asynapsed 
chromosomes and sex body inactivation through its interaction with XIST RNA (Ganesan et 
al., 2002; Royo et al., 2010) that causes the male-specific infertility in Brca1-mutated mice. 
1.6 Aims of this thesis 
Despite the substantial amount of current literature, more information is required about the 
functions of BRCA1 and how variants or pathogenic mutations affect BRCA1’s roles in 
tumour suppression. This thesis investigates the effects of the C61G mutation on mouse 
Brca1, including its E3 ubiquitin ligase activity in vitro, how cells with two copies of the Brca1 
C61G allele respond to DNA-damaging agents. Homozygote Brca1 C61G mice are embryonic 
lethal (Drost et al., 2011) and this thesis will describe the breeding of these mice with 53bp1-
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null mice to produce living 53bp1-/-Brca1C61G/C61G offspring. MEFs were isolated from these 
mice and were used to further study Brca1-related cellular functions, but also a mouse 
model provided an organism in which the Brca1 C61G mutation could cause tumour 
development.  
This project investigated the effect of the Brca1 C61G mutation on mouse protein, mouse 
cells and the mouse as an organism and this has provided valuable information into the 
degree at which the C61G mutation effects Brca1-dependent genome stability. This 
information will contribute to a better understanding of why cancer risk is high in BRCA1 
C61G carriers and potentially, which drugs are effective in treating BRCA1-C61G tumours 




Chapter 2 – Materials and methods. 
Materials 
2.1 Drug and radiation treatments 
2.1.1 Ionising Radiation 
Cells were placed inside the irradiator case. The machine was programmed with the number 
of seconds (5 Gray= 157 seconds) that gave the desired level of exposure (measured in Gray) 
to the 137Caesium source. Cells were returned to the 37°C incubator.  
2.1.2 Drug treatments 
The following table (Table 2.8) contains the DNA-damaging drugs (Cisplatin, CPT, HU, 
Olaparib, Veliparib, MMC) and the cell manipulation drugs (LMB and CHX). These were used 
at the doses specified in the each experiment for the time stated (Table 2.8).  
Table 2.1 – Drug treatments 
Drug Stock concentration Solution Company 
Cisplatin Made up fresh Saline Sigma 
Camptothecin (CPT) 10mM stock DMSO Sigma 
Hydroxyurea (HU) 1M stock H2O Sigma 
Olaparib 50mM DMSO Santa Cruz Biotechnology 
Veliparib 50mM DMSO Santa Cruz Biotechnology 
Mitomycin C (MMC) make up fresh H2O Abcam 
Leptomycin B (LMB) 10ng/ml Ethanol Sigma 
Cycloheximide (CHX) 100mg/ml DMSO Sigma 
2.2 Microscopy 
Images were taken using a Leica DM6000B microscope with Leica LAS software and a HCX 
100x/1.4 oil lens. This Leica uses a HBO lamp with a 100W mercury short arc UV bulb light 
source and four filter cubes, A4, L5, N3 and Y5. The filters that were used in this thesis were 




2.3 PCR mutagenesis primer sequences 
Primer sequences were designed to be of 15 bp or more with either a C or G base. They 
matched the cDNA of the vector used but contained base pair changes that created the 
codon for the desired change to sequence (Table 2.9). Primers were diluted in dH2O.  
Table 2.2 – PCR mutagenesis primer sequences 
Primer name Primer sequence 
C61G Forward GCCCGTCGCAGGGGCCGCTGTGTAAAAATGAAATTACC 
C61G Reverse GGTAATTTCATTTTTACACAGCGGCCCCTGCGACGGGC 
I26A Forward CCTGGAATGCCCGGCCTGCCTGGAACTGATTAAAGAACC 
I26A Reverse GGTTCTTTAATCAGTTCCAGGCAGGCCGGGCATTCCAGG 
P62R Forward CGTCGCAGTGCCGCCTGTG 
P62R Reverse CACAGGCGGCACTGCGACG 
L82R Forward CGCTTTTCTCAGCGCGCGGAAG 
L82R Reverse CTTCCGCGCGCTGAGAAAAGCG 
R93A Forward CCTCAAGATAAACGCACAATTGGACAGC 
R93A Reverse GCTGTCCAATTGTGCGTTTATCTTGAGG 
R93E Forward CCTCAAGATAAACGCACAATTGGACAGC 
R93E Reverse GCTGTCCAATTGTGCGTTTATCTTGAGG 
2.4 Antibodies 
Primary and secondary antibodies used in the western blotting and immunofluorescent 
experiments are detailed in table 2.10 and 2.11 below. They were used at the stated 
dilutions in Milk or 10% FBS:PBS.  
Table 2.3 – Primary antibodies 
Protein Animal Supplier Dilution IF/WB 
53bp1 (ab172580) Rabbit Abcam 1:2000 IF 
β-tubulin (ab6046) Rabbit Abcam 1:5000 WB 
β-actin (ab8226) Rabbit Abcam 1:4000 WB 
γH2AX (ab2893) Rabbit Abcam 1:4000 IF 
γH2AX (ab184520) Mouse Abcam 1:4000 IF 
Brca1 (GH118) Mouse gift from Jos Jonkers  neat IF/WB 
CtIP (AC-R0192-1) Rabbit Millipore 1:2000 WB 
Cyclin A (ab38) Mouse Abcam 1:1000 IF/WB 
FANCD2 (NB100-182) Rabbit Novus 1:2000 IF/WB 
Flag-tag (M2, F3165) Mouse Sigma 1:4000 WB 
GAPDH (ab8245) Mouse Abcam 1:2000 WB 





Rabbit Sigma 1:1000 WB 
Histone 4 (ab10158) Rabbit Abcam 1:5000 WB 
Hoechst (94403) N/A Sigma 1:20000 IF 
Rad51 (H-92, sc-8349) Rabbit Santa Cruz 1:1000 IF 
Ubiquitin (P4D1, sc-8017) Mouse Santa Cruz 1:2000 WB 
Table 2.4 – Secondary antibodies 
Secondary antibody Animal Supplier Dilution IF/WB 
Goat anti-Mouse Alexa Fluor 555 Goat Life technologies 1:2000 IF 
Goat anti-Rabbit Alexa Fluor 488 Goat Life technologies 1:2000 IF 
Donkey anti-Mouse Alexa Fluor 488 Donkey Life technologies 1:2000 IF 
Donkey anti-Rabbit Alexa Fluor 555 Donkey Life technologies 1:2000 IF 
Rabbit anti-Mouse HRP Rabbit DAKO 1:5000 WB 
Swine anti-Rabbit HRP  Swine DAKO 1:5000 WB 
2.5 Buffers 
LB broth – 10g LB broth powder (Sigma) in 500ml H2O 
LB agar – 1 LB agar capsule (Thermo Fisher) in 500ml H2O 
50x TAE buffer – 2M Tris base, 17.5% acetic acid (Glacial), 10% 0.5M EDTA pH8 
Urea buffer – 0.25M Tris pH6.8, 8% SDS, 40% Glycerol, 6M Urea, 10% β-mecaptoethanol 
PBS – 1 PBS tablet (Sigma) in 200ml H2O 
SDS running buffer – 10% 10x Tris/Glycine/SDS in 90% H2O 
Transfer buffer – 10% 10x Tris/Glycine, 10% methanol, 80% H2O 
Lysis buffer – 50mM sodium phosphate pH7, 300mM sodium chloride, 5% glycerol, 10mM β-
mercaptoethanol 
Wash buffer – 50mM sodium phosphate pH7, 300mM sodium chloride, 5% glycerol, 10mM 
β-mercaptoethanol, 50mM imidazole 
Dialysis buffer – 25mM Tris-HCl pH7.5, 10% glycerol, 2mM DTT, 150mM potassium chloride 
10x Ubiquitin ligase buffer – 0.5M Tris-HCl pH7.5, 50mM magnesium chloride, 5mM DTT 
4x SDS sample loading buffer – 0.25M Tris pH6.8, 8% SDS, 40% Glycerol, 6M Urea, 10% β-
mecaptoethanol, dyes to colour desired 
Cell fractionation buffer 1 – 50mM Hepes-KOH pH7.5, 140mM sodium chloride, 1mM EDTA, 
10% glycerol, 0.5% NP40, 0.25% Triton X 
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Cell fractionation buffer 2 – 10mM Tris-HCl pH8, 200mM sodium chloride, 1mM EDTA, 
0.5mM EGTA 
Cell fractionation buffer 3 – 10mM Tris-HCl pH8, 100mM sodium chloride, 1mM EDTA, 
0.5mM EGTA, 0.1% Na-Deoxycholate, 0.5% N-Lauroylsarcosine 
Crystal Violet stain – 0.5% Crystal Violet, 50% Methanol, 49.5% H2O 
 
Methods 
2.6 Bioinformatic techniques 
2.6.1 Sequence retrieval and alignments 
Gene and protein sequences were taken from Ensembl (Cunningham et al., 2015) and 
aligned using BLAST (Camacho et al., 2009).  
2.6.2 Molecular structure alignment 
1JM7 is the solution structure of human BRCA1:BARD1 RING domain heterodimers (Brzovic 
et al., 2001b). This structure and SWISS-MODEL (Biasini et al., 2014) was used to thread the 
mouse Brca1:Bard1 RING domain sequences to predict the structure used in this thesis. 2C4P 
is the crystal structure of human ubiquitin-conjugating enzyme UbcH5a (Dodd et al., 2004) 
and it was used to map on the E2 predicted binding surface onto Brca1:Bard1. SWISS Pdb-
Viewer was used to visualise and manipulate molecular structures (Guex and Peitsch, 1997).  
2.6.3 Measuring WB protein band density 
Using ImageJ (Schneider et al., 2012), protein band from scanned western blot films were 
measured for density. The area of these plotted density peaks from these bands was 
measured and used to correlate to the amount of protein detected by the antibody on the 
western blot.  
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2.7 Molecular Biology 
2.7.1 Bacterial transformations 
For DNA production, performed under sterile conditions, 10µl of Escherichia coli DH5α 
(Bioline) was pipetted into pre-chilled Eppendorf’s alongside 1-50ng of the desired DNA 
plasmid. These were incubated on ice for 15 minutes and heat shocked for 30 seconds at 
42°C. Eppendorf’s were placed on ice for 2 minutes before 100µl of Luria Bertani (LB) was 
added to the tube and gentle mixed through flicking. These cultures were placed into a 37°C 
incubator for 45-60 minutes. The cultures were next spread onto LB agar plates containing 
the relevant antibiotics and incubated overnight at 37°C. This thesis utilises vectors with 
either Ampicillin or Kanamycin antibiotic resistance, and LB agar plates contain either 
50µg/ml of Ampicillin or Kanamycin.  
For protein production culture under sterile conditions, 5-10µl of Escherichia coli BL21 (DE3) 
were placed in a pre-chilled Eppendorf alongside 100ng of the desired protein producing 
vector. This remained on ice for 20-40 minutes before exposing the Eppendorf to 42°C for 45 
seconds. This is returned to ice for 2 minutes prior to 100µl of LB is added to the tube and 
flicked to mix. The tube was incubated for 45 minutes (or overnight for two vectors) and 
spread onto LB agar plates with the correct antibiotic(s) matching the antibiotic resistance 
gene in the DNA vector(s).  
2.7.2 Plasmid DNA preparation 
Half of a single bacterial colony was picked from the LB antibiotic agar plate and placed into 
either a 5ml (Miniprep), 20-100ml (Midiprep) or 500-1000ml (Maxiprep) of LB with 50µg/ml 
of the antibiotic matching the antibiotic resistance gene in the DNA vector. This culture was 
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incubated overnight at 37°C. Using a centrifuge, the bacterial was separated from the LB by 
spinning at 3000rpm for 30 minutes. DNA was extracted from the bacterial pellet using 
GeneJET Miniprep, Midiprep or Maxiprep kits (ThermoFisher) following the manufacturer’s 
protocol.  
2.7.3 Quantification of nucleic acids 
DNA quantification was performed using ND-1000 software and a Labtech 
Spectrophotometer. dH2O or TE buffer (GeneJET kit, ThermoFisher) was used as a blank 
measurement.  
2.7.4 PCR mutagenesis 
PCR was used to amplify and mutate DNA vectors using primers that contained a mutation 
directed to a specific site in the vectors gene. dNTPs (Bioline) and Pfu DNA polymerase 
(Thermo) were used using the following recipe (Table 2.1) and PCR programme (Table 2.2) 
for PCR mutagenesis.  
Table 2.5 – PCR mutagenesis DNA polymerase mastermix 
Ingredient Stock concentration Final concentration Volume in 50μl 
DNA variable 1ng - 
Pfu buffer 10x 1x 5μl 
dNTPs 10mM 200μM 1μl 
PfU 2.5 Units/μl 2.5 Units 0.5μl 
Forward primer 20μM 0.8μM 2μl 
Reverse primer 20μM 0.8μM 2μl 
dH2O - - made up to 50μl 
Table 2.6 – PCR mutagenesis amplification programme 
Step Temperature (°C) Time Cycles 
Starting denaturing 98 2 minutes 1 
Denaturing 98 1 minute 18 
Annealing of primers 65 30 seconds 18 
Extension of DNA 72 10 minutes 18 
Finalising extension 72 5 minutes 1 
Hold 4 ∞ - 
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PCR programme times in table 2.2 were adjusted to 5°C less than the lowest optimum 
annealing temperature for the primers and the length of the DNA vector.  
2.7.5 Restriction enzyme digest 
DNA vector solutions that were subject to mutation through PCR mutagenesis were treated 
with Dpn1 restriction enzyme. 2µl of Dpn1 restriction enzyme was added to 25µl of PCR 
mutagenesis solution (50µl total) and stored at 37°C for 1 hour. 10µl of both the Dpn1 treated 
and untreated were run on a DNA electrophoresis gel.  
Mouse genotyping samples that were amplified using the Brca1 C61G loci primers were 
treated with EcoNI restriction enzyme for 1 hour at 37°C. Some samples were exposed to 
65°C for 20 minutes to stop the EcoNI enzyme action. 10µl of the untreated and EcoNI 
treated samples were run on a DNA electrophoresis gel to separate and visualise the DNA 
bands.  
2.7.6 Agarose gel electrophoresis 
DNA electrophoresis gels were made with 2% agarose gel for separating mouse genotyping 
samples and 1% for PCR mutagenesis DNA vector samples. Agarose gels were made with 
agarose, 1x TAE buffer and a 1:100,000 dilution of ethidium bromide (final concentration 
0.1μg/ml). Bioline HyperLadders 100bp or 1kb were used to measure the length of the DNA 
bands produced. 10µl of sample and 2µl of loading buffer (QIAGEN) (5µl of DNA ladder was 
loaded) were run on either the 2% agarose gel for 45 minutes at 110V or the 1% gel for 120V 




2.7.7 DNA sequencing 
PCR mutagenesis samples were sequenced to confirm the desired mutation by diluting the 
sample to 10ng/µl and sent to be used with T7 forward and reverse primers to Source 
Biosciences. Source Bioscience use Sanger sequencing and the results were analysed using 
SeqMan software.  
2.8 Protein methods  
2.8.1 Bradford assay 
Cells were harvested in 8M urea buffer (without dye) and sonicated using the Misonix 
Microson ultrasonic cell disruptor XL2000). The typical sonication treatment for a 200μl 
sample was using ~6 watts for 40 second, repeated twice with a wait step on ice in between 
sonication but the treatment depended on the viscosity and volume of the protein solution. 
Part of the sonicated protein extract was diluted 1 in 10 and 10µl were added to wells in a 
clear 96 well plate in triplicate. A range of known BSA (Bovine Serum Albinum) standards 
were also added to wells in triplicate to measure alongside the experimental samples. 200µl 
of Bradford reagent (Sigma) was added to each well. This plate was read at 595nm on a 
Victor plate reader. The approximate concentration of protein in each experimental sample 
was estimated using the reading from the known BSA concentrations. The triplicates were 
averaged and this was used for dilution so that all samples could be equally loaded onto a 
Western blot.  
2.8.2 SDS Polyacrylamide Gel Electrophoresis (SDS PAGE) 
Polyacrylamide gels were made using Bio-Rad gel casting equipment using the following 
recipe table (Table 2.3). Both 6% and 15% acrylamide gels were topped with a 5% stacking 
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gel. Resolving gels were covered in water-saturated isobutanol to set and then removed, 
before the stacking gel was added with a well comb.  
Table 2.7 – SDS Polyacrylamide gel recipes 
Ingredient (ml) Resolving gel Stacking gel  
6% 15% 5% 
dH2O 8.5 3.7 2.7 
30% polyacrylamide mix 3.2 8 0.67 
1.5M Tris pH8.8 4 4 - 
1.0M Tris pH6.8 - - 0.5 
10% SDS 0.16 0.16 0.04 
10% APS 0.16 0.16 0.04 
TEMED 0.016 0.016 0.004 
Total volume 16ml 16ml 4ml 
Once polyacrylamide gels were set they were placed in corresponding Bio-Rad tanks with 
another gel or a buffer holding plate. The space between the gels and the tanks were then 
filled with 1x SDS Running buffer before samples were loaded alongside 10µl PageRuler Plus 
Prestained Protein Ladder.  
Ubiquitin ligase assay samples were run on either a 15% gel or a Novex 4-20% Tris-Glycine 
Mini Protein Gel and run for 90 minutes at 150V. All other protein lysates were run on a 6% 
or 15% gel depending on the size of protein that was being blotted. They were run at either 
90 or 120V for varying times depending on the size of desired protein. Gels were Western 
blotted. 
2.8.3 Western blotting 
Protein samples run on SDS PAGE gels were transferred into membrane (PVDF immobillon) 
using electrophoresis. The transfer cassettes were set up with transfer buffer soaked 
sponges and 3mm filter paper. Methanol was used to activate the membrane and washed 
with transfer buffer before being place onto the SDS PAGE gel. The gel/membrane was 
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placed onto the prepared cassette, the loaded cassette was put into the transfer tank and 
filled with 1x transfer buffer. This was run at either 90 volts for 90 minutes to blot for Brca1 
and FANCD2, or at 100 volts for an hour for all other proteins. The membrane with proteins 
bound was placed into 5% milk (Marvel) made with 0.1% Tween in PBS (PBST) for 1 hour to 
block. The membrane was washed with PBST 3 times for 5-10 minutes and then placed into 
the primary antibody (Table 2.10). The membrane was washed in the same manner as 
before and after being placed in secondary antibodies conjugated with HRP (or two 
consecutive secondary antibodies for Brca1) (Table 2.11). Once washed the membrane was 
exposed to an ECL mix (either ECL Prime Western Blotting Detection Reagent, Amersham, or 
Clarity Western ECL Blotting substrate (Bio-Rad). X-ray film (Fuji X-ray film, Fisher Scientific) 
was exposed to the membrane for varying lengths of time and developed using a Xograph 
Compact X4 developer.  
2.8.4 Protein expression 
Transformed bacterial colonies with the desired protein expression vector(s) were picked 
from agar plates and placed into 50ml LB broth containing the corresponding antibody 
(concentrations of antibody stated in 2.2.1) to the vector(s). This was left overnight at 37°C. 
In the morning, 1ml of the culture was taken and added in a 1:1 ratio with 80% glycerol to 
create a 40% glycerol stock of the desired colony, to be stored at -80°C. This glycerol stock 
was then be used to pick from instead of an agar plate. The remaining culture was added to 
1 litre of LB broth with the correct antibiotics and placed at 37% for 1-2 hours to grow. After 
this time, IPTG (200mM final concentration) was added to induce the bacterial to produce 
protein and incubated overnight at 25°C in a shaking incubator. 
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2.8.5 His-tag protein isolation 
The protein expressing bacterial culture (Section 2.2.1) was centrifuged at 300rpm for 15 
minutes and the supernatant removed. The pellet of bacteria was suspended and lysed using 
Lysis buffer and left on ice for 2 minutes. The lysed bacteria was sonicated twice for 40 
seconds on 20% intensity with a rest step on ice in between sonications. This lysate was 
centrifuged for 15 minutes at 13000rpm to pellet the cell debris before adding the 
supernatant to 500µl of Nickel beads (Qiagen). This was rotated at 4°C overnight. The beads 
were washed three times using ice-cold Wash buffer for 10 minutes at 4°C. The beads were 
pelleted between washes and after the final wash. The supernatant was removed and 
replaced with 400µl of ice-cold Lysis buffer with 500mM of Imidazole and placed on ice for 1 
hour. The beads were pelleted by centrifuge for 2 minutes at 1000rpm. The supernatant was 
placed into a dialysis column and placed in Dialysis buffer at 4°C overnight. The protein 
solutions were aliquoted and stored at -80°C.  
2.8.6 Ubiquitin ligase activity assay 
Purified E3 enzyme (or E3 heterodimer as is BRCA1 and BARD1) and any experimental 
mutated E3 enzyme were diluted to equal concentrations and 10μl was added into two 
tubes (two tubes to each purified enzyme). The first tube of each had 10μl of ubiquitin ligase 
buffer (Section 2.11) added to it, and the second tube had 10μl of Ubiquitin ligase mix (Table 
2.4) added to it. This was timed with 15 second intervals until all tubes had contained 20μl of 
solution. Samples were kept at 37°C for 30 minutes, at which time (with 15 second intervals 
and in the same order) 10μl of pre-warmed SDS sample loading buffer was added to stop the 
reaction. These were kept at 95°C for 5 minutes before loading onto a SDS PAGE gel for 
Western blotting.  
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Table 2.8 – Ubiquitin ligase mix  
Stock Final 
concentration 
Volume per reaction (μl)  
ATP 100mM 10mM 1  
E1 enzyme 400μl/ml 10μl/ml 1  
E2 enzyme 1.25μl/ml 0.25μl/ml 1  
Ubiquitin 2.5μl/ml 0.0125μl/ml 0.5  
Ubiquitin ligase buffer 10x 1x 1  
dH2O - - 5.5     
10μl total  
2.9 Cell Biology 
2.9.1 Tissue culture 
Primary MEFs were kept in 1% gelatin-coated flasks and dishes until immortalised. MEFs 
were grown in DMEM (Dulbeccos Modified Eagle Medium) with 1% Penicillin/Streptomycin 
and 10% FBS (Fetal Bovine Serum). The NIH3T3 cell line was kept in DMEM with 1% 
Penicillin/Streptomycin and 10% NBCS (New Born Calf Serum). They were incubated at 37°C 
with 5% CO2 in Corning Flasks (T25/T75/T150). Cells were passaged when 70-80% confluent 
using 1xTrypsin/EDTA, and resuspended in media. The percentage of cell-suspended media 
was transferred to a new flask depended on the size of flask or dish they were going to grow 
in.  
2.9.2 Thawing cells 
Frozen cell aliquots were placed into a 37°C water bath. Once thawed, they were 
immediately transferred into a 15ml tube and gently resuspended with 5ml of pre-warmed 
media. Cells were spun at 1400rpm for 5 minutes and the supernatant was removed. Again, 
the cell pellet was resuspended gently in 5ml of pre-warmed media and pipetted into a T25 
flask (Corning). The cells were placed into the cell culture incubator to settle.  
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2.9.3 Freezing cells 
Trypsinised cells from a 90% confluent flask were spun down at 1500rpm for 5 minutes. The 
pellet was resuspended in freezing medium (80% FCS:20% DMSO or 80% NBCS:20% DMSO) 
allowing 1ml for each cryovial. The cryovials were placed in an isopropanol freezing box and 
placed at -80°C for 24 hours, before being transferred to liquid nitrogen for long storage. 
2.9.4 Isolation of MEFs 
Female mice that were pregnant at embryonic day 14.5 (E14.5) were euthanized using a CO2 
euthanasia chamber. The pregnant female was dissected using a laparotomy surgery, her 
uterine horn was excised and each embryo was dissected out of the horn. The embryos were 
washed in 1xPBS and all tissues from the mother were removed. Embryos were placed in 
individual 10cm petri dishes and macerated with forceps and scalpels as small as possible. 
These cells were collected in PBS and spun at 1000rpm for 3 minutes, the supernatant was 
discarded and the pellet of cells was resuspended in 1xTrypsin for 5 minutes at 37°C. The 
cells were centrifuged at 1500rpm for 3 minutes and the supernatant was discarded. Fresh 
media (supplemented DMEM) was used to resuspend cells and they were placed in a 10cm 
petri dish coated in 1% gelatin. This was considered passage 0 and cells were labelled with 
their embryo number. Whilst passaging these fast growing MEFs, cells were taken in passage 
1 for DNA isolation and genotyping. MEFs were kept in the same conditions and in the same 
media as stated in section 2.4.1.  
2.9.5 Immortalisation of MEFs 
MEF (passage 2) cells were plated at three varying densities (2, 2 or 3 x105 cells) in a gelatin 
(1% gelatin in sterile H2O) -coated 6-well dish and left to grow overnight. 7μg of SV40 Large T 
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antigen vector (pBsSVD2005, AdGene) was transfected into each 6-well containing the MEFs 
using Lipofectamine LTX reagent and PLUS reagent (ThermoFisher) as per manufacturer’s 
instructions. The media was replaced 16 hours after treatment and cells were passaged 
when they became confluent.  
Once cells had senesced, they were no longer passaged and media was replaced every other 
day. Once the cells started to grow again and changed morphology, passaging resumed as a 
normal immortal cell line.  
2.9.6 Cell fractionation 
Trypinised cells were pelleted before being gently suspended in 200μl of Cell Fractionation 
Lysis Buffer 1 (CFLB1) and kept on ice for 10 minutes. Cells were centrifuged at 4000rpm for 
1 minute to pellet the nuclei and the supernatant was kept as the cytoplasmic fraction. The 
nuclei pellet was resuspended gently in 200μl of CFLB2 and kept at room temperature for 10 
minutes. The nuclei mix was centrifuged at 4000rpm for 1 minute and the supernatant 
discarded. The remaining pellet was resuspended in 200μl of ice-cold CFLB3. This is the 
nuclear fraction and was sonicated (~4 watts for 30 seconds with a minute wait step on ice in 
between the two sonications) before run on an SDS PAGE gel and western blotted.  
2.9.7 Immunofluorescent staining 
Cells (approximately 2x104) were grown in each 24-well, with a coverslip overnight. Cells 
were untreated or treated depending on the experiment. Cells to be stained for 
Brca1/γH2AX and 53bp1/γH2AX were treated with 4% PFA for 10 minutes, 1 hour after 
treatment with 5 Gray IR. They were permeablised with 0.5% Triton/PBS solution for 5 
minutes before washing with PBS and storing in PBS. Cells to be stained for FANCD2 were 
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permeablised and fixed after being treated with 250ng/ml of MMC for 24 hours (no release 
from MMC). These cells were first pre-extracted with 0.2% Triton/PBS for 2 minutes before 
being fixed with 4% PFA for 10 minutes. These cells were further extracted using 0.5% 
Triton/PBS for 5 minutes before washing with and stored in PBS. Cells to be stained with 
Rad51/Cyclin A were fixed at 4 hours after 5 Gray IR or at the 24 hour time point of 250ng/µl 
MMC treatment. Cells were fixed in 4% PFA for 10 minutes, before being treated with -20°C 
Methanol and kept at -20°C for 10 minutes. After this permeabilisation cells were washed 
with PBS and stored in PBS. Cells were stored for up to three days before the antibodies 
were applied.  
Prepared cells in PBS were washed with PBS/FCS (80% 1xPBS:20% FCS) before blocking in 
PBS/FCS for 5-30 minutes. Primary and secondary antibodies (Table 2.10/11) were made up 
to specified dilution (unless neat) in PBS/FCS. Cells were incubated with primary antibody 
solutions from 1 hour to overnight at 4°C. Before the secondary antibody solution was added 
to cells, the cells were washed with PBC/FCS 3 times. The secondary antibodies were 
conjugated to a be excited at specific wavelengths for visualisation, and to prevent weak 
signals cells were kept in the dark at 4°C whist being were treated with secondary 
antibodies. After secondary antibodies were left on for 1-2 hours, the cells were washed 
three times with PBS and treated with 4% PFA for 10 minutes. Cells were washed with PBS 
and treated with Hoechst (Table 2.10) for 3 minutes before again washing in PBS. The cells 
were stored in PBS in the dark at 4°C until they could be mounted onto slides.  
Slides were mounted in Immunomounting media (DAKO) and kept in the dark at 4°C until 
visualised with a microscope.  
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2.9.8 Colony survival assays 
Cells were plated in 6 well dishes with 20,000 cells in each well and grown overnight in the 
tissue culture incubator. Cells were treated with the specific drugs or irradiated, the next day 
(Table 2.5). After treatment cells were washed and trypsinised to be re-plated at 2 cell 
densities (two plates of each density) (Table 2.6). Re-plated cells were kept in an incubator 
for either 10 or 14 days (Brca1 C61G MEFs – 10 days, Brca1 Δ11 MEFs – 14 days) before 
fixing and staining with Crystal violet. This was washed off with PBS and dried before 
counting the number of colonies. The number of untreated colonies was used to measure 
the survival of treated cells.  
Table 2.9 – Colony assay treatments 
Treatment Doses Treatment length 
Ionising radiation (IR) 1, 3, 5, 8 Gray n/a 
Cisplatin 5,10, 20, 30 μM 1 hour 
Camptothecin (CPT) 20, 40, 80, 100 μM 16 hours 
Hydroxyurea (HU) 0.2, 0.4, 0.8, 1 mM 16 hours 
Olaparib 2, 4, 10, 20 μM 90 minutes 
Veliparib 2, 4, 10, 20 μM 90 minutes 
Table 2.10 – Colony assay plated cell numbers 
Drug Number of cells used in duplicate at each dose 
Gray Untreated 1 3 5 8 
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Veliparib 100x4 100x4 100x4 100x2, 
200x2 
100x2, 200x2 
2.10 Mouse breeding and dissection 
2.10.1 Mice creation 
2.10.1.1 Brca1 C61G mice 
The Brca1 C61G allele in mice was created by Drost et al and the mutation in the 61st codon 
of TGT to GGT substituted a glycine to a cysteine (Figure 2.1a) in the targeting vector (Drost 
et al., 2011). It also created an EcoNI restriction enzyme cut site due to the nucleotide 
change. The targeting vector, which contained the Brca1 region spanning exon 3 and exon 5, 
was electroporated into mouse embryonic stem cells (ES cells) where it recombined within 




Figure 2.1 – The creation of the Brca1 C61G allele 
[a] shows the nucleotide sequences of the region surrounding the 61st codon, of the wild-type 
(Brca1+) and the mutated allele (Brca1C61G). It shows in red the change T>G that causes the 
cysteine, the 61st amino acid, to become a glycine. It also shows the EcoNI cut site created by 
this nucleotide change. Alternate codons are shown in black and grey. [b] shows the cloning 
strategy used by Drost et al (2), to create the Brca1 C61G allele in mice. The targeting vector 
(purple) contained exons 3 and 5 and a neomycin gene (green arrow) flanked by 2 LoxP sites 
(yellow arrowheads). Cells successfully identified as having the target vector recombined into 
the genomic DNA (blue) were treated with Cre recombinase which removed the Neomycin 




flanking the neomycin gene which was used for selection of successful recombination. The 
neomycin gene and one of the Lox P sites were removed from the genome by treatment 
with Cre recombinase. This left the Brca1 C61G allele that contains the C61G mutation, the 
EcoNI cut site and a remaining LoxP site. 
2.10.1.2 53bp1-null mice 
The 53bp1-null mice were created by Ward et al, by removing exon 5 of 53bp1 using the 
BamH1 and Xho restriction enzymes (Figure 4.1c) (Ward et al., 2003a). This was replaced by 
a neomycin gene and this gene was used for selection of successful creation of the 53bp1-
null allele.  
2.10.2 Mouse breeding 
The mice were bred on the University of Birmingham BMSU licence (Caroline Chadwick 
breeding licence (70/8198)) and all practices complied with the Home Office Animal 
(Scientific Proceedures) Act 1986. Mice were monitored daily by fully trained staff of the 
BMSU who maintain the breeding colonies to the standards of the Home Office guidelines. 
Mice were culled by neck dislocation or CO2 euthanasia chamber if found to be showing 
signs of pain, distress, discomfort or any signs of morbidity (or if at the time limits of the 
project licence). My personal licence (PIL) is 70/25120. 
Timed matings were set up through members of the animal house who separated the 
specific animals from the colony. These animal were placed in a cage together and observed 
for the presence of a vaginal plug, once this was seen the stud male was removed from the 
cage. This would allow for the taking of MEFs at embryonic day 14.5 (E14.5).  
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Colony breeding for multiplying numbers or for setting up the breeding crosses to test 
fertility, were set up by placing the mice of the desired genotype in a new cage (now the 
breeding cage) and allowed to breed unmanaged (i.e. they were not watched for the 
presence of a vaginal plug and the male was not removed from cage). Litters born to these 
mice were sexed and had ear clipping taken at approximately two weeks old. The ear 
clippings were used to isolate DNA for genotyping. At three weeks, the mice were weaned 
and placed in segregated male or female cages. Mice were monitored by the animal house 
staff and all procedures and care upheld Home Office regulations and recommended 
practice.  
2.10.3 Mouse Genotyping methods 
Ear clippings were taken at 2 weeks from the offspring of mated mice and DNA was isolated 
from these samples. The DNA was isolated using DirectPCR Lysis Reagent (Mouse Tail) 
(Viagen Biotech) using their recommended protocol (25:1 ratio buffer to Proteinase K).  
The remaining LoxP site in the Brca1 C61G mouse gene and EcoNI site created by the T>G 
nucleotide change have allowed two ways of PCR genotyping using either of these molecular 
signatures. The first strategy used PCR primers in Brca1 intron 4 that are either side of the 
LoxP site, creating either an approximately 200 (wild-type allele) or 300 (C61G allele) base 
pair (bp) DNA product and this size increase allowed for differentiation between the alleles 
(Figure 2.1a and figure 4.1a and b). The second strategy used PCR primers in Brca1 that span 
from intron 4 into exon 5 (Figure 2.1b and figure 4.1a and b). This region included codon 61 
in which the C61G mutation has been created and therefore it included the EcoNI restriction 
enzyme cut site. Once this region was amplified by PCR, the DNA product was cut by an 
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EcoNI enzyme and the resulting DNA products were examined for size to differentiate the 
alleles. If the 931 bp PCR product was uncut then it did not contain the C61G mutation and 
was wild-type. If the PCR product was cut and produced two bands of approximately 640 
and 290 bps then the allele contained the C61G mutation (Figure 2.1b). 
The 53bp1 alleles of the mice were genotyped using PCR primers that amplified across the 
exon 5 and created either a band of 465bp representing the wild-type 53bp1 allele and a 
band of 270bp representing the 53bp1 allele with exon 5 deleted and the remaining 
neomycin gene in its place (Figure 4.1c).  
All three methods of genotyping used GoTaq Green Master Mix (Promega) and the following 
PCR recipe (Table 2.6) and PCR programme (Table 2.7).  





Volume in 50μl 
DNA variable 1μg - 
GoTaq buffer 2x 1x 5μl 
Forward primer 10μM 0.4μM 2μl 
Reverse primer 10μM 0.4μM 2μl 
Middle primer (53bp1 only) 10μM 0.4μM 2μl 
dH2O - - made up to 
50μl 
Table 2.12 – Mouse genotyping PCR programme 
Step Temperature (°C) Time Cycles 
Starting denaturing 98 2 minutes 1 
Denaturing 98 1.5 minutes 35 
Annealing of primers 55 1 minutes 35 
Extension of DNA 72 30 seconds 35 
Finalising extension 72 5 minutes 1 
Hold 4 ∞ - 
The resulting PCR products were run on a 1% agarose electrophoresis gel (Section 2.2.6) to 
separate the PCR products by size for genotyping. 
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2.10.4 Mouse sterility 
Mice were set up according to normal breeding cross procedure and the lack of litters after 3 
months was assumed to be due to infertility (all genotype crosses except this including male 
53bp1-/-Brca1C61G/C61G mice produced offspring in this time). 4 male 53bp1-/-Brca1C61G/C61G 
mice were placed with proven fertile-genotype females and none produced offspring.  
Male littermates with varying genotypes were dissected at a range of ages and their testes 
examined and compared. These were dissected as in 2.2.5, 8 males of each genotype were 
dissected; the organs from half of each genotype were formalin (4%) fixed and stored at 4°C 
and the other half of mice had their organs frozen in liquid nitrogen and stored at -80.  
2.10.5 Dissection 
Mice were culled using a CO2 Euthanasia chamber or through neck dislocation and the Home 
Office regulated procedure. Mice were dissected through a laparotomy surgical cut and the 
following organs were examined and formalin fixed; intestines, spleen, stomach, liver, 
ovaries and uterine horn or testes and seminiferous tubules, kidneys, lungs, heart and 
thymus. During dissection other organs were examined for any other abnormalities but not 
taken unless abnormal, such as mammary glands, lymph nodes and skin. All tissues were 
fixed in 4% formalin solution and stored at 4°C.  
2.10.6 Tumour histology 
Fixed tumours were kept in formalin and sent to HistologiX, an independent 
immunohistochemistry and contract histology laboratory (Nottingham, UK), where they 
were embedded in wax and sectioned. Slides were stained with H&E and imaged. Images, 
tissues and slides were returned alongside a report from their pathologist (David Fairley, 
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human and mouse tissue pathologist). This report identified which abnormal organs were 
cancerous and the likely type of tumour, or what kind of abnormality if not cancer.  
2.11 Statistics 
All results that were tested were between means from two genotypes to see if there was a 
significant difference between genotypes response in the experiment. Mean results are the 
average of at least three repeated experiment means, of which each experiment had 3 or 
more individual repeats. Any outliers were eliminated only when they met the criteria after a 
Grubbs test. A Type 2 two-tailed student t-test was used as the means are from two non-
paired normally distributed samples.  
Kaplan-Meier statistical method was used to assess the survival analysis/tumour formation 




Chapter 3 – The BRCA1 RING domain is highly conserved and its 
ubiquitin ligase activity is comparable between mice and humans. 
3.1 Introduction 
Mouse models provide an invaluable platform for exploring genetic diseases and are 
essential for the development of therapies. Mice are a genetically alterable mammal that 
has a short life span and can be kept in a relatively small space. This allows for large numbers 
of mice in each study and the duration of the study to be short. Mice are also easy to treat 
with therapies and since they age quicker, there is more potential to identify any long-term 
effects of treatments.  
There have been many mouse models created to look at breast cancer and to look at the 
progression of disease when the Brca1 gene is mutated. As discussed in section 1.5, many 
homozygote mutations in Brca1 are embryonic lethal or cause tumourigenesis (Figure 1.8) 
suggesting Brca1 is needed for embryonic development and genome integrity. 
The desired reproduction of a human disease in the mouse is not always achieved and this 
can be due to the differences between mice and humans. For example, the affected protein 
may have a different role, interact with different protein pathways, or have a different 
catalytic rate in mice compared to humans. Therefore it is important to start by identifying 
the similarities and differences between mouse and human BRCA1 protein. 
BRCA1’s most prominent features include a RING domain at its N-terminus and two BRCT 
domains at the C-terminus (Figure 1.2). The N-terminal RING domain of BRCA1 forms a 
heterodimer with the N-terminal RING domain of BARD1 (Figure 1.4) (Hashizume et al., 
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2001; Morris et al., 2002; Wu et al., 1996), and this interaction is crucial for the stability of 
BRCA1 (Brzovic et al., 2003; Hashizume et al., 2001; Joukov et al., 2001) (see section 1.3). 
The N-terminal RING domain of BRCA1 and the formation of the BRCA1:BARD1 heterodimer 
is essential for the only known catalytic function of BRCA1, its E3 ubiquitin ligase activity 
(Chen et al., 2002; Hashizume et al., 2001). BARD1 is not currently recognised (in the 
literature, Morris lab results suggest otherwise) to have any contribution in the production 
of polyubiquitin chains aside from aiding BRCA1 stability (Brzovic et al., 2003; Hashizume et 
al., 2001; Joukov et al., 2001). BARD1 has 2 tandem BRCT domains at the C-terminus, as does 
BRCA1, and the BRCT domains in both BRCA1 and BARD1 enable the heterodimer complex 
to be recruited into the nucleus and to sites of double-strand breaks (DSBs) (Chen et al., 
2006; Fabbro et al., 2002; Kim et al., 2007b; Liu et al., 2007b; Rodriguez et al., 2004; Sobhian 
et al., 2007; Wang et al., 2007; Wang and Elledge, 2007).  
The importance of BRCA1’s E3 ubiquitin ligase function in the development of cancer is 
controversial and the role of the E3 ubiquitin ligase function in cells is not understood 
(Section 1.3.3). As discussed in the introduction (Section 1.2.1-2), there are BRCA1 N-
terminal missense mutations found in patients that correlate with cancer incidence and this 
implies there is a role for the N-terminus RING domain in tumour suppression. However it is 
not known whether it is the alteration of the catalytic activity of BRCA1 that is the driver 
behind this tumourigenesis.  
This chapter will start by comparing the amino acid sequences between mouse and human 
BRCA1 and BARD1 RING domains to identify any significant differences that could affect the 
ubiquitin ligase function of the heterodimer. Finally, the ability of the wild-type and mutated 
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mouse N-terminal Brca1:Bard1 heterodimer to replicate the rate of in vitro polyubiquitin 
chain formation of the human N-terminal BRCA1:BARD1 heterodimer will be assessed.  
3.2 Mouse and human BRCA1 have a conserved N-terminal RING domain 
Human BRCA1 is located on the reverse strand of chromosome 17 and mouse Brca1 is 
located on the reverse strand of chromosome 11 (Table 3.1). Human BRCA1 is longer than 
mouse Brca1 but they have the same number of exons (Table 3.1). At a nucleotide level, 
mouse Brca1 has a similarity of 75.22% (Clustal 2.1) to human BRCA1 and they are 56% 
identical in their amino acid transcript. The N-terminal RING domain (aa1-103) in BRCA1 is 
83.5% identical in mice to humans (Figure 3.1a).  
Table 3.1 – BRCA1 gene and protein comparison between mice and humans 
BRCA1 Chromosome Nucleotides Exons Amino 
acids 
Human 17 7094 24 1863 
Mouse 11 6572 24 1812 
To investigate the molecular structure of mouse Brca1 and Bard1 N-terminal RING domains 
the NMR (Nuclear magnetic resonance) structure that was resolved for the human 
BRCA1:BARD1 RING domains (Brzovic et al., 2001b) (Figure 1.2 and 1.4) was used as a 
template to produce the predicted molecular structure that is used in this thesis. The RING 
domain equips BRCA1 with its ability to function as an E3 ubiquitin ligase (Chen et al., 2002). 
It is made up of two α-helices at either end of the domain and in the centre there are two 
loops that are held in position by two zinc ions and a small helix (Figure 3.1c). The zinc ions 
are held by regions of cysteine and histidine residues on the two loops and these are 




Figure 3.1 – BRCA1 N-terminal RING domain comparison between human and mouse 
protein 
ENSEMBL protein sequences and CLUSTALW2 multiple sequence alignment tool were used to 
align the human and mouse BRCA1 N-terminal RING domain protein sequences [a]. Site I and 
Site II show the residues that hold the zinc ions that maintain the RING domain structure (red 
letters). The characters depict the consensus between the residues in the alignment. The 
asterisk ‘*’ indicates a fully conserved or identical residue, the colon ‘:’ indicates residues with 
highly similar properties, the period ‘.’ indicates residues with weakly similar properties and a 
space ‘ ‘ indicates residues that lack conservation of residue properties. 
[a] shows the differences in the mouse BRCA1 RING domain amino acid sequence compared 
to human BRCA1 RING domain amino acid sequence. [b] identifies the specific residue 
differences and the predicted effect of the residue change is scored using the Grantham 
scale. [c] shows the mouse Brca1 and Bard1 RING domain heterodimer modelled on the NMR 
structure of the human BRCA1:BARD1 heterodimer. Brca1 (red) has two contacting α-helices 
with two zinc loops and a small helix making up the RING domain structure. Bard1 is shown 
in purple. Zinc ions are shown as blue spheres and the side chains of the residues that differ 
in humans are shown in blue. 
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importance for maintaining the RING domain structure. There are 17 residue differences 
between the mouse and human BRCA1 RING domain and these residues mostly have low 
impact as determined by the low Grantham score (Figure 3.1b, c)(Grantham, 1974). The 
Grantham score gives a number to the physiochemical differences between two amino acids 
which is used to indicate the degree of change when a residue is substituted (Grantham, 
1974). This conservation of the RING domain is indicative that it is an important functional 
region. 
3.3 Mouse and human BARD1 have a conserved N-terminal RING domain 
Since BRCA1 is part of a heterodimer with BARD1 and is required for the protein stability and 
N-terminal function of BRCA1 (Brzovic et al., 2003; Hashizume et al., 2001; Joukov et al., 
2001), it is important to examine the similarity between mouse and human BARD1 when 
looking at BRCA1.  
Table 3.2 – BARD1 gene and protein comparison between mice and humans 
BARD1 Chromosome Nucleotides Exons Amino 
acids 
Human 2 5499 13 777 
Mouse 11 5659 11 765 
Mouse BARD1 nucleotide sequence is 79.53% identical to human BARD1 (Clustal 2.1) and 
70% identical in amino acid sequence. The C-terminus of BARD1 contains two BRCT domains 
and there is an ankyrin repeating domain on the N-terminal side of the BRCT domains. The 
N-terminus of BARD1 contains a RING domain but this has no known E3 ubiquitin ligase 
function and is reported to be the non-catalytic partner of the heterodimer (Wu et al., 1996) 
despite the RING domain in BARD1 having a similar molecular structure to BRCA1 (Figure 




Figure 3.2 – BARD1 N-terminal RING domain comparison between human and mouse 
protein 
ENSEMBL protein sequences and CLUSTALW2 multiple sequence alignment tool were used to 
align the human and mouse BARD1 N-terminal RING domain amino acid sequences [a]. Site I 
and Site II show the residues that hold the zinc ions that maintain the RING domain structure 
(red letters). The characters depict the consensus between the residues in the alignment. The 
asterisk ‘*’ indicates a fully conserved or identical residue, the colon ‘:’ indicates residues with 
highly similar properties, the period ‘.’ indicates residues with weakly similar properties and a 
space ‘ ‘ indicates residues that lack conservation of residue properties. [a] shows the 
differences in the mouse BARD1 RING domain compared to human BARD1 RING domain 
sequence. [b] identifies the specific residue changes and the predicted effect the residue 
change is scored using the Grantham scale. [c] show the mouse Brca1 and Bard1 RING 
domain heterodimer modelled on the NMR structure of the human BRCA1:BARD1 
heterodimer. Bard1 (purple) has two contacting α-helices with two zinc loops making up the 
RING domain structure. Brca1 is shown in red. Zinc ions are shown as blue spheres and the 
side chains of the residues that differ in humans are shown in blue. 
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domain but does have two sites that hold zinc ions in place (Figure 3.2a, c). There are 15 
amino acids that are different in the mouse transcript but most have a low impact as 
determined by the Grantham Score (Figure 3.2b)(Grantham, 1974). This similarity between 
the RING domains in mice and humans is indicative of a conserved function between these 
species (Joukov et al., 2001). 
 3.4 In vitro ubiquitin ligase assay considerations 
There are several components needed to form polyubiquitin chains in an in vitro ubiquitin 
ligase assay; E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme, E3 ubiquitin 
ligase enzyme, ubiquitin and ATP (Hershko et al., 1983). The reaction also needs a substrate 
on which the ubiquitin is bound, unless the E3 ubiquitin ligase has the ability to make free 
polyubiquitin chains or self-ubiquitinate. This substrate can be a targeted protein or an 
ubiquitin moiety to form chains of polyubiquitin. E1 enzymes-activate ubiquitin and load this 
onto the E2 conjugating-enzyme (Haas and Siepmann, 1997). The conjugated ubiquitin-E2 
complex then associates with an E3 ubiquitin enzyme which transfers the ubiquitin onto a 
specific substrate forming an isopeptide bond (Pickart and Eddins, 2004).   
It is important to consider the human-to-mouse conservation of the purified enzymes that 
are being used in the in vitro ubiquitin ligase activity, as the combination of mouse and 
human proteins could alter the rate of polyubiquitin chain production. Ubiquitin is a highly 
conserved protein and is identical in humans and mice. E1 enzymes do not contact E3 
enzymes so there is no human protein-mouse protein contact. E2 enzymes do contact the E3 




Figure 3.3 – In vitro ubiquitin ligase assay using Brca1:Bard1 heterodimer produced from 
co-expression or single protein expression 
An in vitro ubiquitin ligase assay western blot probed with the ubiquitin antibody (P4D1) and 
a His-tag antibody. [a] shows the size shift in ubiquitin caused by the production of 
polyubiquitin chains in the assay. The His-tag blot [b] shows the sizes and relative amount of 
His-tagged Brca1 (aa1-300) and His-tagged Bard1 (aa26-142). The ubiquitin mix (+) contains 
ubiquitin, ATP, E1 enzyme and UbcH5a. mBr+mBa represents mouse Brca1 (mBr) and mouse 
Bard1 (mBa) N-terminal protein purified from separate cultures. mBr/mBa represents mouse 




enzyme UbcH5α was used in all in vitro ubiquitin ligase experiments in this thesis as it has 
been shown to be important for Brca1 E3 ubiquitin ligase activity in vitro (Brzovic et al., 
2003; Mallery et al., 2002). Mouse UbcH5a has 40 silent differences in its nucleotide 
sequence compared to human UbcH5a therefore the protein is identical and is predicted not 
to alter the rate of activity in an in vitro ubiquitin ligase assay. 
Mouse Brca1 and mouse Bard1 RING domain cDNA sequences have been produced in 
individual vectors with different antibiotic resistance genes. The mouse Brca1 RING domain 
sequence for protein purification consists of amino acids 1-300 and is His- and Flag-tagged 
and the vector has an ampicillin resistance gene. The mouse Bard1 RING domain for protein 
purification consists of amino acids 26-142 and is His- and HA-tagged and has a kanamycin 
resistance gene.  
When first attempting to make purified protein of the N-terminus Brca1 and Bard1, E. coli 
colonies producing either Brca1 (mBr) or Bard1 (mBa) RING domain were used and the 
resulting proteins were combined (mBr+mBa) (Figure 3.3). The resulting mix of Brca1 and 
Bard1 heterodimer did not have E3 ubiquitin ligase function. Due to the separation of Brca1 
and Bard1 RING domains in two vectors with different antibiotic resistance genes, it was 
possible to isolate E. coli colonies with both vectors by selecting with both antibiotics. These 
colonies were used to make purified Brca1/Bard1 heterodimer (mBr/mBa). This protein had 
E3 ubiquitin ligase function (Figure 3.3) suggesting that heterodimer ubiquitin ligase activity 
is dependent on translation of Brca1 and Bard1 in the same cell. Unpublished data (Morris 
lab) and the literature (Hashizume et al., 2001; Joukov et al., 2001) suggest that when BARD1 





Figure 3.4 – In vitro ubiquitin ligase assay comparing the ubiquitin ligase activity of human 
and mouse wild-type Brca1:Bard1 heterodimer 
An in vitro ubiquitin ligase assay western blot using the ubiquitin antibody (P4D1) and a His-
tag antibody. The black line indicates the removal of lanes from the blot. The ubiquitin blot 
shows the size shift caused by the production of polyubiquitin chains in the assay. The His-tag 
blots shows the sizes and relative amount of human (h) and mouse (m) His-tagged Brca1 
(aa1-300) and His-tagged Bard1 (aa26-142). The ubiquitin mix (+) contains ubiquitin, ATP, E1 




relationship is not the same for the contrary situation. The fact that only co-expressed 
Brca1:Bard1 has catalytic activity in figure 3.3 supports the idea that Bard1 stabilises Brca1. 
This highlights the need for the Brca1:Bard1 heterodimer to be formed for Brca1 stability 
and for Brca1 to function as an E3 ubiquitin ligase. 
3.5 Comparing mouse and human in vitro ubiquitin ligase activity 
Due to the differences in the human and mouse Brca1:Bard1 RING domains, it is important 
to investigate if the heterodimers from both species have the same efficiency at ligating 
polyubiquitin chains.  
An in vitro ubiquitin ligase assay using equivalent amounts of wild-type human and mouse 
Brca1 and Bard1 proteins showed that the mouse and human heterodimers make a 
comparable amount of polyubiquitin chains within 30 minutes (Figure 3.4). This suggests 
that both species heterodimers have a similar efficiency as an E3 ubiquitin ligase in vitro. 
This is important for any results that compare the human and mouse Brca1:Bard1 
heterodimer ubiquitin ligase activity in vitro and may allude to having similar activity in cells. 
3.6 BRCA1 C61G patient mutation causes a reduction in in vitro ubiquitin 
ligase activity of mouse protein 
BRCA1 C61G is a patient mutation that correlates with cancer incidence in families with 
hereditary breast and ovarian cancer (Gorski et al., 2000). It is a nucleotide mutation that 
causes a change in the 61st amino acid from a cysteine to a glycine. This residue is important 
for maintaining a zinc ion that is required for the RING domain structure (Figure 3.5 and 
3.6a) (Brzovic et al., 2001b; Brzovic et al., 2003; Joukov et al., 2001; Ruffner et al., 2001) and 
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this mutation is known to alter BRCA1:BARD1 heterodimer binding (Brzovic et al., 2003; 
Hashizume et al., 2001; Joukov et al., 2001; Morris et al., 2006; Wu et al., 1996). The BRCA1  
 
 
Figure 3.5 – Molecular modelling of Brca1 residue substitutions 
This figure shows the mutated residues used to explore the ubiquitin ligase activity were 
modelled using the predicted molecular structure of mouse Brca1:Bard1 heterodimer. Brca1 
is shown in red and Bard1 is shown in grey. Zinc ions are shown as blue spheres. C61 is shown 





Figure 3.6 – Brca1 structural models of the residue changes C61G, I26A, P62R and L82R 
The mutated residues used to explore the ubiquitin ligase activity were modelled using the 
predicted molecular structure of mouse Brca1:Bard1 heterodimer. Brca1 is shown in red and 
Bard1 is shown in purple. Zinc ions are shown as blue spheres. 
[a] show the side chain alteration of residue 61 from a cysteine to a glycine (C61G), shown in 
black. [b] show the side chain alteration of residue 26 from an isoleucine to an alanine (I26A), 
shown in blue. [c] show the side chain alteration of residue 62 from a proline to an arginine 
(P62R), shown in green. [d] show the side chain alteration of residue 82 from a leucine to an 




C61G mutation has been used in the literature as a mutation that reduces ubiquitin ligase 
activity (Brzovic et al., 2003; Hashizume et al., 2001; Mallery et al., 2002; Morris et al., 2006; 
Ruffner et al., 2001). The residue, C61, cannot be determined as directly influential to the 
ubiquitin ligase activity of BRCA1 because it cannot be separated from its necessity in the 
RING domain structure and heterodimer binding. 
I26A is also a substitution shown to reduce the ubiquitin ligase function of BRCA1 but it does 
not alter the BRCA1:BARD1 heterodimer binding (Brzovic et al., 2003). Therefore it has been 
associated with the ability to separate the functional importance of BRCA1 ubiquitin ligase 
activity and the structural importance of the BRCA1:BARD1 heterodimer binding on BRCA1 
stability. It changes the 26th amino acid from an isoleucine to an alanine (Figure 3.5 and 
3.6b) and this residue change is reported to affect the binding between BRCA1 and the E2 
conjugating enzyme (Brzovic et al., 2003).  
P62R is a substitution in the RING domain loop that does not alter the zinc binding sites. This 
substitution can show that other residues in the zinc ion loops may be functionally important 
without directly altering zinc ion binding residues. It changes a proline to an arginine at 
amino acid 62 (Figure 3.5 and 3.6c).  
L82R is a substitution at the bottom of the paired α-helices that is used to alter the binding 
between BRCA1 and BARD1. It changes a leucine to an arginine at amino acid 82 (Figure 3.5 
and 3.6d).  
The BRCA1 P62 residue was suggested to have significance in BRCA1’s interaction with the 




Figure 3.7 – Residue alterations in mouse Brca1 that reduce the formation of polyubiquitin 
chains produced by the Brca1:Bard1 heterodimer 
This figure shows an in vitro ubiquitin ligase assay western blot using the ubiquitin antibody 
(P4D1) and the Flag- and HA-tag antibodies. The ubiquitin blot shows the size shift caused by 
the production of polyubiquitin chains in the assay. The ubiquitin mix (+) contains ubiquitin, 
ATP, E1 enzyme and UbcH5a. The Flag blots show the sizes and relative amount of mouse 
Brca1 (aa1-300) and the HA blots show the sizes and relative amounts of mouse Bard1 





(Brzovic et al., 2001b). The equivalent residue of P62 in cCbl was predicted to have van de 
Waals interactions with UbcH7, an E2 conjugating enzyme (Brzovic et al., 2001b). In the 
same study, the BRCA1 L82 residue was shown to be a hydrophobic interfacing residue in 
the helices bundle that is the contact surface for BRCA1 and BARD1 (Brzovic et al., 2001b). 
Any substitution of the P62 residue is likely to reduce the stability of the RING domain 
structure and a substitution at P82 is likely to affect the strength of the binding between 
BRCA1 and BARD1. P62R and L82R were used as substitutions in a yeast-2 and yeast-3-hybrid 
experiment (unpublished data, James Beesley, Morris lab) that showed that they both 
reduced the binding between BRCA1 and BARD1, and the binding of the heterodimer to 
UbcH5a, an E2 conjugating enzyme.  
C61G, I26A, P62R, L82R are shown in their positions in the mouse Brca1:Bard1 heterodimer 
in figure 3.6. These residue alterations were made in mouse Brca1 protein to investigate in 
vitro whether they reduce the efficiency of the mouse Brca1:Bard1 heterodimer to produce 
polyubiquitin chains. Figure 3.7 shows an ubiquitin ligase assay using equivalent levels of 
Brca1 and Bard1 mouse protein that is wild-type (WT) or has the described residue 
substitutions (C61G, I26A, P62R, L82R). It shows that in comparison to wild-type Brca1 
protein, these substitutions show a reduced ability for form polyubiquitin chains and that 
these residues are essential for ubiquitin ligase activity.  
This experiment infers that these specific residues in the Brca1 RING domain, the structure 
of the Brca1 RING domain, the Brca1:Bard1 heterodimer binding and the interaction 
between Brca1 and the E2 conjugating enzyme are all essential for E3 ubiquitin ligase 
activity. However it does not identify in which way the patient mutation C61G alters the 
100 
 
ubiquitin ligase activity and it also does not infer that these substitutions would have the 
same effect on the heterodimer structure and binding, or the ubiquitin ligase activity in vivo. 
It would therefore be important to use cell-based techniques such as an 
immunoprecipitation with tagged-Brca1 to assess the ability of Bard1 to bind to Brca1 and 
whether this heterodimer complex formed in vivo would display a similar reduction in ligase 
activity.  
3.7 Bard1 variant causes a reduction in in vitro ubiquitin ligase activity of 
the mouse Brca1:Bard1 heterodimer.  
Unpublished data from Dr Ruth Densham (Morris lab) has isolated a residue change in 
human BARD1 (R99A/E) that does not affect the binding ability of the BRCA1:BARD1 
heterodimer, but does alter the in vitro ubiquitin ligase activity of the heterodimer in 
humans. The residue in human BARD1 is amino acid 99 which is an arginine, the 
corresponding residue in the mouse Bard1 protein is amino acid 93 which is also an arginine 
(Figure 3.8). This conserved arginine residue lies on the Bard1 α-helix at the front of the 
protein (Figure 3.8b-i) and the R side chain sticks out of the heterodimer complex and 
slightly towards Brca1 (Figure 3.8b-i, ii). Upon further modelling Densham et al, suggest that 
this residue would interact with the ubiquitin in a loaded ubiquitin-E2 complex as it was 
interacting with BRCA1. When the R99 residue is substituted by an alanine residue (R99A) or 
a glutamic acid residue (R99E), this alters the ubiquitin ligase activity of the BRCA1:BARD1 
heterodimer. The R99E residue replacement greatly reduces the ubiquitin ligase activity of 
the heterodimer compared to a milder reduction caused by the R99A substitution. This 




Figure 3.8 – R93/R99 residue in human and mouse Bard1 RING domain 
ENSEMBL protein sequences and CLUSTALW2 multiple sequence alignment tool were used to 
align the human and mouse BARD1 N-terminal RING domain protein sequences [a]. The 
characters depict the consensus between the residues in the alignment. The asterisk ‘*’ 
indicates a fully conserved or identical residue, the colon ‘:’ indicates residues with highly 
similar properties, the period ‘.’ indicates residues with weakly similar properties and a space 
‘ ‘ indicates residues that lack conservation of residue properties. The arginine residue at 
position 99 in humans and 93 in mice is shown in orange. Red letters show the residues that 
hold the zinc ions; site I and site II. [b] shows the R93 residue used was modelled using the 
predicted molecular structure of mouse Brca1:Bard1 heterodimer. Brca1 is shown in red and 
Bard1 is shown in purple. Zinc ions are shown as blue spheres. [b and c] shows the side 
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residue of R93 (black). [b, i] shows R93 in the Brca1:Bard1 heterodimer from the front view 
and [b, ii] shows R93 in the Brca1:Bard1 heterodimer from the left-side view, through Bard1. 
[c, i] shows a close up view of the arginine side chain of R93. [c, ii] shows the side chain 
alteration when R93 is changed to an alanine (R93A). [c, iii] shows the side chain alteration 
when R93 is changed to a glutamic acid residue (R93E).  
heterodimer and the affect caused by the R99E residue charge reverse shows the side chain 
is important for BARD’s role. A model of the R99 residue change in mouse Bard1 using the 
NMR-resolved human heterodimer, displays the physical effect changing the arginine 
residue at amino acid 93 to alanine or glutamic acid. It shows the modification of size and 
angle of the residue side chain (Figure 3.8c-i, ii, iii). The R93A change would reduce the 
amino acid side chain size dramatically which would reduce its protrusion from the 
heterodimer. The R93E change would cause the side chain to be angled in towards the 
heterodimer. Both of these changes would be predicted to alter its ability to bind to E2-
loaded ubiquitin as Densham et al suggest. Purified mouse Brca1:Bard1 heterodimer was 
made with the R93A and R93E mutation and used to perform an in vitro ubiquitin ligase 
activity assay. Equivalent levels of Bard1 wild-type, R93A and R93E protein in complex with 
wild-type Brca1, shows that the ubiquitin ligase activity of the mouse Brca1:Bard1 
heterodimer is reduced slightly by the R93A residue change and dramatically reduced, but 
not abolished, by the R93E residue change (Figure 3.9). This demonstrates that the R93 
substitution has the same effect on mouse Brca1:Bard1 heterodimer ubiquitin ligase activity 
as the human heterodimer suggesting the mechanism of Bard1 interaction with an E2-
loaded ubiquitin is likely to be conserved.  
3.8 Discussion  
This chapter has shown that the N-terminal RING domains of BRCA1 and BARD1 are highly 




Figure 3.9 – R93 residue alterations in mouse Bard1 that reduce the ubiquitin ligase 
activity of the Brca1:Bard1 heterodimer 
An in vitro ubiquitin ligase assay western blot using the ubiquitin antibody (P4D1) [a] and the 
Flag- and HA-tag antibodies [b]. [a] shows is the ubiquitin blot showing the size shift caused 
by the production of polyubiquitin chains in the assay. The ubiquitin mix (+) contains 
ubiquitin, ATP, E1 enzyme and UbcH5a. The Flag blots shows the sizes and relative amount of 
mouse Brca1 (aa1-300) and the HA blots show the sizes and relative amounts of mouse 
Bard1 (aa26-142) [b]. WT (wild-type), R93E and R93A show the mutation status of Bard1. 
The assay was loaded twice, the first lane with the neat output of the assay (1) and with 
second lane being diluted 1:1 (0.5).  
104 
 
the RING domains of Brca1 and Bard1 are both important for in vitro ubiquitin ligase activity 
of the Brca1:Bard1 heterodimer. This activity can be altered by the destabilisation of Brca1 
zinc ion loop structure (C61G and P62R), the disruption of the heterodimer binding (Brca1 
L82R), and the alteration of specific residues important for binding to ubiquitin ligase 
components (Bard1 R93A/E) or to the E2 conjugating enzyme (Brca1 I26A).  
There are several substrate suggestions onto which the ubiquitin is ligated by the 
BRCA1:BARD1 heterodimer complex (Section 1.3.1) but it is not fully understood if any of 
these are important for the tumour suppression function of BRCA1. In the in vitro ubiquitin 
ligase assay, the substrate is ubiquitin to form polyubiquitin chains or the Brca1:Bard1 
complex, i.e. autoubiquitination. It has been shown that BRCA1 is predominantly associated 
with the formation of K6-linked polyubiquitin chains (Morris and Solomon, 2004; Wu-Baer et 
al., 2003), and the cause for this specificity for chain type or specificity of what substrate on 
which these chains form is also unknown. The specificity of an E3 ubiquitin ligase for its 
substrate is suggested to be conferred by the E3 enzyme (Berndsen and Wolberger, 2014; 
Plechanovova et al., 2012) and it is the structural configuration of the ubiquitin loaded-E2, 
E3 enzyme and substrate that is suggested to induce a particular polyubiquitin chain type 
(Chen and Pickart, 1990; Hofmann and Pickart, 1999; van Nocker and Vierstra, 1991).  
This data shows that BARD1 has a role in BRCA1’s catalytic function and this suggests that 
BARD1 may also have tumour suppressive properties through this role. This could emphasise 
the importance for more widespread BARD1 sequencing in patients that have hereditary 
breast and ovarian cancer (De Brakeleers et al., 2016; Gonzalez-Hormazabal et al., 2012; 
Klonowska et al., 2015; Liu et al., 2013; Ratajska et al., 2012). These results provide more 
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information for helping to predict the effects of BRCA1 variation of unknown significance 
(VUS) (section 1.2.1) seen in patients with cancer and can help them make more informed 
choices on potential therapies and prophylactic actions (section 1.2.4).  
These results can help us predict the residues that can alter the catalytic activity of the 
Brca1:Bard1 heterodimer but it does not allude to the function of the ubiquitin ligase activity 
in a cell, or what these residue changes would alter in the molecular pathways in cells.  
The comparisons between mouse and human BRCA1 and BARD1 are crucial to 
understanding the phenotypes we see in BRCA1 mouse models and understanding the scope 
to which animal models can help with investigating BRCA1 mutations. The strong 
conservation of the RING domain and similar in vitro ubiquitin ligase activity seen in this 
chapter suggest that molecularly Brca1 and Bard1 are comparable in humans and mice. The 
only way to know if human BRCA1 patient mutations can replicate human disease is to 




Chapter 4 – The Brca1 C61G protein is degraded by the proteasome 
and is less efficient at recruiting to double-strand DNA breaks. 
4.1 Introduction 
As discussed in the introduction, BRCA1 C61G mutation is a common missense mutation 
found to correlate with a high risk of tumourigenesis in families with hereditary breast and 
ovarian cancer (Section 1.2). Many studies on the alteration of BRCA1 protein caused by the 
C61G amino acid substitution have been published and the results have been varied (see 
section 1.3.3). Unfortunately, there isn’t a human cancer cell line that contains the BRCA1 
C61G mutation available and previously BRCA1 C61G DNA vectors have been expressed in 
breast or cancer cell lines. There are several problems with this approach. Firstly, cancer cell 
lines contain multiple mutations which allow the cells to become immortal and it is difficult 
to predict if these existing mutations affect how BRCA1 or BRCA1 C61G functions. Secondly, 
normal breast cells are difficult to work with because they do not have the same 
proliferative potential as cancer cells and can be hard to transfect DNA and RNA for 
expression. Thirdly, cDNA vectors cannot always be expressed at a level that is relative to 
endogenous and therefore may not be regulated as endogenous protein.  
Despite these caveats, research into BRCA1 has shed light on the regulation and expression 
of BRCA1 protein, its localisation and degradation, and the recruitment or changing 
localisation of BRCA1 protein (Section 1.3.1). 
Genetically altering the mouse genome has greatly helped in evading some of these 
problems. The mouse genome is relatively consistent in a colony and can be altered without 
resulting mutations in unknown genes occurring. However mice can still develop 
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spontaneous gene alterations that could lead to a phenotype. Mouse embryonic fibroblasts 
(MEFs) isolated from genetically engineered embryos are highly proliferative in the first few 
passages of culture before they senesce. There are methods of immortalising MEFs using an 
alteration of a tumour suppressor gene or oncogene that allow the cells to proliferate an 
indefinite number of times, and the effects of these gene changes are well studied.  
As discussed in section 1.5, many Brca1 mouse models have been created and they have 
provided a full organism and cells in which to study the effects of a Brca1 mutation. The 
majority of homozygote Brca1 mutations are embryonic lethal (Section 1.5.1 and figure 1.8) 
and the deletion of 53bp1 from Brca1 Δ11-deleted and Brca1-null mice has been shown to 
rescue this embryonic lethality (Cao et al., 2009).  
The Brca1 C61G mutation has been genetically engineering into mice to study the specific 
effects of this common patient mutation in cells with the hope to understanding the path of 
tumourigenesis (Drost et al., 2011). Brca1 C61G homozygote mice are embryonic lethal and 
MEFs could not be isolated from the embryos (Drost et al., 2011). With the discovery that 
the depletion or deletion of the 53bp1 protein can rescue the lethality of the homozygote 
Brca1 Δ11 mutation, 53bp1-/-Brca1C61G/C61G mice were bred with 53bp1-null mice in attempt 
to rescue the embryonic lethality of these mice.  
This chapter investigates the creation of MEFs from 53bp1-/-Brca1C61G/C61G mouse embryos, 
and uses these MEFs to look at the Brca1 C61G protein in the cell. This includes the levels of 
Brca1 protein, its localisation, its degradation and the recruitment of BRCA1 protein to sites 
of DNA double-strand break repair. 
108 
 
4.2 The creation and detection of the Brca1 C61G and 53bp1-null alleles 
Dr Jo Morris created the Brca1 C61G mice which were published in Drost et al (Drost et al., 
2011). The C61G change was created in a targeting vector by genetically mutating the 61st 
codon from TGT to GGT which also created an EcoNI restriction enzyme (see Chapter 2.5.1 
and 2.5.3). This vector was then recombined into the genome and the neomycin selection 
gene was removed using Cre recombinase and flanking LoxP sites. The Brca1 C61G allele can 
be genotyped by PCR amplification using either the remaining LoxP (larger fragment) or the 
EcoNI site (ability to be cut) to separate from the wild-type allele (Figure 4.1a,b).  
Ward et al (Ward et al., 2003b) created the 53bp1-null allele by the excision of exon 5 using 
BamH1 and Xho restriction enzyme cut sites, and replacing the region with a neomycin gene 
that was used for the selection of successful clones (Figure 4.1c and section 2.5.1). The 
region that was excised was approximately 450 bps in length and the neomycin replacement 
DNA region is approximately 250 bps in length. PCR amplification over this region created a 
wild-type allele band of 465 bps and the 53bp1-null allele created a band of 270 bps (Figure 
4.1c). 
4.3 The creation of the 53bp1-/-Brca1C61G/C61G mice and cells 
As discussed in the introduction (Section 1.5.3) the homozygote 53bp1-null mice are not 
embryonic lethal (Ward et al., 2003b) and the homozygote Brca1 C61G mice are embryonic 
lethal (Drost et al., 2011), the background of all the breeding mice had to be 53bp1-null. We 
started the project by crossing 53bp1-/- mice with mice that were heterozygote for the Brca1 




Figure 4.1 – Genotyping the Brca1 and 53bp1 allele 
 [a] shows the Brca1 allele genotyping method that uses the presence of the remaining LoxP 
site in the allele to identify the Brca1 C61G allele. The black arrows represent the location of 
the forward (Fwd) and reverse (Rev) primers used to PCR this region in intron 4 of Brca1. The 
wild-type allele (blue) produces an approximately 200 base pairs DNA product after PCR and 
the insertion of the LoxP site (yellow arrowhead) causes the Brca1 C61G allele (purple) PCR 
product to be approximately 300 base pairs in length. [b] shows the genotyping method that 
uses the EcoNI cut site (red arrowhead) for recognition of the Brca1 C61G allele. The black 
arrows represent the location of the forward (Fwd) and reverse (Rev) primers used to PCR 
across this region, encompassing part of intron 4 and part of exon 5 of Brca1. The PCR 
reaction with these primers creates a DNA product of 931 base pairs. The Brca1 C61G allele 
(purple) contains an EcoNI site which is cut when treated with EcoNI restriction enzyme to 
produce two DNA products; one is 640 base pairs in length and the other is 290 base pairs. 
The wild-type allele (blue) remains uncut as the EcoNI site is absent. [c] shows the cloning 
strategy of creating the 53bp1-null allele and how it is genotyped. The use of the normally 
occurring BamH1 and Xho restriction enzyme sites in the wild-type 53bp1 allele (blue) were 
used to excise a region of 53bp1 encompassing exon 5. A targeting vector (orange) 
containing a neomycin gene (green) was inserted into this region creating the 53bp1-null 
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allele. The black arrows represent the location of the forward (Fwd) and reverse (Rev) 
primers that are used to PCR amplify exon 5 and its surrounding region. The DNA product 
created by the wild-type allele is 465 base pairs in length and contains exon 5. The 53bp1-null 
allele produces a DNA product that is 270 base pairs in length and contains the neomycin 
gene.  
[a] shows the three breeding 
crosses (separated by dashed 
lines) and their offspring that 
was needed to create a 
mouse with the desired 
phenotype (53bp1-/-
Brca1C61G/C61G). The first cross 
is needed to create mice with 
both the 53bp1-null allele 
and the Brca1 C61G allele. 
The second cross involved 
the offspring of the first cross 
(blue box and arrow) 
breeding with a homozygote 
53bp1-null mouse to create 
offspring which are 
homozygote for the 53bp1-
null allele and heterozygote 
for the Brca1 C61G allele. 
These mice are then bred 
together as the third cross in 
which it is possible to create 
mice which are 53bp1-/-
Brca1C61G/C61G (red box). The 
purple numbers are the 
predicted ratio at which the 
genotype is expected from 
the parental cross. [b-d] 
show the genotypes of 
mouse embryonic fibroblasts 
(MEFs) isolated from the 
third cross in [a]. [b] and [c] 
show the Brca1 allele 
genotyping results and [d] 
shows the 53bp1 genotyping 
results. (WT= wild-type 
allele, Het= heterozygous for 
Figure 4.2 – Breeding crosses 




the mutant allele and Hom= homozygote for the mutant allele). [b] show the DNA products 
after EcoNI restriction enzyme digest from a PCR using the EcoNI digest PCR genotyping 
method and [c] shows the DNA products from a PCR using the LoxP PCR genotyping method 
described in figure 4.2. Both Brca1 genotyping methods shows that embryo samples 1 and 2 
contain only wild-type allele of Brca1, embryo samples 4 and 5 are heterozygote for the 
Brca1 C61G allele and embryo samples 3 and 6 and homozygote for the Brca1 C61G allele. 
[d] shows the DNA products from a PCR using the 53bp1-null allele genotyping method 
(Ward et al., 2003b). It shows that all embryo samples are homozygote for the 53bp1-null 
allele. The first and second cross were started by Dr Jo Morris and James Beesley. James 
Beesley aided in genotyping mice for part of my time on this project.  
 
(Figure 4.2a) to create the 53bp1+/-Brca1+/C61G mice for the next parental pairing. The second 
cross backcrossed the 53bp1+/-Brca1+/C61G mice with 53bp1-null mice to product mice that 
were heterozygote for the Brca1 C61G allele with two deleted copies of 53bp1. This created 
the parents for the final cross of two 53bp1-/-Brca1+/C61G mice which should produce the 
expected Mendelian ratio of 1:4, resulting the desired 53bp1-/-Brca1C61G/C61G mouse. This 
cross produced 53bp1-/-Brca1C61G/C61G mice that lived to adulthood and MEFs were isolated 
from the mother at embryonic day 14 (Section 2.4.4) from the 53bp1-/-Brca1+/C61G parental 
cross.  
Table 4.1 – Summary of the mouse embryonic fibroblasts genotypes  
53bp1-null Brca1 C61G Brca1 Δ11 Immortalized 
53bp1+/-Brca1+/C61G Heterozygote Heterozygote - SV40 Large T antigen 
53bp1-/-Brca1+/+ Homozygote Wild-type - SV40 Large T antigen 
53bp1-/-Brca1+/C61G Homozygote Heterozygote - SV40 Large T antigen 
53bp1-/-Brca1C61G/C61G Homozygote Homozygote - SV40 Large T antigen 
53bp1+/+Brca1Δ11/Δ11 Wild-type - Homozygote Spontaneous (Xu et 
al., 2001c) 
53bp1-/-Brca1Δ11/Δ11 Homozygote - Homozygote Spontaneous 
(Bunting et al., 
2010) 
The mice and MEFs produced from these breeding crosses were all genotyped using the 
discussed methods in the above section 4.2. The timed breeding cross to isolate MEFs 




Figure 4.3 – Whole cell protein extracts from mouse embryonic fibroblasts 
This figure shows two western blot results of whole cell protein extracts from MEFs with their 
genotypes depicted below. – represents the mutant allele (53bp1-null or Brca1 C61G) and the 
+ represents the wild-type allele. The molecular weights are predicted using Prestained 
PageRuler protein ladder and shown on the right of the blot. The bands predicted to be the 
Brca1 or 53bp1 are shown using arrows (far right). [a] shows three blots; the first blot was 
probed with the mouse Brca1 antibody GH118, the second blot was probed with a 53bp1 
antibody and the third blot was probed with a β-actin antibody. [b] shows two blots; the first 
blot was probed with the mouse Brca1 antibody GH118 and the second blot was probed with 




Figure 4.4 – Average density of combined Brca1 protein bands from cytoplasm and nuclear 
fractionation western blots 
This figure shows a bar chart of the comparative levels of combined Brca1 protein in 
cytoplasmic and nuclear extracts from 3 western blots using fresh lysates. Each Brca1 blot 
was treated with the Brca1 GH118 antibody. Protein levels were measured using ImageJ 
analysis of the density of bands from western blot films. The error bars shows standard error 
and the labelled significant p value from the t-test (type 2 two-tailed student t-test) is 
indicated between the samples.  
of PCR genotyping the Brca1 C61G allele showed that embryos 1 and 2 were wild-type for 
Brca1, embryos 4 and 5 were heterozygote for the Brca1 C61G allele, and embryos 3 and 6 
were homozygote for the Brca1 C61G mutation (Figure 4.2b-c). The 53bp1 PCR genotyping 
of the 53bp1 allele showed that all the embryos were homozygote for the 53bp1-null 
mutation (Figure 4.2d). These embryos were cultured to produce MEFs and were 
immortalised using the SV40 large T antigen gene (details in methods 2.4.5). Table 4.1 shows 
the genotypes of the MEFs that are discussed in this chapter. 
4.4 The determination of Brca1 C61G protein levels in cells 
The immortalised MEFs were then used to investigate the effect of the C61G mutation on 
the cell as a whole, starting with Brca1 C61G protein. Figure 4.3a and b are the results of two 
western blots showing levels of Brca1 protein in whole cell extracts from the above 
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described MEFs and Brca1 Δ11-deleted MEFs (with and without 53bp1 wild-type allele) (gift 
from Andre Nussenzweig). Full-length BRCA1 has been shown to be approximately 220 kDa 
in humans (Chen et al., 1995; Chen et al., 1996; Huber et al., 2001; Ruffner and Verma, 1997; 
Scully et al., 1996) and approximately 210 kDa in mice (Huber et al., 2001). The Brca1 Δ11 
MEFs have no full-length Brca1 but do produce an approximately 92 kDa fragment like the 
Brca1 isoform that is recognised by this Brca1 antibody (Figure 4.3a, b: lanes 5 and 6) (Huber 
et al., 2001). The GH118 Brca1 antibody was made using an epitope from the C-terminal end 
of the Brca1 protein. Human BRCA1 isoforms are predicted to be 96 and 110 kDa (Huber et 
al., 2001; Qin et al., 2011; Thakur et al., 1997).  
Figure 4.3a and b show the varied nature of the GH118 antibody on whole cell extract 
samples run on a western blot. Due to this, the Brca1 protein levels were measured by 
estimating the band density using ImageJ of the cell and nuclear fractions of the Brca1 C61G 
MEFs and combining the totals. This was done for three separate experiments and compared 
in figure 4.4. This shows that in cells with one copy of Brca1 C61G there is a reduction in 
Brca1 levels and when both copies of Brca1 are mutated, there is a further reduction in 
Brca1 protein.  
When used for western blotting, the Brca1 antibody (GH118) produces a weak signal and 
produces multiple non-specific bands and requires a large amount of protein to be loaded to 
be visible. The digestion of a large number of cells into a small volume allowing a large 
amount of protein to be loaded for this experiment, may be responsible for some of the 
variety in protein levels and why it is less variable when the cytoplasm and nuclear fractions 
are run as separate samples, however it could be due to varying Brca1 protein levels in the 
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MEFs themselves. The use of multiple other antibodies (List in Table 2.10 and 2.11) that 
target Brca1, unfortunately, did not produce any band that correlating with the size of Brca1 
protein. There are papers that suggest BRCA1 levels vary during the cell cycle (Chen et al., 
1996; Choudhury et al., 2004; Croke et al., 2013; Gudas et al., 1996; Hayami et al., 2005; Liu 
et al., 2010; Ruffner and Verma, 1997; Scully et al., 1997b; Vaughn et al., 1996; Wu et al., 
2010), but not all papers have replicated this (Escribano-Diaz et al., 2013). The multiple ways 
in which BRCA1 is degraded have been published (Blagosklonny et al., 1999; Hammond-
Martel et al., 2010; Liu et al., 2010; Lu et al., 2007; Lu et al., 2012; Peng et al., 2015; Qin et 
al., 2011; Stebbing et al., 2015; Wang et al., 2014b; Wu et al., 2010; Xian Ma et al., 2003; 
Zhang et al., 2012), and some papers that show the altered-C61 residue can cause BRCA1 to 
be readily degradable (Brzovic et al., 1998; Brzovic et al., 2001a; Choudhury et al., 2004; 
Wang et al., 2014b), but not all agree (Campbell et al., 2001; Lu et al., 2007; Nelson and Holt, 
2010). Further investigation is needed to explain this variety.  
Figure 4.3a also shows the absence of 53bp1 protein in MEFs with two copies of the 53bp1-
null allele, and the presence of 53bp1 protein in MEFs with one or two copies of the 53bp1 
wild-type allele, confirming the removal of full-length 53bp1 protein in these cells.  
4.5 Brca1 C61G protein levels in the nucleus and cytoplasm 
BRCA1 has nuclear localisation sequences (NLS) (Chen et al., 1996; Fabbro et al., 2002; 
Thakur et al., 1997; Wang et al., 2014b; Wilson et al., 1997) and nuclear export signals (NES) 
(Fabbro et al., 2002; Rodriguez and Henderson, 2000; Rodriguez et al., 2003a; Rodriguez et 
al., 2004) that regulate the localisation of BRCA1 protein. BRCA1-interacting proteins have 




Figure 4.5 – Nuclear and cytoplasm separation of mouse embryonic fibroblasts 
[a] shows a western blot results from a nuclear and cytoplasm fractionation of MEFs with 
their genotypes depicted below. The molecular weights are predicted using Prestained 
PageRuler protein ladder and shown on the right of the blot. The Brca1 protein band is shown 
with an arrow. The first blot is probed with mouse Brca1 antibody GH118, the second blot is 
probed with a GAPDH antibody, the third blot is probed with an antibody recognising Histone 
4 and the final blot was probed with a βactin antibody. Samples 1-4 are the samples from the 
cytoplasm fraction and samples 5-8 are samples from the nuclear fraction. Further details of 
the protocol are in section 2.4.6. [b] shows a bar chart showing the average levels of Brca1 
protein from 3 separate experiments from each MEF genotype compared with the 53bp1-/-
Brca1+/+ sample. The first section shows the level of Brca1 protein in the nuclear fractions and 
the second section shows the level of Brca1 protein in the cytoplasmic fractions. The error 
bars shows standard error and the significant p values from a t-test (type 2 two-tailed 
student t-test) are indicated. Protein levels were measured using ImageJ analysis of the 




(Fabbro et al., 2002; Rodriguez and Henderson, 2000; Rosen et al., 2006; Vikrant et al., 
2015). BRCA1 NES (aa81-99) is enclosed by the BRCA1:BARD1 heterodimer interface and the 
exposure of the NES (aa81-99) (Rodriguez and Henderson, 2000) in BRCA1 N-terminus is 
predicted to export BRCA1 through the CRM1 nuclear export channel for degradation in the 
cytoplasm (Fabbro et al., 2004b; Rodriguez and Henderson, 2000). Since the BRCA1 C61G 
mutation has been shown to alter the structure of the RING domain (Brzovic et al., 1998; 
Brzovic et al., 2001a; Wang et al., 2014b) potentially exposing the NES (Rodriguez and 
Henderson, 2000), nuclear/cytoplasm fractionation was used to investigate Brca1 C61G 
protein levels in the nucleus. Figure 4.5a shows that the levels of Brca1 in MEFs with one 
copy of Brca1 C61G (lanes 1, 3, 5 and 7) are reduced compared to homozygote wild-type 
Brca1 MEFs (lanes 2 and 6), in both the cytoplasmic (lanes 1-4) and the nuclear (lanes 5-8) 
fractions. Further reduction of Brca1 levels are seen in the cytoplasm and nucleus when 
MEFs are homozygote for the Brca1 C61G mutation (lanes 4 and 8). The presence of Histone 
4 and GAPDH in each extract shows the fractionation of nuclear and cytoplasmic proteins 
and β-actin is the loading control.  
This experiment was repeated 3 times and the densitometry of the Brca1 protein bands 
were measured using ImageJ (Section 2.1.3). The MEFs with only wild-type Brca1 were set as 
one in each experiment and used to compare against Brca1 levels in the other MEFs. Figure 
4.5b shows the average of these comparative Brca1 protein level values from the three 
experiments and the p values from the t-test statistics on these results is in Table 4.4. These 
results show that the reduction in Brca1 in the nuclear fraction is significantly different in 
cells with one or two copies of Brca1 C61G from cells with only wild-type Brca1 protein. In 
the cytoplasmic fractions, there is a significant reduction between the MEFs with one or two 
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copies of Brca1 C61G in a 53bp1-null background compared to the 53bp1-/-Brca1+/+ MEFs. 
This suggests that the homozygote C61G mutation in Brca1 does reduce the levels of Brca1 
protein present in the nucleus and in cytoplasm in 53bp1-null cells.  
Table 4.2 – P values from a t-test performed on the comparable Brca1 protein levels in the 
nucleus and cytoplasm  















0.00004 0.327748 0.013292 0.087849 0.119967 0.38464 
53bp1-/- 
Brca1+/+ 
- 0.026241 0.000646 - 0.557874 0.00087 
53bp1-/- 
Brca1+/C61G 
- - 0.020137 - - 0.002835 
If there was an increase of Brca1 protein in the cytoplasm that matched the decrease in 
protein in the nucleus, this would suggest that Brca1 C61G is exported from the nucleus. 
However, as we see a decrease of Brca1 protein in the cytoplasm of 53bp1-null MEFs, there 
are three possibilities: Brca1 C61G protein is highly degradable in both the nucleus and the 
cytoplasm, Brca1 C61G protein is exported from the nucleus and then rapidly degraded, or 
Brca1 C61G protein is not made to the same levels wild-type protein. If mRNA were unstable 
and less Brca1 protein was made, then it would be unlikely to see the same levels of Brca1 
protein across the MEF genotypes (Section 4.4 and figure 4.4) or papers in the literature 
suggesting C61G does not alter BRCA1 protein levels (Campbell et al., 2001; Lu et al., 2007; 
Nelson and Holt, 2010). Previous papers have looked at BRCA1 degradation and have not 
suggested a correlation in BRCA1 mRNA and BRCA1 protein degradation (Blagosklonny et al., 
1999; Choudhury et al., 2004; Gudas et al., 1996; Joukov et al., 2001; Liu et al., 2010; Lu et 
al., 2007; Stebbing et al., 2015; Vaughn et al., 1996; Xian Ma et al., 2003), and Drost et al, 
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show Brca1 C61G mice tumours have the expected levels of Brca1 mRNA expression (Drost 
et al., 2011).  
4.6 The nuclear export of Brca1 C61G protein 
As discussed, BRCA1 has several NES sequences that are recognised by the CRM1 nuclear 
export protein and CRM1’s action can be blocked using Leptomycin B (LMB) (Ossareh-Nazari 
et al., 1997; Wolff et al., 1997). Previous literature can be split into papers that show LMB is 
effective in stopping BRCA1 from being exported from the nucleus (Brodie et al., 2001; 
Rodriguez and Henderson, 2000; Rodriguez et al., 2004) and papers that show LMB does not 




Figure 4.6 – Ratio of Brca1 protein in nuclear to cytoplasm and LMB treatment 
This figure shows a nuclear (N) and cytoplasm (C) fractionation of MEFs treated with ethanol 
(EtOH) or treated with 5 µM Leptomycin B (LMB) for 6 hours. The molecular weights are 
predicted using Prestained PageRuler protein ladder and shown on the right of the blot. The 
band predicted to be the Brca1 are shown using arrows (right). The genotype of the samples 
is depicted below. The first blot was probed with the mouse Brca1 GH118 antibody, the 
second blot was probed with an antibody specific to Histone 4, the third blot was probed with 




showed that neither BRCA1 wild-type, nor C61G, foci localisation is altered by LMB (Nelson 
and Holt, 2010). Figure 4.6b shows the nuclear and cytoplasm fractions of LMB- treated 
MEFs (5 µM for 6 hours). GAPDH and Histone 4 show the separation of cytoplasm and 
nucleus and β-actin is used as the loading control. Due to the unclear nature of the western 
blot no determination can be made to determine if LMB does affect the localisation of Brca1 
or Brca1 C61G protein. This result needs to be repeated further with an antibody that is 
more specific when used in western blot. 
4.7 Degradation of Brca1 and Brca1 C61G protein 
It is debated as to whether the degradation of BRCA1 C61G is quicker (Brzovic et al., 1998; 
Brzovic et al., 2001a; Choudhury et al., 2004; Wang et al., 2014b) than wild-type BRCA1 or 
the same (Campbell et al., 2001; Lu et al., 2007; Nelson and Holt, 2010). To assess the 
degradation of Brca1 C61G, MEFs that were homozygote for either Brca1 wild-type or Brca1 
C61G only were either mock treated (0 hour) or treated with Cycloheximide (CHX, 100 µM) 
for 2, 4, 6 or 8 hours (Figure 4.7a). Cycloheximide inhibits protein synthesis without affecting 
RNA production (Young et al., 1963). CtIP was used as a known protein that shows 
degradation in the 8 hour time period of CHX treatment, regardless of BRCA1 mutation 
status (Yu et al., 2006). β-actin is used as a loading control.  
The CHX time course (Figure 5.7a) is not clear enough to determine if there is a quantifiable 
or relevant change in the degradation of Brca1 protein between the genotypes of the MEFs.  
Therefore, this experiment should be repeated with multiple Brca1 antibodies and a time 
point before drawing any conclusions. BRCA1 has also been reported to be degraded by the 
proteasome (Blagosklonny et al., 1999; Brodie and Henderson, 2010; Choudhury et al., 2004; 
Hammond-Martel et al., 2010; Hayami et al., 2005; Lu et al., 2007; Stebbing et al., 2015; 
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Wang et al., 2014b; Zhang et al., 2012) after being ubiquitinated by other E3 ubiquitin ligases 
(not autoubiquitination) (Choudhury et al., 2004; Lu et al., 2007; Lu et al., 2012; Wang et al., 
2014b; Zhang et al., 2012). The proteasomal degradation can be blocked by the use of the 
proteasomal inhibitor MG132 (Rock et al., 1994). Figure 4.7b shows a time course spanning 8 
hours of DMSO (D) or MG132 treated MEFs with either wild-type or C61G Brca1 protein. 
Cyclin A is known to accumulate in cells after MG132 treatment (Geley et al., 2001). Whilst a 
small change in Brca1 protein could be said to be seen in figure 5.7b, the GH118 Brca1 
antibody does not allow for an accurate or clearly determinable result between genotypes. 
This experiment should also be repeated with a different Brca1-spefic antibody.  
4.8 Ionising radiation-induced foci formation in Brca1 C61G cells 
Figures 4.8-12 show 7 different cell lines that have varying genotypes summarised in table 





Figure 4.7 – Exploring Brca1 protein degradation using Cycloheximide and MG132 
[a] shows a western blot of whole cell extract MEF samples untreated (0) or treated with 100 
µM Cycloheximide (CHX) for 2, 4, 6 or 8 hours. The molecular weights are predicted using 
Prestained PageRuler protein ladder and shown on the right of the blot. The band predicted 
to be the Brca1 are shown using arrows (right). The genotype of the samples is depicted 
below. The first three letterboxes show 3 exposures of a single blot probed with mouse Brca1 
GH118 antibody. The fourth letterbox shows a blot probed with a CtIP antibody and the final 
blot was probed with a β-actin antibody. [b] shows a western blot of whole cell extract MEF 
samples treated with DMSO (D) for 8 hours or treated with 5 µM MG132 for 2, 4, 6 or 8 
hours. The molecular weights are predicted using Prestained PageRuler protein ladder and 
shown on the right of the blot. The band predicted to be the Brca1 are shown using arrows 
(right). The genotype of the samples is depicted below. The first three letterboxes show 3 
exposures of a single blot probed with mouse Brca1 GH118 antibody. The fourth letterbox 




used as an epithelial seeding layer for other cells (such as stem cells or primary cells) but is 
also used as a wild-type mouse cell line. The 53bp1 wild-type Brca1 exon 11-deleted MEFs 
were published by Cao et al (Cao et al., 2009) and their 53bp1-null counterparts were 
published by Ward et al (Ward et al., 2003b).  
4.8.1 53bp1 ionising radiation-induced foci 
The 53bp1-/-Brca1C61G/C61G mice are viable with the removal of 53bp1 (Section 4.3) and this is 
likely to be due to the removal of the homologous recombination (HR) block caused by 
53bp1 (Bouwman et al., 2010; Bunting et al., 2010; Bunting et al., 2012; Cao et al., 2009) 
(Section 1.5.3). The 53bp1-null mutation does not produce any full-length 53bp1 protein 
(Figure 4.4a) and therefore it cannot form ionising radiation-induced foci (IRIF) (Ward et al., 
2003b). Figure 4.8 shows immunofluorescent stained untreated cells stained for DNA 
(Hoechst), 53BP1 and the DNA damage marker, γH2AX. As discussed previously (Section 
1.4.1), 53BP1 binds to DNA ends and can be used as a marker for DSBs. 
This figure shows that the cells with two copies of the 53bp1-null mutation do not produce 
53bp1 foci spontaneously unlike cells with a wild-type copy of 53bp1. Figure 4.9 shows cells 
stained as the previous figure (Figure 4.8), but the cells were treated with 5 Gray of ionising 
radiation (IR) 1 hour before fixation (Schultz et al., 2000). As shown in this figure, IR causes 
an increase in γH2AX foci in all cell lines and an increase of 53bp1-γH2AX co-localising foci in 
cell lines that have a wild-type copy of 53bp1 as expected (Schultz et al., 2000; Ward et al., 









Figure 4.9 – 53bp1 and γH2AX immunofluorescent foci in IR-treated cells 
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Figure 4.8 – 53bp1 and γH2AX immunofluorescent foci in untreated cells 
This figure shows a panel of images of untreated cells stained to show the nucleus (Hoechst-
blue), γH2AX (green) and 53BP1 (red). Further details of the immunofluorescent staining 
protocol is discussed in section 2.4.7. The genotype of the cells is stated on the left of the row 
and the final images on the row (far right) are a merged image of all stains (MERGE). White 
lines outline the nucleus of the cells. Scale bar is 5 µm.  
Figure 4.9 – 53bp1 and γH2AX immunofluorescent foci in IR-treated cells 
This figure shows a panel of images of cells after 1 hour of exposure to 5 Gray of ionising 
radiation and stained to show the nucleus (Hoechst-blue), γH2AX (green) and 53BP1 (red). 
Further details of the immunofluorescent staining protocol is discussed in section 2.4.7. The 
genotype of the cells is stated on the left of the row and the final images on the row (far 
right) are a merged image of all stains (MERGE). White lines outline the nucleus of the cells. 
Scale bar is 5 µm.  
4.8.2 Brca1 ionising radiation-induced foci 
BRCA1 produces foci when cells are treated with IR (Li and Yu, 2013; Scully et al., 1997a; Wei 
et al., 2008) although, unlike 53bp1, BRCA1 IRIF are not just representative of DSB ends as 
BRCA1 may also form at other sites of DNA damage or stress (Au and Henderson, 2007) 
(Section 1.4.2). However, the majority of DNA damage caused by IR is DSBs and the BRCA1 
foci that co-localise with γH2AX are likely to be DSBs (Paull et al., 2000). Cells were not 
treated or treated with 5 Gray of IR and fixed after 1 hour, a time suggested to be when 
BRCA1 is localised to orchestrate HR (Paull et al., 2000; Wei et al., 2008), and stained for 
DNA (Hoechst), Brca1 (GH118) and γH2AX. Figure 4.10 shows untreated cells that have a 
background level of γH2AX staining and a few Brca1 foci, showing spontaneous DNA damage 
and non-IR-induced Brca1 and γH2AX foci. Figure 4.11 shows cells treated with IR have a 
higher level of γH2AX foci (as seen in figure 4.9) and a large induction of Brca1-γH2AX co-
localising foci in cells with a wild-type copy of Brca1. However, 53bp1-/-Brca1C61G/C61G cells 
show very few Brca1-γH2AX co-localising foci suggesting Brca1 C61G does not form as many 
foci as wild-type Brca1. To quantify this further, 100 IR-treated cells from 3 separate 








Figure 4.11 – Brca1 and γH2AX immunofluorescent foci in IR-treated cells 
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Figure 4.10- Brca1 and γH2AX immunofluorescent foci in untreated cells 
This figure shows a panel of images of untreated cells stained to show the nucleus (Hoechst-
blue), γH2AX (green) and Brca1 (red). Further details of the immunofluorescent staining 
protocol are discussed in section 2.4.7. The genotype of the cells is stated on the left of the 
row and the final images on the row (far right) are a merged image of all stains (MERGE). 
White lines outline the nucleus of the cells. Scale bar is 5 µm.  
Figure 4.11- Brca1 and γH2AX immunofluorescent foci in IR-treated cells 
This figure shows a panel of images of cells after 1 hour of exposure to 5 Gray of ionising 
radiation and stained to show the nucleus (Hoechst-blue), γH2AX (green) and Brca1 (red). 
Further details of the immunofluorescent staining protocol are discussed in section 2.4.7. The 
genotype of the cells is stated on the left of the row and the final images on the row (far 
right) are a merged image of all stains (MERGE). White lines outline the nucleus of the cells. 
Scale bar is 5 µm.  
4.12b,c). Brca1-γH2AX co-localising foci were also counted in 100 cells in the untreated cells 
in two of these experiments (Figure 4.12a). Untreated cells contain sites of DNA damage 
(shown by γH2AX foci) because the cells naturally incur spontaneous DNA damage through 
normal cellular activities. In the untreated cells, there was a significant increase in the 
number of Brca1-γH2AX co-localising foci in 53bp1-/-Brca1+/+ MEFs compared 53bp1+/-
Brca1+/C61G MEFs. This could be predicted since the removal of 53bp1 is known to increase 
the amount of DSBs that are repaired through HR (Bouwman et al., 2010; Bunting et al., 
2010; Bunting et al., 2012; Cao et al., 2009) so there would be more sites of DNA damage 
(γH2AX) that co-localise with Brca1 foci. The removal of wild-type Brca1 has been suggested 
to allow NHEJ to progress at sites of DSBs (Bunting et al., 2010) and therefore the decreased 
number of Brca1-γH2AX co-localising foci in the 53bp1-/-Brca1+/C61G and 53bp1-/-Brca1C61G/C61G 
(although not significantly for the latter) may be a result of this. Although it is also possible 
that the reduction seen in the MEFs with one or two copies of Brca1 C61G (with or without 
wild-type 53bp1) are due to the C61G mutation altering the ability of the protein to localise 
to DNA damage.  
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There were significantly fewer cells with more than 5 co-localising Brca1-γH2AX foci in the 
53bp1-/-Brca1C61G/C61G MEFs suggesting that Brca1 C61G protein is dramatically less efficient 
at localising to DSBs (Figure 4.12b). The C61G mutation in BRCA1 causes a structural change 
which could alter its interaction with proteins that causes the reduction in localisation of 
Brca1 to IRIF. As discussed, the C61G mutation has been shown to alter the binding between 
BRCA1 and BARD1, and this interaction, at least partially, is responsible for BRCA1 
localisation to DSBs (Greenberg et al., 2006; Li and Yu, 2013; Wei et al., 2008).  
When looking at the number of cells with either 1, 2, 3, 4, 5 or no Brca1-γH2AX foci (Figure 
4.12c), we see that there are significantly fewer cells with 4 or 5 Brca1 C61G-γH2AX foci 
compared to cells with a wild-type Brca1. This alongside the presence of Brca1 C61G-γH2AX 
foci in the untreated cells suggested that Brca1 foci can still form and the reduction of Brca1 
C61G protein (Figures 4.3-7) could partially be the cause of the reduced foci. It may be that 
fewer Brca1 C61G molecules are localising to each DSBs and this low level of protein is not 
detected or visible within the range of sensitivity of this IF antibody (GH118) or this 












Figure 4.12 – Counts of Ionising-radiation-induced Brca1 foci 
[a] shows a bar chart of the average number of co-localised γH2AX and Brca1 foci in 
untreated MEFs. These results are from two separate experiments each with 100 cells. Error 
bars present standard error. [b] shows a bar chart of the average percentage of cells with 
more than 5 Brca1 foci that co-localise with γH2AX foci of 100 cells from three separate 
experiments. All cells were treated with 5 Gray of ionising radiation and fixed after 1 hour. 
The genotypes of the cells are as stated below. The error bars represent standard error and 
the asterisks (*) show which results are significantly different with a p value of less than 0.05 
after a t-test (Type 2 two-tailed student t-test). [c] shows a bar chart of the average 
percentage of cells with each number of Brca1 foci that co-localise with γH2AX foci from 
three separate experiments. All cells were treated with 5 Gray of ionising radiation and fixed 
after 1 hour. The genotypes of the cells are as stated in the key. The error bars represent 
standard error and the asterisks (*) show which results are significantly different with a p 
value of less than 0.05 after a t-test (Type 2 two-tailed student t-test). Further details of the 
immunofluorescent staining protocol is discussed in section 2.4.7.
 
Figure 4.13 – Number of cells with more than three Brca1 foci that do not co-localise with 
γH2AX foci 
This figure shows a bar chart of the number of cells with more than three Brca1 foci that do 
not co-localise with γH2AX foci. These are the results from two separate experiments and the 
error bars represent standard error. Cells were either untreated or treated with 5 Gray of 
ionising radiation and fixed after an hour. The cells genotypes is indicated in the key below 











Figure 4.14 – Levels of γH2AX foci in untreated and IR-treated cells 
[a] shows a bar chart of the average number of γH2AX foci in two separate experiments each 
with 100 cells. The genotypes are stated below and the error bars shows standard error. The 
lines refer to the genotypes between which there is a significant difference (a p value of less 
than 0.05) determined by a t-test (Type 2 two-tailed student t-test). [b] shows a bar chart of 
the average intensity of γH2AX stain in untreated MEFs of the genotypes indicated. [c] shows 
a bar chart of the average intensity of γH2AX stain of cells an hour after being treated with 5 
Gray of IR. [b,c] These results are from n=1. The red bars are the Brca1 C61G MEFs and the 
blue bars are the Brca1 Δ11 MEFs. 
Figure 4.12b also shows an increase in Brca1-γH2AX co-localising foci in 53bp1-/-Brca1+/+ 
MEFs. Since the 53BP1 antagonises BRCA1 action in orchestrating HR (Bouwman et al., 2010; 
Bunting et al., 2010; Bunting et al., 2012; Cao et al., 2009), this increase in Brca1-γH2AX foci 
could show that more DSBs are being repaired via HR than NHEJ. This increase in HR is seen 
in the literature (Bouwman et al., 2010; Bunting et al., 2010; Bunting et al., 2012; Cao et al., 
2009).  
The Brca1 exon 11-deletion allele does not form full-length Brca1 protein (Figure 4.3b) but 
produces an approximately 92 kDa protein (Huber et al., 2001). Although this protein is 
described to be a predominantly cytoplasmic protein (Qin et al., 2011; Thakur et al., 1997), 
in figure 4.11 it is clear that it does form Brca1-γH2AX foci in response to DSBs as reported in 
Hubert et al (Huber et al., 2001). The Brca1 GH118 antibody epitope maps to the C-terminus 
of Brca1 and this localisation suggests the C-terminus of the Brca1 Δ11 protein is still 
structurally recognisable by this antibody. This does bring into question the functional 
nature of Brca1 Δ11 as discussed in the introduction and its use as a Brca1-deficient control.  
As previously stated, BRCA1 can form foci that do not represent DNA damage and do no co-
localise with γH2AX (Au and Henderson, 2007). To see if the Brca1 C61G mutation alters 
these foci, cells from the previously described experiment (n=2, 100 cells from each 
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experiment) were also counted for the number of Brca1 foci that do not co-localise with 
γH2AX (Figure 4.13). In the untreated condition, there was a decrease in number of cell with 
more than three Brca1 foci that do not co-localise with γH2AX in cells without a wild-type 
53bp1 and a further decrease in cells with one or two copies of Brca1 C61G (Figure 4.13). 
Whilst there is a difference between the number of cells with more than three non-γH2AX 
co-localising Brca1 foci in these MEFs, it is difficult to say what this means without further 
investigation into the function behind these Brca1 foci. It can be said that the reduction in 
these foci is not necessarily caused by the Brca1 C61G mutation because the 53bp1+/-
Brca1+/C61G MEFs have a Brca1 C61G allele, and has the greatest number of cells with more 
than three Brca1 non-co-localising foci. It could be speculated that the function behind these 
Brca1 foci is not affected by the Brca1 C61G mutation, or is only affected in a 53bp1-null 
background.   
Due the removal or mutation of two tumour suppressing genes (53bp1 and Brca1), it is 
important to see if there is an increased level of γH2AX foci in these cells and this represents 
the level of unrepaired DNA damage in these cells. Cells were either untreated or treated 
with 5 Gray IR and fixed after 1 hour and stained with for with γH2AX antibody. Figure 4.14a 
shows the average number of γH2AX foci in each cell of the various genotypes from two 
experiments each with 100 cells counted. This shows that the number of γH2AX foci in cells 
without a wild-type copy of 53bp1 is significantly increased. This agrees with previous 
literature that the removal of 53bp1 causes genome instability (Ward et al., 2003b). This 
increase is partially alleviated in 53bp1-/-Brca1+/C61G MEFs, perhaps due to the reduction in 
wild-type Brca1 leading to more error-free repair in these cells. The 53bp1-/-Brca1C61G/C61G 
MEFs do appear to have a decrease in γH2AX foci compared to the 53bp1-/-Brca1+/C61G MEFs, 
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but the error bars on the results of these two experiments (n=2) are too great for this to be 
determined. If this were to be confirmed, this would indicated that the increase in 
unresolved DNA damage caused by the removal of 53bp1 can be compensated for by the 
mutation of Brca1.  
When cells are treated with IR, the DNA damage is greatly increased at the γH2AX stain can 
appear as foci or as pan staining due to the large number of foci. Due to this, the nuclei of 
cells can be measured for the intensity of γH2AX stain and compared to an average 
background level of stain to determine the degree of increase in intensity representing the 
increase in DNA damage. Figure 4.14b shows the measure of γH2AX intensity in the 
untreated Brca1 C61G MEFs and the Brca1 Δ11 MEFs and figure 4.14c shows the γH2AX 
intensity in the corresponding IR-treated MEFs. The Brca1 Δ11 MEFs shows the expected 
phenotype which is that there is more unresolved DNA damage (γH2AX intensity), in cells 
with wild-type 53bp1 than without 53bp1. Figure 4.14b shows that there is a small decrease 
in γH2AX intensity in cells lacking wild-type 53bp1 and again with one or two Brca1 C61G 
alleles. This does not completely correlate with the γH2AX foci count in figure 4.14a in that 
the 53bp1+/-Brca1+/C61G MEFs show less DNA damage than cells without 53bp1. Due to this 
and this data being of 100 cells in a single experiment, before any conclusions can be made 
this could need to be repeated multiple times. Figure 4.14c has the same caveat of needing 
to be repeated. This figure does show that there is more unresolved DNA damage 1 hour 
after IR in 53bp1-/-Brca1Δ11/Δ11 MEFs than those with 53bp1, which would agree with 53bp1 
being needed for the speedy NHEJ repair. The 53bp1-/-Brca1+/+ MEFs do show an increase in 
γH2AX intensity compared to the 53bp1+/-Brca1+/C61G MEFs which may be for the same 
reason. The presence of two Brca1 C61G mutations appears to alleviate some of the DNA 
138 
 
damage in 53bp1-null cells, but with the 53bp1-/-Brca1+/C61G MEFs having increased levels of 
γH2AX intensity and the lack of repeats, no conclusions can be formed.  
4.9 Discussion 
This chapter has shown that the Brca1 C61G homozygote embryonic lethality can be rescued 
by the genetic deletion of 53bp1. The rescuing of the embryonic lethality suggests that the 
C61G missense mutation causes Brca1 protein to be altered so that it can no longer remove 
the 53bp1-dependent block in HR, despite the mutation being a single amino acid 
substitution.  
Previous research has suggested that the C61G mutation causes dramatic effects to Brca1 N-
terminal structure that can cause the BRCA1 RING domain to become less stable, inactive as 
an E3 ubiquitin enzyme and be less able to bind to BARD1 (Brzovic et al., 1998; Brzovic et al., 
2001a; Brzovic et al., 2003; Choudhury et al., 2004; Hashizume et al., 2001; Joukov et al., 
2001; Mallery et al., 2002; Morris and Solomon, 2004; Nelson and Holt, 2010; Ruffner et al., 
2001; Wang et al., 2014b; Wu et al., 1996). These alterations can change the localisation and 
degradation of Brca1 protein. The data in this chapter supports that when Brca1 C61G is 
expressed at endogenous levels, there is less Brca1 C61G protein compared to wild-type 
Brca1 protein (Figure 4.4), and it is less detectable at sites of DNA damage than Brca1 wild-
type protein (Figure 4.12b,c).  
The reduction in Brca1 protein in the nucleus (Figure 4.4) and the dramatic reduction of 
Brca1 C61G-γH2AX foci after IR (Figure 4.12) in the homozygote Brca1 C61G mice, may cause 
HR defects and genomic instability that could lead to embryonic lethality. However, this data 
has shown Brca1 C61G protein and foci are not completely abolished, presenting the 
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question of whether these DSBs are repaired via HR. These results could suggest that the 
C61 residue is important for Brca1-dependent DSB repair once it reaches DSBs, perhaps 
through the maintenance of the N-terminal heterodimer structure with Bard1 or its 
importance in E3 ubiquitin ligase activity.  
It has been reported, and is shown in figure 4.11, that Brca1 Δ11-deleted protein can localise 
to DSBs and that it may have function as it mimics a naturally occurring isoform of Brca1 (Au 
and Henderson, 2007; Huber et al., 2001). The Brca1 Δ11-deleted cells also have a milder 
phenotype compared to Brca1-null cells (Section 1.5.3) which suggests that the Brca1 Δ11 
protein may be able to compensate for the loss of full-length Brca1. Since codon 61 is in the 
Exon 11-deleted isoforms, it likely to affect all N-terminal functions of Brca1 and the Brca1 
C61G mutation may reduce the protein levels of multiple Brca1 isoforms. The Brca1 C61G 
allele may cause a more severe phenotype than Brca1 Δ11-deleted MEFs that is more like a 
Brca1-null phenotype.  
The effect on cytoplasmic and nuclear Brca1 C61G protein levels and its localisation does 
suggest that the C61G mutation cannot be seen as a mutation that only affects the N-
terminal functions of Brca1 nor as a separation-of-function mutation. Therefore, these MEFs 
cannot be used to support a function of the E3 ubiquitin ligase activity of Brca1. However, 
these cells have shown that this Brca1 N-terminal patient mutation, that does not appear as 
severe in sequence alteration as a truncating mutation, can have large effects on the Brca1 




Chapter 5 – Changes in cellular functions due to the Brca1 C61G 
mutation. 
5.1 Introduction 
In humans, the C61G mutation in a BRCA1 allele correlates to an increased risk of a person 
developing breast and ovarian cancer which is more likely to become a cancer that is difficult 
to treat (Section 1.2.1). This is the driving force behind exploring the effects of this specific 
mutation to tumourigenesis and cellular responses to chemotherapeutic agents. Many of the 
chemotherapeutic agents aim to cause large amounts of DNA damage that require BRCA1-
dependent homologous recombination (HR) to repair, which is erroneous in BRCA1-mutated 
tumours. This leads to an overwhelming amount of unrepaired DNA damage, causing the cell 
to die through an inability to divide correctly (mitotic catastrophe) or through apoptosis 
(programmed cell death).  
It has been shown that BRCA1-mutated tumours or BRCA1-mutated cancer cell lines are 
sensitive to specific double-strand break (DSB)-inducing agents, such as platinum agents 
(Cass et al., 2003; Tassone et al., 2003; Tassone et al., 2009) and poly (ADP)-ribose 
polymerase (PARP) inhibitors (PARPi) (Farmer et al., 2005; Fong et al., 2009; Turner et al., 
2008).  
BRCA1-mutated cells are sensitive to PARP inhibitors because they take advantage of 
synthetic lethality (Farmer et al., 2005; Fong et al., 2009; Lord et al., 2008). This is when 
blockage of several pathways of DNA damage repair causes lethality due to unrepaired DNA 
lesions. PARP inhibitors block the repair of ssDNA breaks (SSBs) (Gradwohl et al., 1990; 
Ménissier-de Murcia et al., 1989; Strom et al., 2011) which are converted into DSBs during 
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replication and are repaired through BRCA1-dependent HR (Liu et al., 2008; Satoh and 
Lindahl, 1992). Therefore when you treat BRCA1-mutated tumours with PARP inhibitors, 
SSBs are not repaired and in replication they become DSBs that cannot be repaired by HR 
due to the absence of BRCA1. This leaves the naturally occurring DSBs and the PARP 
inhibitor-induced DSBs (from SSBs) to be repaired through error-prone DSB repair pathways 
such as non-homologous end-joining (NHEJ). This leads to an overwhelming amount of DNA 
damage or errors and mutations in the DNA, which can be too many to repair or too 
damaging for the cell to survive and the cell will undergo apoptosis or mitotic catastrophe.  
Platinum agents, such as Cisplatin (Pascoe and Roberts, 1974; Royer-Pokora et al., 1981) and 
Mitomycin C (MMC) (Iyer and Szybalski, 1963), cause DNA crosslinks (or interstrand 
crosslinks; ICL) that are repaired by the FANC/HR pathway. BRCA1 mutated cancer cells are 
sensitive to these agents because mutated BRCA1 is not able to function and repair is 
impaired (Bhattacharyya et al., 2000; Bouwman et al., 2010; Bunting et al., 2012; Garcia-
Higuera et al., 2001; Long et al., 2014; Sawyer et al., 2015). Although it has been shown that 
the removal of 53bp1 from Brca1 mutated cells can restore HR (Bouwman et al., 2010; 
Bunting et al., 2010; Cao et al., 2009), it has also been shown that this does not rescue DNA 
crosslink repair (Bunting et al., 2012), suggesting BRCA1 has a 53bp1-independent role in 
DNA crosslink repair. 
BRCA1 mutated cells can become resistance to platinum-based agents (Fong et al., 2010; 
Rottenberg et al., 2008; Taniguchi et al., 2003) and in some studies this has been shown to 
be due to secondary BRCA1 reversion mutations (Norquist et al., 2011; Swisher et al., 2008) 
or wild-type BRCA1 allele overexpression (Husain et al., 1998; Johnson et al., 2013) 
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hypothesized to allow functional HR. BRCA1 mutated cells have also been shown to become 
insensitive to PARPi’s (Rottenberg et al., 2008) and in some studies PARPi resistance 
correlates with resistance to platinum-based drugs (Fong et al., 2010; Johnson et al., 2013; 
Norquist et al., 2011). Jaspers et al, and Oplustilova et al, show that the reduction in 53BP1 
protein (via shRNA targeting) or mutation in 53BP1, reduces the sensitivity of BRCA1 
mutated cells to PARPi’s (Jaspers et al., 2013; Oplustilova et al., 2012). Both papers suggest 
that it is the restoration of HR (shown by Rad51 foci in Jaspers et al) that causes this 
resistance to PARPi treatment (Jaspers et al., 2013; Oplustilova et al., 2012). In agreement 
with these papers, Johnson et al showed in some ovarian carcinomas that BRCA1 
overexpression alongside a reduction in 53BP1 protein confers resistance to platinum-based 
drugs and PARPi’s (Johnson et al., 2013).  
The development of drug resistance in BRCA1 mutated cells and the resistance caused by 
the removal of 53BP1 protein, highlights the need to study how these drugs cause sensitivity 
in BRCA1 mutated cells and how 53BP1 can alter these cells’ sensitivity to each agent.  
It is widely thought that the loss of the wild-type allele of BRCA1 in people who carry a 
BRCA1 mutation is the first step in tumourigenesis, but there is more evidence that this may 
not be the case. Some studies have shown that BRCA1 roles in DNA repair may be impaired 
by the loss of one BRCA1 allele, called haploinsufficiency (Cousineau and Belmaaza, 2007; 
Cressman et al., 1999b; Ernestos et al., 2010; Zhang et al., 1998). If BRCA1 mutations do 
cause haploinsufficiency, then it is perhaps necessary to look at the processes that happen 
before a BRCA1 mutation carrier develops cancer. This chapter will use both heterozygote 
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and homozygote Brca1 C61G cells to ascertain if this mutation causes haploinsufficiency in 
the cells response to DNA-damaging agents in the absence of 53bp1.  
This chapter will also look at the response of 53bp1-/-Brca1+/C61G and 53bp1-/-Brca1C61G/C61G 
cells to DNA-damaging agents that create DSBs in different ways. This will help isolate which 
Brca1 DNA damage repair roles are independent of 53bp1.  
Since the removal of 53bp1 has rescued the embryonic lethality of homozygote Brca1 C61G 
mice (Section 4.3), this chapter will also look at whether HR is functional in these mouse 
embryonic fibroblasts (MEFs) by looking at the formation of Rad51 foci after IR. It will also 
examine the response of the FANC and HR pathways after MMC in 53bp1-/-Brca1C61G/C61G 
cells, by looking at the formation of FANCD2 foci and Rad51 foci.  
5.2 Brca1 C61G sensitivity to DNA-damaging agents 
To further investigate if the removal of 53bp1 from Brca1 C61G mutant mice would also 
restore DSB repair, the previously described MEFs (Section 4.3) were treated with a range of 
doses of different DNA-damaging agents and the survival of these cells was measured in a 
clonogenic survival assay (Section 2.4.8). Brca1 Δ11 (exon 11-deleted) MEFs, (with or 
without 53bp1) were also subjected to the same experiment as a comparison, however, they 
cannot be directly compared as they have been spontaneously immortalised, unlike the 
Large T antigen immortalised Brca1 C61G MEFs (Table 4.1). 
It is important to note that 53bp1+/-Brca1+/C61G MEFs are used to compare with the results of 
the 53bp1-null homozygote MEF lines (which have either wild-type Brca1 alleles, or are 
heterozygote or homozygote for the Brca1 C61G mutation), as they possess a single wild-
type copy of the 53bp1 and Brca1 allele and one mutated allele. The literature suggests that 
144 
 
the removal of one copy of wild-type 53bp1 does not cause any sensitivity to DNA-damaging 
agents (Ward et al., 2003b). As for the Brca1 C61G allele, the 53bp1-null Brca1 C61G 
heterozygote cell line can be used to test for a heterozygote or a haploinsufficient 
phenotype. 
5.2.1 Ionising Radiation 
Ionising radiation (IR) produces many types of DNA damage (Painter, 1974) but gamma 
radiation predominantly causes DSBs (Yamamoto et al., 1985). BRCA1 is well known to play 
multiple roles in the repair of DSBs (Section 1.4.1) and the C61G mutation is thought to alter 
BRCA1’s role in DSB repair (Drost et al., 2011; Li and Yu, 2013; Nelson and Holt, 2010) (this is 
contested by Fan et al, (Fan et al., 2001b)). The removal of 53bp1 from Brca1 mutated mice 
rescues embryonic lethality and the HR repair defect (Bouwman et al., 2010; Bunting et al., 
2010; Bunting et al., 2012; Cao et al., 2009).  
BRCA1 is needed for efficient NHEJ (Bau et al., 2004; Bau et al., 2006; Coupier et al., 2004; 
Lee et al., 2000; Wang et al., 2006; Zhong et al., 2002b; Zhuang et al., 2006) through aiding 
micro-homology annealing (Zhong et al., 2002b) and precise end-joining (Wang et al., 2006; 
Zhuang et al., 2006). BRCA1 also has a role in the localisation of NBS1 (Kitagawa et al., 2004) 
and ATM (Wang et al., 2006) which is important for NHEJ.  
MEFs without a wild-type 53bp1 allele are known to be sensitive to IR because 53bp1 is 
important for the promotion of NHEJ (Ward et al., 2003b) to repair DSBs. As expected, 
53bp1-/-Brca1+/+ and 53bp1-/-Brca1+/C61G MEFs show significantly (p<0.05) reduced survival 
after treatment with 3, 5 or 8 Gray of IR (Figure 5.1a) compared to 53bp1+/-Brca1+/C61G cells. 
Cells with two copies of Brca1 C61G were significantly more sensitive to IR than cells with 
145 
 
one wild-type copy of Brca1 and one C61G mutated copy of Brca1 after 3 or 5 Gray of IR, 
suggesting that the C61G mutation does alter the ability of Brca1 to respond to IR-induced 






Figure 5.1 – Colony survival assays of MEFs after treatment with ionising radiation or 
Cisplatin 
[a] and [b] are colony survival assay results showing the survival of MEFs after treatment 
with varying doses of ionising radiation (IR) (0, 1, 3, 5 or 8 Gray) and [c] and [d] are colony 
survival assay results showing the survival of MEFs after treatment with varying doses of 
Cisplatin (0, 5µM, 10µM, 20µM and 30µM). The key on the left refers to the point shape and 
colour that depict each genotype. * represent points that are significantly different from each 
other (shown by black line) with a p value of <0.05 from a t-test. Error bars show standard 
error. Results are the average 3 or more separate experiments, each with 3 or more 
replicates.  
increased sensitivity may not be due to faulty HR but because of BRCA1’s role in NHEJ. Both 
the homozygote Brca1 Δ11 MEFs, with or without 53bp1 wild-type allele, were equally 
sensitive to IR (Figure 5.1b) despite of the literature showing that the removal of 53bp1 from 
the homozygote Brca1 Δ11 MEFs rescues the sensitivity of DSB-inducing agents (Bouwman 
et al., 2010; Bunting et al., 2010).  
5.2.2 DNA crosslinking agents 
Cisplatin is a DNA crosslinking agent (Pascoe and Roberts, 1974) and BRCA1 has a role in 
DNA crosslink repair (Bhattacharyya et al., 2000; Bouwman et al., 2010; Bunting et al., 2012; 
Garcia-Higuera et al., 2001; Sawyer et al., 2015). It has been shown that Brca1-defective cells 
are sensitive to DNA crosslinks (Bhattacharyya et al., 2000; Bouwman et al., 2010; Bunting et 
al., 2012; Garcia-Higuera et al., 2001; Sawyer et al., 2015) and removal of 53bp1 from 
Brca1Δ11/Δ11 cells, does not rescue this phenotype (Bunting et al., 2012). Although a rescue of 
Cisplatin sensitivity was seen in 53bp1-/-Brca1Δ5-13/Δ5-13 cells (Bouwman et al., 2010).  
In alignment with the literature (Mohni et al., 2015), figure 5.1c shows there is no difference 
in sensitivity to Cisplatin in cells without a wild-type copy of 53bp1 and those with (53bp1+/-
Brca1+/C61G and 53bp1-/-Brca1+/C61G), suggesting 53bp1 does not play a role in DNA crosslink 
repair. Cells with two copies of Brca1 C61G do show significant (p<0.05) sensitivity to 
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Cisplatin (with doses of 5, 10 or 20μM, suggesting that the C61G mutation does impair the 
role Brca1 has in DNA crosslink repair. Brca1 Δ11 MEFs are reported (Bunting et al., 2012) to 
be sensitive to DNA crosslinking agents with or without 53bp1 and figure 5.1d agrees with 
this finding. Figures 5.1c and d, both show that the removal of 53bp1 does not alter the 
sensitivity in Brca1-mutated cells, suggesting that Brca1’s role in DNA crosslink repair is 
independent of 53bp1.  
5.2.3 Topoisomerase inhibitor 
Topoisomerase enzymes relieve the stress of overwound DNA by inducing DNA breaks, 
allowing the DNA to unwind, and then the break is repaired (Poccia et al., 1978). 
Topoisomerase I relieves DNA stress by causing a SSB in the DNA which allows the tension to 
resolve and then reanneals the break (Liu and Wang, 1979). Camptothecin (CPT) is a 
topoisomerase I inhibitor which allows topoisomerase I to cause a SSB but does not allow it 
to anneal (Hsiang et al., 1985). It also does not allow topoisomerase I to release the DNA 
causing a bound complex of CPT, DNA and topoisomerase I (Hsiang et al., 1985). In the 
presence of CPT, topoisomerase I is covalently bound to the 3’ end of the SSB that it has 
created which leave the protein-DNA complex that needs to be cleaved to be resolved 
(Hsiang et al., 1985). CPT is therefore a poison. If these protein-DNA complexes and the 
involved SSB remain unrepaired, they are converted into DSBs during DNA replication (Liu et 
al., 2008; Satoh and Lindahl, 1992).  
Cells with two copies of Brca1 C61G show significantly (p<0.05) reduced survival after CPT 
treatment (20, 40 or 80μM) than cells with one or two copies of wild-type Brca1 (Figure 
5.2a). This suggests Brca1 has a role in resolving the DNA damage after treatment with CPT. 
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Cells with one wild-type copy of 53bp1 and one Brca1 C61G allele appear to be more 






Figure 5.2 – Colony survival assays of MEFs after treatment with Camptothecin or 
Hydroxyurea 
[a] and [b] are colony survival assay results showing the survival of MEFs after 16 hours of 
treatment with varying doses of Camptothecin (0, 20µM, 40µM, 80µM and 100µM) and [c] 
and [d] are colony survival assay results showing the survival of MEFs after 16 hours of 
treatment with varying doses of Hydroxyurea (0, 0.2mM, 0.4mM, 0.8mM and 1mM). The key 
on the left refers to the point shape and colour that depict each genotype. * represent points 
that are significantly difference from each other (shown by black line) with a p value of <0.05 
from a t-test. Error bars show standard error. Results are the average 3 or more separate 
experiments, each with 3 or more replicates.  
without 53bp1 (significantly for doses 20 and 80μM), suggesting 53bp1 hinders the repair of 
CPT lesions (Figure 5.2a). Previous papers have showed that the removal of 53bp1 (in a wild-
type Brca1 cell) can render cells resistant to CPT (Nakamura et al., 2006). But other papers 
have shown that 53bp1 depletion in the U20S cell line to sensitize cells to CPT (Yoo et al., 
2005). Brca1 Δ11 cells without 53bp1 are not significantly sensitive to CPT treatment as seen 
in Bunting et al (Bunting et al., 2010), but when they do have 53bp1 protein 
(53bp1+/+Brca1Δ11/Δ11) they are comparatively more sensitive (Figure 5.2b). Statistical analysis 
using a t-test showed that only at 20µM did CPT cause a significant difference in sensitivity in 
the Brca1 Δ11 MEFs, despite the cell survival difference seen between 53bp1+/+Brca1Δ11/Δ11 
and 53bp1-/-Brca1Δ11/Δ11 MEFs at higher doses of CPT. This agrees with the result that 53bp1 
has a role in antagonising the repair of CPT-induced DNA damage.  
5.2.4 DNA replication stress-inducing agents 
Replication stress can be induced when the ribonucleotide reductase enzyme (RNR) is 
inhibited and nucleotides are not available for replication to continue (Levenson and Hamlin, 
1993). This leads to replication fork stalling which, after a period of time, leads to replication 
forks collapsing into DSBs (Saintigny et al., 2001). Hydroxyurea (HU) is a RNR inhibitor (Sinha 
and Snustad, 1972) which temporarily stalls replication forks that can be restarted if HU is 
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removed, or become DSBs if HU is present for an extended period of time, such as 16 hours 
(Saintigny et al., 2001).  
53bp1-null cells containing one or two copies of Brca1 C61G show a reduced cell survival 
after a 16 hour treatment of HU (53bp1-/-Brca1+/C61G- all doses;53bp1-/-Brca1C61G/C61G- 0.8mM 
only) (Figure 5.2c) compared to cells with only wild-type Brca1. 53bp1+/-Brca1+/C61G cells 
shows a variable intermediate phenotype and 53bp1-/-Brca1+/C61G cells are significantly more 
sensitive to HU than cells with two copies of Brca1 C61G at doses 0.2 and 0.8mM. This may 
suggest that a single copy of Brca1 C61G does alter the resolution of HU-induced DSBs which 
is enhanced by the removal of 53bp1. Supporting this, the removal of 53bp1 has been shown 
to sensitise cells to HU (Tripathi et al., 2007). However, this does not help explain why cells 
with no wild- type 53bp1 and two copies of Brca1 C61G are not as sensitive as 53bp1-/-
Brca1+/C61G cells. This could be further supported by the use of other replication stress-
inducing agents, to look for similar results. Brca1 Δ11 cells show greater sensitivity to HU 
when 53bp1 is removed in figure 5.2d, which agrees with figure 5.2c that the lack of 53bp1 
does make Brca1-mutated cells more sensitive to HU-induced DNA damage. 
5.2.5 PARP inhibitors 
PARPi’s target poly (ADP)-ribose polymerase (PARP) enzyme which is important for the 
creation of PAR chains at sites of single-strand breaks (Altmeyer et al., 2009). These chains 
lead to the correct recruitment of repair proteins to ensure the single-strand breaks are 
repaired (Gradwohl et al., 1990; Ménissier-de Murcia et al., 1989; Strom et al., 2011); 
otherwise single-strand breaks will become a double-strand break during replication (Liu et 
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al., 2008; Satoh and Lindahl, 1992). PARPi’s have been used to overburden BRCA1 and 






Figure 5.3 – Colony survival assays of MEFs after treatment with Olaparib or Veliparib 
[a] and [b] are colony survival assay results showing the survival of MEFs after 2 hours of 
treatment with varying doses of Olaparib (0, 2µM, 4µM, 10µM and 20µM) and [c] and [d] are 
colony survival assay results showing the survival of MEFs after 2 hours of treatment with 
varying doses of Veliparib (0, 2µM, 4µM, 10µM and 20µM). The key on the left refers to the 
point shape and colour that depict each genotype. * represent points that are significantly 
different from each other (shown by black line) with a p value of <0.05 from a t-test. Error 
bars show standard error. Results are the average 3 or more separate experiments, each with 
3 or more replicates.  
therefore cells die (through apoptosis or mitotic catastrophe) (Bryant et al., 2005; Farmer et 
al., 2005). Olaparib and Veliparib are both PARPi’s but they have slightly different results in 
the lesion that is created on the DNA (Murai et al., 2012). Both Olaparib and Veliparib inhibit 
PARP which hinders single-strand break repair, but they have the potential to stabilise the 
PARPi/PARP/DNA complex (Murai et al., 2012). Veliparib creates a weaker DNA/PARP 
complex than Olaparib, and falls off the DNA readily (Murai et al., 2012), leaving the single-
strand break unrepaired. Olaparib does not disassociated with the DNA/PARP complex 
easily. This action by Olaparib creates a lesion on the DNA that needs to be removed before 
the DNA damage can be repaired, making Olaparib a poison. Any single-strand break that is 
not repaired is converted to a DSB during replication. Due to the difference in Olaparib and 
Veliparib potency, more Veliparib is needed to produce the same PAR reduction than 
Olaparib (Murai et al., 2012).  
Cells with functional HR DSB repair are not sensitive to PARPi’s as when the SSBs are 
converted into DSBs they are repaired efficiently. If the cell is HR-defective (such as a 
homozygote Brca1 mutation) than the DSBs created in replication will be repaired by a less 
error-free repair pathways (i.e. NHEJ) which will lead to unrepaired DNA or mutated DNA. In 
cells that have a wild-type copy of Brca1 and 53bp1 (53bp1+/-Brca1+/C61G MEFs), HR repair will 
not be defective and therefore will not be sensitive to PARPi’s.  
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Previous papers (Bunting et al., 2010; Bunting et al., 2012) have reported that 53bp1 
removal from Brca1-mutated cells renders resistance to PARPi, and 53bp1 loss is seen in 
some PARPi resistance Brca1-mutated mouse tumours (Jaspers et al., 2013; Johnson et al., 
2013).  
Figure 5.3a shows that there is no significant reduction in cell survival after Olaparib 
treatment between MEFs carrying one or two copies of the Brca1 C61G allele and MEFs with 
only wild-type Brca1. Brca1 C61G homozygote MEFs that have intact 53bp1 are needed to 
determine if the Brca1 C61G does cause sensitivity to PARP inhibitors. From this experiment 
it cannot be said if the removal of 53bp1 plays a role in PARP sensitivity in Brca1 C61G-
mutated cells. Neither the 53bp1-/-Brca1Δ11/Δ11 MEFs, nor the 53bp1+/+Brca1Δ11/Δ11 cells show 
any sensitivity to Olaparib, despite there being a statistically significant difference in colony 
number after treatment. Bunting et al (Bunting et al., 2010), showed that Brca1 Δ11 
homozygote cells were sensitive to the PARPi Ku58948, and that the removal of 53bp1 
alleles from homozygote Brca1 Δ11 MEFs reduced this sensitivity. Figure 5.3b does not show 
an increase sensitivity in 53bp1+/+Brca1Δ11/Δ11 MEFs to Olaparib which does not replicate the 
sensitivity to PARPi using these MEFs in Bunting et al (Bunting et al., 2010).  
Figure 5.3c shows no difference in sensitivity between 53bp1-/-Brca1C61G/C61G cells and 
53bp1+/-Brca1+/C61G cells after Veliparib treatment. The only significantly different data point 
(p<0.05) between these cells is at 10µM of Veliparib but this small difference is unlikely to 
convey any functional significance between the genotypes. Brca1 Δ11 cells with 53bp1 also 
lack sensitivity to Veliparib but cells without 53bp1 appear to have a small growth advantage 
(due to their being more growth than untreated cells) (Figure 5.3d). Although there are 
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significant data points, this data is unlikely to be functionally relevant and would need to be 
repeated with various clones of each genotype and several PARP inhibitors with similar 
properties as Veliparib, before it can be said to show a functional growth advantage.  
Brca1 Δ11 homozygote MEFs show no sensitivity to Olaparib and Veliparib despite Bunting 
et al papers (Bunting et al., 2010; Bunting et al., 2012) showing Brca1 Δ11 MEFs are sensitive 
to the PARP inhibitor Ku58948 and this sensitivity can be rescued by the removal of 53bp1. 
One reason for this difference may be that Ku58948 have slightly different activities to 
Olaparib and Veliparib. Another reason could be that the Brca1 Δ11 MEFs have acquired 
unknown mutations during culture that have altered their sensitivity to PARP inhibitors. This 
could be determined by using multiple early passage clones from the cell line or a MEF line 
from a genetically identical embryo.  
Unfortunately the results in this section cannot determine if Brca1 C61G does cause 
sensitivity to PARP inhibitors as there isn’t a 53bp1 wild-type Brca1 C61G homozygote 
control MEF line. It is important to note that the PARPi’s were confirmed to be active 
because other members of the lab were using the stocks at the same time and getting 
positive sensitivity data. These results have also not been able to replicate previous PARP 
sensitivity seen in the Brca1 Δ11 homozygote cells. Therefore more experiments using 
multiple clones and 53bp1-reconsituted Brca1 C61G homozygote MEFs are needed to 
investigate the role of 53bp1 removal on Brca1 C61G MEFs.  
5.3 IR-induced Rad51 foci and HR 
As discussed in the introduction (Section 1.4.1), Rad51 localises to the sites of resected DNA 
that is coated in pRPA, where it displaces the RPA and directly connects with the single-
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stranded DNA (Sung and Robberson, 1995). Rad51 polymers provide a filament that can find 









Figure 5.5 – Ionising radiation treated MEFs stained for Rad51 foci 
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Figure 5.4 – Untreated MEFs stained for Rad51 foci  
This figure shows a panel of images of untreated cells stained to show the nucleus (Hoechst-
blue), Cyclin A (green) and Rad51 foci (red). The genotype of the MEFs are stated on the left 
of the row and the final images on the row (far right) are a merged image of all stains 
(MERGE). White lines outline the nucleus of the cells. Scale bar is 5µm.  
 
Figure 5.5 – Ionising radiation treated MEFs stained for Rad51 foci  
This figure shows a panel of images of cells treated with 5 Gray of ionising radiation and 
fixed 4 hours post-IR. They were then stained to show the nucleus (Hoechst-blue), Cyclin A 
(green) and Rad51 foci (red). The genotype of the MEFs are stated on the left of the row and 
the final images on the row (far right) are a merged image of all stains (MERGE). White lines 





Figure 5.6 – Foci count of Rad51 foci in Cyclin A positive untreated and IR-treated cells 
[a] shows the percentage of cells with more than 5 Rad51 foci in Cyclin A positive cells in 
untreated cells. [b] shows the percentage of cells with more than 5 Rad51 foci in Cyclin A 
positive cells 4 hour after being treated with ionising radiation. These percentages are from 3 
separate experiments in which 100 cells of each condition were analysed. The error bars 
represent standard error and the asterisks (*) show which data points are significantly 
different from each other with a p value of less than 0.01 after a t-test (type 2 two-tailed 






resected DNA (Saleh-Gohari and Helleday, 2004; Sung, 1994). This is a pinnacle step making 
this type of DSB repair predominantly error-free (Saleh-Gohari and Helleday, 2004). The use 
of a sister chromatid as a template means cells must be in S or G2 phase to perform HR 
(Saleh-Gohari and Helleday, 2004).  
Rad51 is used as a marker to show that HR is induced and Rad51 foci formation is defective 
in many HR protein-mutated cells (Bhattacharyya et al., 2000; Digweed et al., 2002; 
Godthelp et al., 2002; O'Regan et al., 2001; Yuan et al., 1999). It is important to note that 
although Rad51 is downstream of proteins that are important for HR, it is not the final step. 
Rad51 foci do not indicate successful ligation of the DSB DNA strands or if the DSB repair was 
error-free. Figures 5.4 and 5.5 are of MEFs that were either untreated or exposed to 5 Gray 
of IR, and fixed after 4 hours. The cells were permeablised (See methods section 2.4.7) and 
stained for Cyclin A (green), Rad51 (red) and DNA (Hoechst-blue). Cells that positively stain 
for Cyclin A are in S or G2 phase of the cell cycle (Carbonaro-Hall et al., 1993), where HR is 
possible due to the presence of a sister chromatid. The untreated MEFs (Figure 5.4) show a 
low level of Rad51 foci in Cyclin A-positive cells. There is a dramatic increase of bright Rad51 
foci in Cyclin A-positive cells in MEFs treated with IR (Figure 5.5). To quantify this further, the 
Rad51 foci in 100 Cyclin A-positive cells of each IR treated condition were counted from 
three separate experiments.  
Figure 5.6a shows there is no significant difference between genotypes in the number of 
Cyclin A positive cells with more than 5 Rad51 foci. This is likely due to there being no defect 
of Rad51 foci in cells with the low level of spontaneous DNA damage caused by any of the 





Figure 5.7 – Foci count of Rad51 foci in Cyclin A negative untreated and IR-treated cells 
[a] shows the percentage of cells with more than 5 Rad51 foci in Cyclin A negative cells in 
untreated cells. [b] shows the percentage of cells with more than 5 Rad51 foci in Cyclin A 
positive cells 4 hours after being treated with ionising radiation. These are results from a 






foci in MEFs with one or two copies of Brca1 C61G. The lack of 53bp1 does appear to affect 
the number of Rad51 foci. 53bp1+/+Brca1Δ11/Δ11 MEFs show a significant decrease (p<0.01) in 
the levels of Rad51 foci but the removal of 53bp1 (53bp1-/-Brca1Δ11/Δ11) increases the 
number of Rad51 foci, which agrees with the previous paper (Bouwman et al., 2010) . This 
rescue suggests that the removal of 53bp1 in Brca1 Δ11 mutated cells restores the ability of 
HR to progress to form Rad51 foci because 53bp1 is absent as an antagonist to DSB end 
resection. The similar level of Rad51 foci in 53bp1-/-Brca1C61G/C61G cells to 53bp1+/-Brca1+/C61G 
cells would suggest that HR is functional up to the point of Rad51 foci production in these 
cells. Drost et al (Drost et al., 2011), use a HR assay to show that the Brca1 C61G mutation 
does reduce the levels of HR, but the Brca1 C61G mutated tumour cells produced Rad51 foci 
unlike the Brca1-null tumour cells. This brings into question whether the C61G mutation is 
important for the presence of Rad51 foci, as the tumour cells will have acquired unknown 
mutations. Unfortunately wild-type 53bp1 Brca1 C61G homozygote cells could not be 
cultured to examine the Rad51 foci in these cells (neither through isolation of 
53bp1+/+Brca1C61G/C61G MEFs nor the re-introduction of 53bp1 cDNA).  
HR should be only possible in S/G2 phase because cells need a copy of the gene, a sister 
chromatid, to complete repair and as a result of this, HR is cell cycle controlled. It is possible 
to see some Rad51 foci in G1 cells due to microhomology repair and/or other functions of 
Rad51 that cause the formation of foci. Figure 5.7a shows that in untreated Cyclin A negative 
cells, indicative of G1, there are more cells with more than 5 Rad51 foci in 53bp1-/- cells than 
those with a copy of wild-type Brca1. This could be an indicator that the removal of 53bp1 
increases the ability of HR to be induced in G1. Cells with one or two copies of Brca1 C61G 
allele show a reduction in the percentage of cells with more than 5 Rad51 foci compared to 
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53bp1-/-Brca1+/+ cells. It has been suggested that the mutation of Brca1 in 53bp1-null cells 
can lead to a partial restoration of NHEJ due to the lack of control of DSB repair choice 
pathway (Bunting et al., 2010). This could be the reason for this difference between the 
genotypes. Figure 5.7b shows cells in G1 after being treated with 5 Gray of IR that have been 
counted for the number of Rad51 foci. Again, there is an increase of cells with more than 5 
Rad51 foci in 53bp1-/-Brca1+/+ cells and a reduction with one or two copies of Brca1 C61G. 
This is likely to be for the same reasons as the differences in Rad51 foci between genotypes 
in the untreated MEFs. However, the increase level of cells with more than 5 Rad51 foci in 
53bp1+/-Brca1+/C61G MEFs could indicate a heterozygote phenotype of a reduced control of 
DSB repair pathway due to the single mutations in 53bp1 and Brca1. Figure 5.7 is based on 
n=1 data and therefore cannot be tested to see if the differences are significantly different. 
Therefore the experiment in this figure will need to be repeated for a conclusive result.  
As discussed, Rad51 foci do not represent the final completion step of HR and figure 5.1a 
shows that Brca1 C61G does cause 53bp1-independent IR sensitivity, which together 
suggests that the Brca1 C61G mutation does have a 53bp1-independent role in the repair of 
DSBs, despite there being no defect in Rad51 foci formation.  
5.4 Heterochromatin and BRCA1 
BRCA1 is involved in regulating chromatin structure which can be disrupted by BRCA1-
mutations (Ye et al., 2001; Zhu et al., 2011). It has been reported to be responsible for both 
condensation (Zhu et al., 2011) and the unfolding of DNA (Ye et al., 2001). Condensed 
regions of chromatin (heterochromatin centres) can be seen using a DNA stain (Hoechst) 




Figure 5.8 – Heterochromatin centres in nuclei 
This figure shows untreated MEFs stained with Hoechst. The lighter grey regions show the 
heterochromatin centres and the darker grey regions in the nucleus represent the less dense 






Figure 5.9 – Heterochromatin centre number alterations 
[a] shows the average number of heterochromatin centres per cell in MEFs. [b] shows the 
number of cells with each number of foci in the indicated range. Error bars show the 
standard deviation. These results were determined through staining the DNA (Hoechst) of 




level of condensation of satellite regions in chromatin resulting in a reduction in 
heterochromatin centres (Zhu et al., 2011). This alteration in condensed regions can alter 
the regulation and transcription of genes and, in turn, this can cause dramatic effects to the 
regulation of cellular processes. Zhu et al, showed that the deregulation of satellite DNA by 
the loss of Brca1 was sufficient to produce Brca1 tumour suppressor-associated defects such 
as genome instability (Zhu et al., 2011). Ye et al, show that Brca1 is needed for de-
condensation of specific regions of DNA (Ye et al., 2001), suggesting that Brca1’s function in 
chromatin organisation may be specific to the region of DNA involved. Figure 5.8 shows 
MEFs fixed and stained with Hoechst to show the heterochromatin centres and the nucleus 
of the cells. 100 cells from this single experiment were analysed for the number of 
heterochromatin centres and these preliminary results are shown in figure 5.9. Figure 5.9a 
shows the average number of heterochromatin centres per cell in the nucleus for each 
genotype. Figure 5.9b shows the number of cells containing the number of heterochromatin 
centres within the stated range. Figure 5.9a shows fewer heterochromatin centres per cell in 
cells without 53bp1 and with one or two copies of Brca1 C61G. Figure 5.9b shows that there 
are more cells within the 11-20, and 21-30 heterochromatin centres per cell range in the 
MEFs that have one or two copies of Brca1 C61G and lack 53bp1. These results could suggest 
that removal of one or two copies of Brca1 C61G further reduces the number of 
heterochromatin centres. This preliminary data could suggest that Brca1 have a role in 
heterochromatin centre number and that Brca1’s role is disrupted by the C61G mutation.  
These results are from 100 cells of each condition from a single experiment and therefore 
would need to be repeated before any conclusions could be made. Also, this data 
interpretation is difficult as these images were not taken using a confocal microscope, and 
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therefore the identification of heterochromatin centres throughout the cells is not as precise 
as on images from a confocal microscope. This could be improved by identification of 
heterochromatin through an antibody that is more specific to heterochromatin than 
Hoechst, such as HP1. This experiment would be improved by using a confocal microscope 
and co-staining with a heterochromatin marker.  
5.5 DNA crosslink repair FANCD2 and Rad51 foci 
As discussed in the introduction, BRCA1 has been shown to have an HR-independent role in 
DNA crosslink repair (Bunting et al., 2012; Long et al., 2014) (Section 1.4.1), which results in 
cells carrying a mutated Brca1 allele being sensitive to MMC and Cisplatin (Bhattacharyya et 
al., 2000; Bouwman et al., 2010; Bunting et al., 2012; Garcia-Higuera et al., 2001; Sawyer et 
al., 2015) even after the removal of 53bp1 (Bunting et al., 2012) (although Bouwman et al, 
did not see this (Bouwman et al., 2010)). BRCA1 is known to be essential for the localisation 
of ubiquitinated FANCD2 (Bunting et al., 2012; Castella et al., 2015; Garcia-Higuera et al., 
2001; Long et al., 2014; Vandenberg et al., 2003; Yeo et al., 2014; Zhang et al., 2010) and 
Rad51 (Bhattacharyya et al., 2000; Long et al., 2014; Sawyer et al., 2015) to sites of DNA 
crosslinks and DSBs, although BRCA1, Rad51 and FANCD2 do colocalise in the nuclear foci in 
S phase without cells being treated with DNA-damaging agents (Hussain et al., 2004; Long et 
al., 2014; Taniguchi et al., 2002).  
MMC (Iyer and Szybalski, 1963) and Cisplatin (Pascoe and Roberts, 1974) are both DNA 
crosslinking agents, but Cisplatin induces intrastrand crosslinks in the DNA at a higher level 
than interstrand crosslinks (Royer-Pokora et al., 1981). Despite this difference MMC and 








Figure 5.11 – Mitomycin C treated MEFs stained for FANCD2 foci 
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 Figure 5.10 – Untreated MEFs stained for FANCD2 foci  
This figure shows a panel of images of untreated cells stained to show the nucleus (Hoechst-
blue) and FANCD2 foci (red). The genotype of the MEFs are stated on the left of the row and 
the final images on the row (far right) are a merged image of all stains (MERGE). White lines 
outline the nucleus of the cells. Scale bar is 10µm.  
 
Figure 5.11 – Mitomycin C treated MEFs stained for FANCD2 foci  
This figure shows a panel of images of cells treated with 250ng/µl of mitomycin C for 24 
hours. They were then fixed and stained to show the nucleus (Hoechst-blue) and FANCD2 foci 
(red). The genotype of the MEFs are stated on the left of the row and the final images on the 
row (far right) are a merged image of all stains (MERGE). White lines outline the nucleus of 
the cells. Scale bar is 10µm.  
Figure 5.1d shows an equal amount of sensitivity to Cisplatin with or without 53bp1, in 
Brca1Δ11/Δ11 cells as previously shown in Bunting et al (Bunting et al., 2012). Figure 5.1c 
showed that cells without 53bp1 and two copies of the Brca1 C61G allele, are also sensitive 
to Cisplatin. To investigate this sensitivity further, cells were treated with MMC (250ng/µl) 
for 24 hours, and the FANCD2 foci were counted.  
In untreated MEFs, there were FANCD2 foci in cells from every genotype (Figure 5.10) and 
when treated with MMC the number of foci greatly increased (Figure 5.11). The average 
number of cells with more than 10 FANCD2 foci in untreated and MMC treated cells is 
displayed in figure 5.12. These averages are from 100 cells counted in each genotype in 
three separate experiments. There is no significant difference between genotypes in the 
number of cells with more than 10 FANCD2 foci in untreated MEFs (Figure 5.12a), suggesting 
that none of the Brca1 mutations or the lack of 53bp1 causes a defect in spontaneously 
induced ICL repair, although the levels of damage may be too small to quantify a difference. 
The 53bp1+/+Brca1Δ11/Δ11 cells show a reduced number of cells with more than 10 FANCD2 
foci (Figure 5.12b) as seen in Bunting et al (Bunting et al., 2012), but the removal of 53bp1 
shows an increase in this number. This is interesting as in Bunting et al (Bunting et al., 2012), 
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they show a small decrease (not significant) in FANCD2 foci in 53bp1-/-Brca1Δ11/Δ11 cells 
compared to Brca1 Δ11 cells with 53bp1, but figure 5.12b shows the opposite. It should also 
be noted that although the Cisplatin sensitivity between these two genotypes is not  
 
 
Figure 5.12 – Foci count of FANCD2 foci in untreated and MMC treated MEFs 
[a] shows the percentage of cells with more than 10 FANCD2 foci in untreated cells. [b] shows 
the percentage of cells with more than 10 FANCD2 foci after being treated with 250ng/µl of 





which 100 cells of each condition were analysed. The error bars represent standard error and 





Figure 5.13 – FANCD2 protein levels after MMC treatment in MEFs 
This figure shows the western blot depicting the protein levels of FANCD2 and β-tubulin in the 






Figure 5.14 – Foci count of Rad51 foci in Cyclin A positive untreated and MMC treated 
MEFs 
[a] shows the percentage of cells with more than 10 Rad51 foci in untreated Cyclin A positive 
cells. [b] shows the percentage of Cyclin A positive cells with more than 10 FANCD2 foci after 
being treated with 250ng/µl of mitomycin C (MMC) for 24 hours. These percentages are from 
3 separate experiments in which 100 cells of each condition were analysed. The error bars 
represent standard error and the significant p values from a t-test are indicated (type 2, two-







Figure 5.15 – Foci count of Rad51 foci in Cyclin A negative untreated and MMC treated 
MEFs 
This figure shows the average number of Rad51 foci untreated and mitomycin C (MMC) 
treated Cyclin A negative cells. Treated cells were treated with 250ng/µl of MMC for 24 
hours. These percentages are from 3 separate experiments. The error bars represent 
standard error and the significant p values from a t-test are indicated (type 2, two-tailed 
student t-test).  
significantly different, figure 5.1d does show a small improvement in survival in 53bp1-/-
Brca1Δ11/Δ11 cells. The removal of both wild-type copies of 53bp1 does not cause a significant 
change in the amount of FANCD2 foci (Figure 5.12a) produced after MMC treatment 
compared to 53bp1+/-Brca1+/C61G MEFs. The presence of two copies of the Brca1 C61G allele 
does significantly increase (p>0.05) the number of FANCD2 foci after MMC. This almost 2-
fold increase has not been reported before with a BRCA1 mutation. This result could indicate 
there is reduced repair and clearance of FANCD2 foci. If this is true, then this may indicate a 
blockage in the DNA crosslink repair response pathway. The increase in FANCD2 foci may be 
due to an increase in FANCD2 protein levels allowing more sites of DNA damage to have 
sufficient protein to be visible using immunofluorescence.  
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Figure 5.13 shows that the levels of FANCD2 are similar across the genotypes suggesting no 
correlation between BRCA1 genotype and FANCD2 protein levels. The increase in protein 
band width in the MMC treated samples is likely to be due to the modified FANCD2 protein 
that has not resolved into a separate band in this experiment. The amount of ubiquitinated-
FANCD2 is known not to be affected by BRCA1 mutation (Bunting et al., 2012; Long et al., 
2014; Vandenberg et al., 2003). 
Rad51 foci were counted in 100 cells, from 3 separate experiments, to see if DNA crosslink 




Figure 5.16 – Untreated MEFs stained for Rad51 foci 
This figure shows a panel of images of untreated cells stained to show the nucleus (Hoechst-
blue), Cyclin A (green) and Rad51 foci (red). The genotype of the MEFs are stated on the left 
of the row and the final images on the row (far right) are a merged image of all stains 





Figure 5.17 – Mitomycin C treated MEFs stained for Rad51 foci 
This figure shows a panel of images of cells treated with 250ng/µl of mitomycin C for 24 
hours. They were then fixed and stained to show the nucleus (Hoechst-blue), Cyclin A (green) 
and Rad51 foci (red). The genotype of the MEFs are stated on the left of the row and the final 
images on the row (far right) are a merged image of all stains (MERGE). White lines outline 
the nucleus of the cells. Scale bar is 10µm.   
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untreated cells and figure 5.17 shows MMC treated cells (24 hours 250ng/µl) stained with 
Cyclin A, Rad51 foci and Hoerchst (DNA). It is clear that the number of Rad51 foci do increase 
in cells upon treatment with MMC in Cyclin A-positive (S/G2 phase) cells, compared to 
untreated cells. Figure 5.14 are the percentage of untreated and MMC-treated cells from 
this experiment that have more than 10 Rad51 foci in S/G2 (Cyclin A positive cells). Whilst 
the untreated (Figure 5.14a) and MMC-treated (Figure 5.14b) MEFs shows the same 
relationship of Rad51 foci between genotypes (more/less in the same genotypes when 
compared), these results are not significantly different. In figure 5.14b, 53bp1 wild-type and 
53bp1-null Brca1 Δ11 MEFs show a similar percentage of cells with more than 10 Rad51 foci, 
although slightly lower percentage is seen in the cells with 53bp1. This is in agreement with 
53bp1 removal failing to rescue the DNA crosslink sensitivity seen in Brca1 Δ11 MEFs. The 
removal of 53bp1 from Brca1-mutated cells does restore the Rad51 foci after IR (Figure 5.6) 
suggesting HR is induced (Bouwman et al., 2010; Bunting et al., 2010; Cao et al., 2009). DNA 
crosslink repair uses the HR pathway for the final stages of repair (Bunting et al., 2012; Hinz 
et al., 2007; Knipscheer et al., 2009; Long et al., 2014) and the NHEJ pathway is antagonised 
through FA signalling to promote this use of HR (Adamo et al., 2010; Lundberg et al., 2001; 
Pace et al., 2010). This idea is consistent with BRCA1 having a 53bp1-independent role in 
DNA crosslink repair and the removal of 53bp1 having little effect on HR repair of DNA 
crosslinks (Bunting et al., 2012; Mohni et al., 2015). In contrast, the removal of wild-type 
53bp1 from MEFs does appear to cause a small increase in Rad51 foci (Figure 5.14b) albeit 
not significant, suggesting there may be a role of 53bp1 in antagonising Rad51 foci formation 
after MMC.  
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Two copies of Brca1 C61G have half the average number of cells with more than 10 Rad51 
foci as cells with one or more copy of wild-type Brca1 (Figure 5.14b). Considering that the 
number of Rad51 foci in 53bp1-/-Brca1C61G/C61G MEFs is comparable to Brca1 wild-type MEFs 
after IR (Figure 5.6), it is interesting that there is a reduction after MMC treatment. Since the 
HR pathway has shown to be functional to the production of Rad51 foci in these MEFs after 
IR, this result suggests that the lack of Rad51 foci after MMC is due to a block on DNA 
crosslink repair that occurs before the HR pathway is used for the DNA repair.  
As discussed in section 5.3, Rad51 foci in Cyclin A negative cells can indicate that the DNA 
repair is not as controlled due to the mutation of Brca1 and 53bp1. This experiment 
quantified the actual number of Rad51 foci, unlike the IR-Rad51 experiment looked for more 
than 5 foci. As in the results after IR (Figure 5.7), there is an increase in Rad51 foci in 53bp1-/-
Brca1+/+ and the same intermediate effect in Brca1 C61G heterozygote MEFs. Although 
MMC-induced ICLs do require parts of HR to repair their DNA, the DNA is repaired in G1 and 
therefore the Rad51 foci in the G1 cells in this experiment are likely to be due to any 
spontaneous DNA damage or the resulting DNA damage due to abnormal ICL repair followed 
by mitosis. Due to this, it is most likely a confirmation of the abnormal DSB repair control in 
G1 and not necessarily to do with these mutations causing effects on the FANC pathway in 
the G1 phase of the cell cycle.  
The decrease in Rad51 foci with the increase in FANCD2 foci seen in 53bp1-/-Brca1C61G/C61G 
MEFs, together could suggest that these MEFs have faulty FANCD2 foci disassembly which 
causes DNA crosslink repair to be blocked before Rad51 foci can be produce. This would 
show that Brca1 C61G alters the role Brca1 in FANCD2 disassembly, not in recruitment or 
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localisation of foci. This is not the case with the Brca1 Δ11 mutation suggesting that these 
mutations have different effects on the role of Brca1 in DNA crosslink repair.  
5.6 Discussion 
This chapter has highlighted the roles of 53bp1 and Brca1 that are dependent-on and 
independent-of each other in response to DNA damage and cellular control.  
53BP1 has well studied roles in NHEJ and in the prevention of DSB end resection which is 
antagonised by BRCA1, but it also has roles in chromosome and telomere stability that are 
independent of BRCA1. This chapter has also shown a Brca1-independent role for 53bp1 in 
the repair of DNA damage after CPT and HU that would be interesting to study further.  
This thesis has agreed with the literature that the removal of 53bp1 from homozygote Brca1-
mutated mice does rescue embryonic lethality, and in cells, the lack of 53bp1 restores the 
formation of Rad51 foci after IR. However, the Brca1 C61G mutation appears to render cells 
sensitive to IR despite the presence of Rad51 foci. The IR sensitivity alongside the 53bp1-
independent sensitivity seen after CPT, HU and Cisplatin, suggest Brca1 has other roles in 
DNA repair that does not involve the removal of 53bp1 from DSB sites.  
Since IR causes multiple types of DNA damage, the sensitivity seen may be due to the same 
lesion-removal defect that causes sensitivity to other DNA-damaging agents. BRCA1 has 
been reported, alongside CtIP and the MRN complex, to be involved in Topoisomerase II-
induced DNA/protein lesions (Aparicio et al., 2016). BRCA1 has a role in the removal of CMG 
protein complex from sites of DNA crosslinks before a DSB is created (Long et al., 2014) 
(Figure 5.18). BRCA1 mutated cells have previously shown a lack of FANCD2 foci after 




Figure 5.18 – Model of BRCA1 function in the DNA crosslink/FANC repair pathway 
This figure shows simplified points in the DNA crosslink repair pathway (blue arrows) 
alongside the evidence shown in this thesis and possibly defects caused by the Brca1 C61G 




therefore explaining the DNA crosslink sensitivity seen in BRCA1-mutated cells (Bouwman et 
al., 2010; Bunting et al., 2012; Garcia-Higuera et al., 2001; Vandenberg et al., 2003; Zhang et 
al., 2010). FANCD2 then localises nucleases that create a DSB and this is repaired through 
HR, which includes the formation of Rad51 foci. In this chapter, the data shows that 53bp1-/-
Brca1C61G/C61G mutated cells have increased levels of FANCD2 foci, which has not been shown 
before, and reduced levels of Rad51 foci (Figure 5.18). This does not support a role for 
BRCA1 that is upstream of FANCD2 localisation to foci, and one speculation is that Brca1 may 
be involved in the disassembly of FANCD2 foci. Since we do not currently have the data to 
pin-point the step at which Brca1 affects the repair. Figure 5.18 shows a model of ICL repair 
and Brca1’s role in this pathway, alongside the possible steps that are faulty to cause the 
phenotype described in this chapter. This data does support a role of BRCA1 in DNA crosslink 
repair that is independent of its role in HR and independent of 53bp1, since there is a 
reduction in Rad51 foci after MMC but not after IR. This is also concurs with the homozygote 
Brca1 C61G cell sensitivity seen after Cisplatin treatment.  
Many of the 53bp1-independent Brca1 phenotypes described in this chapter may lead to the 
DNA damage sensitivity of Brca1 C61G homozygote cells. It has been discussed that the IR 
sensitivity in cells that produce IR-induced Rad51 foci indicative of active HR, may suggest 
that Brca1 C61G homozygote cells do not repair DNA damage in an error-free manner. It has 
been suggested that both NHEJ and HR are possible after the removal of 53bp1 and wild-
type Brca1 (Bouwman et al., 2010; Bunting et al., 2010), but this does not mean that the 
repair in these cells is precise. This reduced control over HR (error-free) and NHEJ (error-
prone) at a DSB is shown in untreated MEFs (Figure 5.7 and 5.15). It may be that the repair 
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leaves errors that could involve sister chromatid exchanges leading to loss of heterozygosity 
or mutation in genes that cause DNA-damaging agent sensitivity.  
Another phenotype that may cause DNA damage sensitivity and genome instability 
described in the Brca1 C61G homozygote cells is the relaxation of the chromatin leading to 
less heterochromatin centres (Figure 5.8). This can lead to the activation of genes and 
transcriptional regulators that alter the global cell response to DNA damage. It has been 
suggested that this alone can promote tumourigenesis (Zhu et al., 2011).  
The literature is contradictory as to whether a single mutated allele of BRCA1 can cause 
cellular defects that promote tumourigenesis without the loss of heterozygosity (LOH). Many 
studies have looked at whether DNA damage repair is altered in patient samples from BRCA1 
mutation carriers with or without cancer and individuals without an inherited BRCA1 
mutation, and the results have been divided. Whilst several papers suggest there is no 
difference in DNA damage repair in BRCA1 mutation carrier cells compared to wild-type cells 
(Baeyens et al., 2002; Baeyens et al., 2004; Baria et al., 2001; Nieuwenhuis et al., 2002; 
Rothfuss et al., 2000), other studies have shown that DNA damage repair is altered in BRCA1 
mutation carrier cells (Barwell et al., 2007; Buchholz et al., 2002; Ernestos et al., 2010; Foray 
et al., 1999; Kote-Jarai et al., 2006; Speit et al., 2000; Speit and Trenz, 2004) and this could 
indicate a problem with DNA repair before the LOH. Febrer et al suggests that DNA repair is 
affected by a loss of a wild-type BRCA1 allele but this repair defect is only seen in M phase of 
the cell cycle (Febrer et al., 2008). Whilst Trenz et al have conflicting results on whether DNA 
repair is fully functional depending on which method is used (Trenz et al., 2003a; Trenz et al., 
2002; Trenz et al., 2003b). Rothfuss et al showed no significant difference between BRCA1-
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mutation carriers and non-carriers for DSB repair, using the Comet assay, but showed that 
BRCA1 mutation carrier cells had abnormal microtubule rate suggesting that some BRCA1 
functions may be affected by the loss of one allele of BRCA1 (Rothfuss et al., 2000). The 
number of patient samples is relatively low in these studies and human samples have the 
disadvantage of having a variety of naturally occurring unknown mutations. Therefore, 
studies have used cell lines to look at BRCA1 heterozygosity or haploinsufficiency.  
There is research that describes a dosage affect caused by a lack of BRCA1 that affects the 
DDR (Baldeyron et al., 2002; Cousineau and Belmaaza, 2007; Snouwaert et al., 1999; You et 
al., 2004; Zhang et al., 1998). You et al, showed that the C61G mutation caused a reduction 
in cell growth in the MCF10A cell line, despite with the presence of wild-type BRCA1 (You et 
al., 2004). This also invites the question of whether mutated BRCA1 protein can cause 
detrimental effects to a cell in a dominant-negative manner, which has been shown in 
multiple studies (Fan et al., 2001b; Sylvain et al., 2002; Zhang et al., 1998). Although 
Moynahan et al has suggested that the expression levels in studies using cell lines to 
investigate haploinsufficiency and dominant-negative BRCA1 mutation, is not physiologically 
sufficient to rescue these defects but the correction of a genomic BRCA1 allele does rescue 
the seen defects (Moynahan et al., 2001a). 
However, Brown et al shows that mice with a truncating Brca1 mutation are radiosensitive 
and have altered mammary development (Brown et al., 2002), Jeng et al shows 
heterozygote Brca1 Δ11 mice develop spontaneous tumours that do not show LOH (Jeng et 
al., 2007), and Cressman et al show that p53 mutated mice have a higher rate of mammary 
tumour development when they have a single allele of Brca1 mutated (Cressman et al., 
189 
 
1999b). These two mouse studies are not affected by the non-physiological expression levels 
Moynahan et al describes (Moynahan et al., 2001a), and show that a single Brca1 mutation 
can lead to cellular defects.  
When examining the 53bp1-/-Brca1+/C61G MEFs responses to DNA-damaging agents, it 
appears that in certain cases cells heterozygote for the Brca1 C61G mutation display a 
different phenotype from the 53bp1-/-Brca1+/+ MEFs. 53bp1-/-Brca1+/C61G cells show an 
identical phenotype to cells that are homozygote for Brca1 C61G in their sensitivity to HU. 
53bp1-/-Brca1+/C61G cells show an intermediate phenotype between 53bp1-/-Brca1+/+ cells and 
53bp1-/-Brca1C61G/C61G cells in their sensitivity to CPT, their number of Rad51 foci in G1 MEFs 
(after IR or MMC) and in their number of heterochromatin centres. These results suggest 
that wild-type Brca1 levels are important for specific roles of Brca1 and that there may be a 
haploinsufficiency seen in Brca1 C61G heterozygote cells. Considering the contradictory data 
on whether the loss of a single BRCA1 allele can produce changes to cellular processes 
discussed in section 5.1, these results agree that haploinsufficiency can cause defects in DNA 
repair and that only some of Brca1’s roles are affected by the one Brca1 wild-type allele. This 
knowledge could influence the way in which BRCA1 mutation carriers are viewed in terms of 
tumour development, as loss of heterozygosity may not be the driving force behind initial 
tumourigenesis.  
Several phenotypes in the 53bp1-null Brca1 C61G homozygote cells are not reproduced in 
the 53bp1-null Brca1 Δ11 homozygote cells: such as the response to Olaparib, the growth 
advantage to Veliparib, the lack of sensitivity to CPT and IR, the change in number of MMC-
induced FANCD2 foci and the restoration in Rad51 foci after MMC. These would suggest that 
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the two Brca1 mutations have altered responses to the same DNA-damaging agents, due to 
the effect of each mutation on the Brca1 protein. Brca1 Δ11 is similar to naturally-occurring 
Brca1 isoforms, and produces an approximately 92 kDa protein (Figure 4.4) which localises 
to DSBs (Figure 4.11), whereas Brca1 C61G is not as effectively recruited to DSBs (Figure 4.11 
and 12) and is reduced in the nucleus compared to cells with wild-type Brca1 protein (Figure 
4.5). This suggests that the Brca1 Δ11 could still have function from the unperturbed RING 
and BRCT domains and therefore may not be comparable to Brca1-null mutations. The Brca1 
C61G mutation appears to be a more dramatic mutation in its phenotype, despite the 
relatively small change to the DNA sequence, compared to the Brca1 Δ11 mutation.  
The results in this chapter also could affect the way in which we think about the treatment 
of Brca1 patients in several ways. Firstly, the removal of 53bp1 does alter Brca1 mutated 
cells response to PARPi’s and therefore 53BP1 expression status could provide a biomarker 
for how BRCA1-mutated cells will react to drug therapy. Secondly, BRCA1 mutations do 
cause haploinsufficiency which leads to tumour development, and therefore there may be 
interventions (drug or otherwise) that are not already used, that could prevent or delay 
tumour development. Finally, the MEFs have provided a way of looking at the phenotypes 
causes by a specific BRCA1 patient mutation, and this has shown that a genetically small 
mutation has had dramatic effects on the entire protein. Therefore, more information is 
needed on how mutations affect the entire protein to predict the effect on the function of 




Chapter 6 – 53bp1-/-Brca1C61G/C61G mice phenotypes  
6.1 Introduction 
Brca1 mouse models (as discussed in section 1.5) have provided a whole organism in which 
to study phenotypes that are produced when Brca1 is mutated. Some mouse models 
produce an increased tumour risk phenotype similar to human BRCA1 mutation carriers 
(Jeng et al., 2007), but not all phenotypes are replicated, i.e. tissue in which the cancer 
develops. Mouse models do not always replicate human disease, but the scientific 
knowledge that is gained by genetically manipulating a mammal far outweigh the 
disadvantages of the discrepancies.  
Many of the Brca1 mutant mice models are homozygote in genotype and most are 
embryonic lethal. There have been no reported cases of a homozygote BRCA1 mutation 
genotype in humans (only compound heterozygotes) suggesting that they are embryonic 
lethal in humans like in the mouse models. There are mutation in other genes (such as p53 
or 53bp1) that show a rescue of the embryonic lethality caused by the homozygote Brca1 
mutation. Although this double mutant condition has never been reported in humans, both 
p53 and 53bp1 are known to be mutated in breast cancers and the cells from the double 
mutant mice may replicate the specific conditions in these cancer cells. Reduced 53bp1 
expression in breast cancer, and specifically in triple-negative breast cancers, is known to 
correlate with reduced survival (Bouwman et al., 2010). With this in mind, the phenotypes 
seen in 53bp1-/-Brca1C61G/C61G mice may provide more information about the functional roles 
of 53bp1 and the Brca1 C61G allele, than they are to provide insight into the development of 
breast cancer in BRCA1 mutation carriers.  
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As discussed in the introduction chapter (Section 1.5), the majority of Brca1 mutated mice 
have an increased rate of tumourigenesis (Tables 6.1 and 6.2) (Bachelier et al., 2003; Berton 
et al., 2003; Cao et al., 2003; Cao et al., 2006; Chodankar et al., 2005; Cressman et al., 1999a; 
Cressman et al., 1999b; Drost et al., 2011; Kim et al., 2004; Liu et al., 2007a; Ludwig et al., 
2001; McCarthy et al., 2007; Shakya et al., 2008; Shakya et al., 2011; Xu et al., 1999a; Xu et 
al., 2001c). Some papers that describe an increased rate of tumour development, are in mice 
that have a conditional tissue-specific mutation in Brca1 (Table 6.2), such as K14-expressing 
epithelial cells, to overcome the embryonic lethality of a homozygote Brca1 mutation 
(Berton et al., 2003; Chodankar et al., 2005; Drost et al., 2011; Liu et al., 2007a; McCarthy et 
al., 2007). These mice can help understanding how the loss of wild-type Brca1 protein can 
cause tumourigenesis in that particular tissue. The embryonic lethality of the Brca1 Δ11 
homozygote mutation can be rescued by mutating one or two p53 alleles (Cao et al., 2003; 
Xu et al., 1999a; Xu et al., 2001c) or both Chk2 alleles (Cao et al., 2006), adult mice of these 
genotypes show an increased rate of tumour formation compared to mice with a wild-type 
Brca1 allele (Table 6.1). Some Brca1 mutant mice which carry a missense mutation, do not 
show embryonic lethality; such as mice with the Brca1 S1598F (Shakya et al., 2011), I26A 
(Shakya et al., 2011) or the S971A (Kim et al., 2004) mutation. But only the S971 and S1598F 
Brca1 mutation show increased tumour incidence (Table 6.1). Brca1F/C61G;p53F/F K14-Cre 
tissue-specific mutation mouse model suggests that the presence of a C61G mutated Brca1 
protein causes tumourigenesis above the rate of Brca1-null mice (both of a p53-null 
background in epithelial cells) suggesting a wild-type Brca1 N-terminus is important for 
tumour suppression. However, the lack of tumour development in the Brca1 N-terminal I26A 
mutated mice (Shakya et al., 2011), does suggest that the N-terminus of Brca1 may not be  
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Table 6.1 – Table of homozygote Brca1 mice with increased rates of tumourigenesis (non-embryonic lethal Brca1 mutations or rescued 
by the removal of p53 or Chk2) 





763;p53-/- (only 3 mice)  
All three mice had lymphomas, one also had hemangiosarcoma. 
Tumours developed between 10-12 weeks 
Lymphomas, organ was not specified 
(Xu et al., 
2001c) 
Brca1Δ11/Δ11;trp53 +/- or 
-/- 





Brca1tr/tr, truncation of 
Brca1 at aa924 
Brca1tr/tr mice developed tumours (76/89; 85%). Control mice 
develop tumours (2/27; 26%) at an older age 
Mediastinal, nodal lymphomas, angiosarcomas, 
spindle cell retroperitoneal sarcomas, breast, 
lung, liver, uterus, kidney, colon, and other, 
including ovarian teratoma 
(Cao et 
al., 2003) 
Brca1Δ11/Δ11;p53+/- Male mice developed lymphoma (30%) before 7 months. Female 
developed mammary tumours from 6-12 months 
Mostly mammary tumours in females, other 
mice developed tumours in the bone brain liver, 






Brca1Δ11/Δ11;p53+/- mice developed T cell thymic lymphomas 
(18/66; 27%) within 12-28 weeks whilst p53+/- mice did not 
develop any tumours in the same time frame. 7 Brca1Δ11/Δ11 mice 
were not embryonic lethal and survived over 1 year without any 
lymphoma incidence. Two of the female Brca1Δ11/Δ11 mice 
developed mammary tumours 
Thymus and mammary tumours 
(Kim et 
al., 2004) 
Brca1S971A/S971A  6 of the mice showed mammary hyperplasia, and 7 out of 8 
females has uteri abnormalities Three of the mice has lost their 
ovaries to uncontrolled growth. When mice were irradiated, 
Brca1S971A/S971A mice started to develop tumours after 3 months 
and at 1 year 80% of mice has tumours compared to 15% in 
control mice 
Mammary gland hyperplasia and uteri and 
ovaries with polyps and show abnormal 
structures. Irradiated mice developed mostly 
lymphomas but also 3 mammary tumours, one 
colon tumour and one uterus tumour 
(Cao et 
al., 2006) 
Brca1Δ11/Δ11;Chk2-/- 72% of Brca1Δ11/Δ11;Chk2-/- mice had mammary tumours at 16 
months (16/22). The average age of incidence was 12 months 
Mostly mammary, ovarian with some liver and 





Brca1I26A/I26A or I26A/- mice showed same level of tumours as 
control mice (18.6% with older age of incidence). S1598F showed 
similar levels of tumours to truncating Brca1 (68.1%; 49/72) 




Table 6.2 – Table of conditionally expressed homozygote Brca1 mice with increased rates of tumourigenesis 
Reference Genotype Tumour incidence Tissue type 
(Xu et al., 
1999a) 
Brca1Δ11/Δ11 or Brca1Ko22/Ko22 
with MMTV-Cre or Wap-Cre 
expression 
3 out of 10 Brca1Ko22/Δ11 MMTV-Cre mice developed tumours and 2 
out of 13 Brca1Ko22/Δ11 Wap-Cre mice developed tumours 
All tumours were mammary tumours 
(Berton et 
al., 2003) 
Brca1Δ11/Δ11 K5-Cre expression Tumours developed after 1 year and by 88 weeks in 72% (13/18) in 
Brca1Δ11/- K5-Cre mice. This was significantly higher than Brca1+/- 
and K5 Brca1Δ11/+ and Brca1Δ11/+ mice. Less than 5% of controls 
developed tumours by 88 weeks 
Majority of tumours were of the inner ear 
canal or oral epithelium. Others tumours 
developed in the skin or vagina, two were 
sarcoma of the gastrointestinal tract and 






Brca1Δ11/Δ11 Fshr-Cre mice developed one ovary solid tumour and 
several kidney cysts. Mice showed atypical ovaries but had not 
developed into tumours. No tumours were found in control mice 
Ovary and kidney tumours 




Brca1Δ11/Δ11 K14-Cre mice developed spontaneous tumours. 
Mammary tumours were only found in Brca1Δ11/Δ11 K14-Cre when 
p53 was also mutated 
High grade mammary tumours developed in 
mice with a Brca1 mutation, which is similar 






Brca1Δ22-24/Δ22-24 BLG-Cre mice developed tumours at a rate of 12% 
(5/43) with a latency of 12-15 months, which is increased 
compared to Brca1+/Δ22-24 BLG-Cre mice. 64% of Brca1Δ22-24/Δ22-
24;p53+/- BLG-Cre mice developed mammary tumours (25/39) 
within 6-46 weeks (all but one by 31 weeks) 
Mammary tumours were the most common 
to develop but some mice had tumours in 





Brca1+/Δ2 mice remained tumour free throughout the study. 35 
tumours were found in 31 of the 33 Brca1Δ2/Δ2 mice 





More tumours (particularly mammary) developed in 
Brca1F/C61G;p53F/F K14-Cre mice than Brca1F/F;p53F/F K14-Cre mice. 
Tumour latency in Brca1F/C61G;p53F/F K14-Cre mice was of 197 days 
and in Brca1F/F;p53F/F K14-Cre mice it was 236 days. Difference 
between mammary tumours is not significant (p=0.056), only 
when skin tumours were taken into account. Less skin tumours in 
C61G than B1-null. and B1-null more often carried both skin and 
mammary tumours 
Mammary and skin tumours formed. More 
Brca1F/F;p53F/F K14-Cre mice developed both 
skin and mammary tumours than mice with 
a C61G mutation  
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needed for tumour suppression. It is important to note that because the presence of Brca1 
C61G protein increased tumour develop compared to Brca1-null mice (Drost et al., 2011), 
suggesting that the Brca1 C61G mutation may lead to a protein that causes a dominant-
negative phenotype that affects tumour suppression, and that the I26A mutation affects the 
ubiquitin ligase activity of the Brca1:Bard1 heterodimer but not the Brca1:Bard1 
heterodimer binding, unlike the C61G mutation (Brzovic et al., 2003). These differences in N-
terminal Brca1 mutations makes it clear that the understanding of the role of the N-terminal 
stability and catalytic function, separately, is important for assessing what role the N-
terminus of Brca1 may play in tumour suppression.  
Despite 53bp1 and Brca1 mutant mice showing an increased rate of tumour development, 
53bp1-/-Brca1Δ11/Δ11 mice (Bunting et al., 2010) did not show any increased tumour formation 
higher than 53bp1-/- mice (Ward et al., 2003a), unlike the p53 mutation rescued Brca1Δ11/Δ11 
mice that did develop tumours at a higher rate than p53 mutated mice (Bachelier et al., 
2003; Xu et al., 1999a; Xu et al., 2001c). This could be because with 53bp1 present Brca1-
mutated cells are being repaired through error-prone methods because HR is not functional 
(Bunting et al., 2010). On top of this, the p53 mutation is likely to allow some cells to pass 
through cell cycle checkpoints despite DNA damage and this on its own can lead to genomic 
instability (p53+/- mice develop tumours (Donehower et al., 1992)) (Kuerbitz et al., 1992). 
Without 53bp1 in the Brca1 Δ11 homozygote cells, the error-free DSB repair pathway of HR 
can occur and Brca1 Δ11 mutated protein still functions as a tumour suppressor.  
The types of tumours that the Brca1-mutated mice produce are varied in their tissue type. 
The Brca1 Δ11 homozygote mice that have been rescued by the removal of p53 or Chk2 (Cao 
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et al., 2003; Cao et al., 2006; Xu et al., 1999a; Xu et al., 2001c) produce Brca1-associated 
mammary tumours and the mice that have a tissue-specific Brca1 mutation (Drost et al., 
2011; Liu et al., 2007a; McCarthy et al., 2007) and the mice with S971A Brca1 mutation 
(which does not cause embryonic lethality) show spontaneous development of mammary 
tumours (Kim et al., 2004). Liu et al show that the epithelial conditional Brca1 Δ11 mutation 
causes mammary tumour development and these tumours are mostly high grade which is 
similar to what is found in human BRCA1-mutated tumours (Liu et al., 2007a). 
Several other mouse models with biallelic Brca1 mutations show an increased rate of 
lymphoma development (Bachelier et al., 2003; Cressman et al., 1999a; Ludwig et al., 2001). 
The lymphomas produced in these mice are mostly T-cell in origin (Bachelier et al., 2003), 
but some nodal lymphomas are B-cell in origin (Ludwig et al., 2001). Jeng et al examined 
heterozygote Brca1 Δ11 mutant mice which showed that 70% of mice developed tumours 
and of those tumours 50% were lymphomas (2 were mammary tumours) (Jeng et al., 2007). 
The irradiation of these mice showed a switch to the majority of tumours being ovarian 
tumours (Jeng et al., 2007). Kim et al and Cao et al described that mice developed tumours 
due to the lack of Brca1 after exposure to a DNA-damaging agent such as IR (Kim et al., 
2009b) or MNAN (Methyl-n-amyl nitrosamine) (Cao et al., 2007) and these tumours were 
found in multiple tissues and included mammary tumours and thymic lymphomas. Other 
mice with DDR associated protein mutations such as in p53 (Dudgeon et al., 2014), ATM (Xu 
et al., 1996) and RNF8 (Li et al., 2010), also show a higher rate of lymphoma development. 
Approximately 8% of 53bp1-/- mice develop CD4+ CD8+ T cell lymphomas within 4-7 months 
(Ward et al., 2003b). It is suggested that these mice develop more lymphomas because 
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53bp1 has a role in V(D)J recombination, which uses NHEJ to insert variation into the T-cell 
receptor which is important for immune responses (Difilippantonio et al., 2008). The 
dysregulation of NHEJ in these cells leads to reduced immune system function because of 
the lack of specific immunoglobulins (Ig’s) that are created using long-range NHEJ for which 
53bp1 is needed to be efficient (Difilippantonio et al., 2008). The lack of 53bp1 in 
lymphocytes also means the DSBs created to induce variation are now repaired in other 
ways which causes genome instability and is predicted to be why lymphocytes become 
lymphomas in these mice (Ward et al., 2003b). 
In the discussed mouse models, the location or region in which Brca1 gene has been 
mutated does not appear to correlate to the tissue type in which the cancer will develop 
(excluding tissue-specific conditional mutations), therefore it is difficult to predict what (if 
any) tumours will develop from specific Brca1 mutations. The variation in tissue in which 
tumorigenesis occurs also poses the question whether Brca1 has specific tumour 
suppressing roles in these tissues, or whether these cells are particularly sensitive to DNA 
repair protein mutations.  
Mutations in DNA repair genes can cause male-specific sterility in mice (Section 1.5.4) 
(Fernandez-Capetillo et al., 2003; Kopanja et al., 2011; Li et al., 2010; Lou et al., 2006; Lu et 
al., 2010; Santos et al., 2010; Simhadri et al., 2014) due to impaired DNA repair (Cressman et 
al., 1999a; Kopanja et al., 2011; Lou et al., 2006; Santos et al., 2010; Schaetzlein et al., 2013; 
Xu et al., 2003; Xu et al., 1996) or a lack of meiotic chromosome crossing over (Boateng et 
al., 2013; Xu et al., 2003) or XY body control during meiosis (Adamo et al., 2008; Fernandez-
Capetillo et al., 2003; Santos et al., 2010). Brca1-mutated mice that are not embryonic lethal 
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have shown infertility in male mice (Figure 1.8) (Cressman et al., 1999a; Ludwig et al., 2001; 
Shakya et al., 2011) but have also shown no infertility in either sex (Kim et al., 2004; Kim et 
al., 2006; Kim et al., 2009b) (Figure 1.8). After the embryonic lethality was rescued in 
homozygote Brca1-mutated mice using mutation in p53 (Xu et al., 2003), Chk2 (Cao et al., 
2006) or 53bp1 (Bunting et al., 2012), the resulting double homozygote mutant male mice 
were infertile and had smaller testes than mice with a wild-type copy of Brca1. The ability of 
the Brca1 mutation to cause male-specific infertility or not, may lead to more information 
about the functional roles of Brca1 in meiosis and the regions of Brca1 that are needed for 
these functions.  
This chapter focuses on the phenotypes of the 53bp1-/-Brca1C61G/C61G mice and compares 
them to their littermates and phenotypes seen in previous Brca1 mutant mouse models. 
6.2 Rescue of embryonic lethality and Mendelian ratio 
As discussed in section 4.3, the 53bp1-null mice (Ward et al., 2003b) and the Brca1 C61G 
heterozygote mice (Drost et al., 2011) were bred together to produce the 53bp1-/-
Brca1C61G/C61G mice, suggesting that the removal of 53bp1 from these mice has rescued the 
embryonic lethality caused by having two Brca1 C61G alleles. The 53bp1-/-Brca1Δ11/Δ11 mice 
were shown to be viable, unlike Brca1Δ11/Δ11 mice (Xu et al., 1999a), and were born at the 
expected Mendelian ratio, showing a full recovery of embryonic development (Bouwman et 
al., 2010; Bunting et al., 2010; Bunting et al., 2012). Figure 6.1a and table 6.3 show the 
number of mice born to multiple parental crosses (both parents were 53bp1-/-Brca1+/C61G) 
and the expected Mendelian ratio and expected numbers of offspring. The 53bp1-/-
Brca1C61G/C61G mice were born at a ratio of 0.192 which is not significantly different from the 
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expected ratio of 0.25 and therefore no defect was seen in the number of living 53bp1-/-
Brca1C61G/C61G mice.  
Table 6.3 – Expected Mendelian ratio and actual ratio of the genotypes of mice born from 
53bp1-/-Brca1+/C61G parental cross (none of the actual genotype ratios are significantly 
different from the expected ratios)  
Numbers Ratios  
Expected Actual Expected Actual 
53bp1-/-Brca1+/+ 53.25 58 0.25 0.272 
53bp1-/-Brca1+/C61G 106.5 114 0.5 0.535 
53bp1-/-Brca1C61G/C61G 53.25 41 0.25 0.192 
Table 6.4 shows the number of male and female 53bp1-/-Brca1C61G/C61G mice born from all 
53bp1-/-Brca1+/C61G parental crosses. Males and females were born at a 0.483 and 0.517 
ratio, which is not significantly different from the expected ratio of 0.5 for both genders, 
suggesting that there is no gender bias in the birth rate of 53bp1-/-Brca1C61G/C61G mice.  
Table 6.4 – Expected ratio and actual ratio of the gender of mice born from 53bp1-/-
Brca1+/C61G parental cross  
Numbers Ratios  
Expected Actual Expected Actual 
Males 103.5 100 0.5 0.483 
Females 103.5 107 0.5 0.517 
These results suggest that the lack of 53bp1 in the homozygote Brca1 C61G mice has 
rescued the embryonic lethality of the mice to produce expected numbers of genotype and 
gender of 53bp1-/-Brca1C61G/C61G mice.  
Figure 6.1b shows the general survival (the number of mice that died from general unknown 
causes, i.e. not tumours) of 53bp1-/-Brca1+/+, 53bp1-/-Brca1+/C61G and 53bp1-/-Brca1C61G/C61G 
mice. 53bp1-/- mice have an increase in the number of non-tumour-related morbidity 





Figure 6.1 – Mendelian Ratio and general survival of 53bp1-/-Brca1C61G/C61G mice 
[a] shows the Mendelian ratios of each genotype that were produced from parental crosses 
of two 53bp1-/-Brca1+/C61G mice. The darker coloured bars represent the expected Mendelian 
ratio for each genotype from this cross, and the lighter coloured bars are the actual ratios of 
each genotype observed from this cross. The number of mice of each genotype from the 34 
litters from 14 breeding pairs, is shown as ‘n=…’. [b] shows the general survival of the mice 
from each genotype across 60 weeks. The decent of the line is the fraction of mice from each 
genotype that were culled due to signs of morbidity that did not have tumours upon necropsy 
and their age at death. The maximum survival is stated as 1, and is equal to the number of 




Figure 6.1b shows that the rate of survival of these mice, is equivalent between the 
genotypes showing that the loss of one or both wild-type copies of Brca1 with the 53bp1-
null background does not cause more non-tumour-related deaths than in 53bp1-/-Brca1+/+ 
mice. This suggests that this phenotype is specific to 53bp1 loss and is not exasperated by 
the Brca1 C61G mutation.  
6.3 Phenotypes of the 53bp1-/-Brca1C61G/C61G mice  
6.3.1 Testes and male sterility  
As discussed in 6.1, some Brca1 mutated mice have shown male-specific infertility (Cao et 
al., 2006; Cressman et al., 1999a; Ludwig et al., 2001; Shakya et al., 2011; Xu et al., 2003) so 
all possible breeding crosses using the 53bp1-/-Brca1C61G/C61G mice were tested (Figure 6.2a). 
From these breeding crosses, all crosses that involved a male 53bp1-/-Brca1C61G/C61G mouse 
did not produce offspring (grey arrows in figure 6.2a). The females of these crosses did 
produce a vaginal plug suggesting that the infertility was not due to a behavioural change 
but due to a defect in the sperm of the 53bp1-/-Brca1C61G/C61G mice (firing blanks).  
On dissection of male mice, the testes of 53bp1-/-Brca1C61G/C61G mice were found to be 
significantly smaller than their littermates (Figure 6.2b,c). This was also noted in other Brca1-
mutated male mice (Cressman et al., 1999a; Shakya et al., 2011) and shown to be due to a 
failure in the pachytene stage of prophase (Cressman et al., 1999a; Shakya et al., 2011; Xu et 
al., 2003). Xu et al showed that the DSB repair and meiosis crossover was faulty in cells with 
two Brca1 Δ11 alleles and this could be the reason for the failure of correct meiosis in 







Figure 6.2 – Male sterility and testes size of 53bp1-/-Brca1C61G/C61G mice 
[a] shows the genotypes of the breeding pair combinations that were tested using either the 
male (blue) or female (red) 53bp1-/-Brca1C61G/C61G mice. The black arrows show the breeding 
crosses that produced live offspring and the grey arrows show the breeding crosses that did 
not produce offspring. At least three of each genotype pairings were tested. [b] shows the 
average size (mm) of testes from 8 males of each genotype. * represent points that are 
significantly different from each other (shown by black line) with a p value of <0.05 from a t-
test. Error bars show standard error. [c] shows 4 sets of testes and seminiferous tubules from 
a range of ages (some littermates) of each genotype. The arrows indicate the smaller testes 
from the 53bp1-/-Brca1C61G/C61G mice. Ruler bars are in centimetres.  
abnormality in the 53bp1-/-Brca1C61G/C61G spermatogenesis, it is not clear if the Brca1 C61G 
mutation causes the same defect in meiosis as previous Brca1 mutated mice.  
6.3.2 Weight 
Some of the Brca1 mutated mice have been smaller than littermates with a wild-type copy 
of Brca1 (Table 6.5) (Cao et al., 2003; Cao et al., 2006; Kim et al., 2009b; Shakya et al., 2011), 
but other papers did not notice any difference in body weight (Bunting et al., 2012; Kim et 
al., 2004; Kim et al., 2006). Figure 6.3a shows there is a small but not significant decrease in 
average body weight of 53bp1-/-Brca1C61G/C61G compared to mice with a wild-type Brca1 allele 
(24.26g compared to 25.32g and 26.19g). Figure 6.3b shows the weight of mice and the age 
at which they were weighed, this also shows that many of the 53bp1-/-Brca1C61G/C61G mice are 
smaller than the majority of mice from the other genotypes, although there are outliers. 
Shakya et al noted a 5-10% body weight decrease in mice with the Brca1 I26A mutation 
(although not statistically significant) (Shakya et al., 2011), and other groups have reported 
an age-related decrease in weight mice carrying Brca1 mutations (Cao et al., 2003; Kim et al., 
2009b). Considering this, it may be that the weight decrease is not large enough to be 




Figure 6.3 – Average weight of 53bp1-/-Brca1C61G/C61G mice 
[a] shows the average weight of mice from each genotype. Error bars show standard error. 
None of these weight are significantly different from each other. [b] shows the weights and 
ages of mice from each genotype. Lines indicate the average weight for the age of the mice. 





Figure 6.4 – Size of spleen and thymus, and age of 53bp1-/-Brca1C61G/C61G mice 
This figure shows the [a] size (mm) of spleen and b] the size (mm) of thymuses and relative 
age of mice of indicated genotypes. The number of mice in each genotype is shown as ‘n=…’. 
Stars indicate a spleen or thymus that was determined to contain a tumour. Lines indicate 





Table 6.5 – Table of Brca1 mice with an altered weight phenotype or normal weight 
Reference Genotype Weight status 
(Cao et 
al., 2003) 
Brca1Δ11/Δ11;p53+/- Mice developed age-related weight loss over 64 
weeks and the difference between 




Brca1Δ11/Δ11;Chk2-/-  Brca1Δ11/Δ11;Chk2-/- mice weight 85% of control 
mice at 6 months and 10% of the mice showed 
further reduced weight with age 
(Kim et 
al., 2009b) 
Brca1S1152A/S1152A Brca1S1152A/S1152A mice had a similar body weight to 
control mice up to 6 months. After this time body 
weight decreased in Brca1 mutant mice whilst the 




Brca1I26A/I26A  Brca1I26A/I26A mice showed a 5-10% body weight 
decrease compared to mice with wild-type Brca1    
(Kim et 
al., 2004) 












Brca1Δ11/Δ11;53bp1-/- phenotypically normal 
 
6.3.3 Spleen and thymus size 
The spleen and thymus was isolated and measured from all dissected mice to ensure any 
enlarged organs could be identified as tumourigenic. This is because previous papers Brca1-
mutated mice papers showing an increased risk of lymphomas (Bachelier et al., 2003; Cao et 
al., 2007; Cressman et al., 1999a; Kim et al., 2006; Ludwig et al., 2001). Figure 6.4 shows the 
size of the spleen (Figure 6.4a) and thymus (Figure 6.4b) of dissected mice and the age at 
which they were dissected. This shows that apart from the organs in which a tumour had 
developed (marked by an asterisk), there was no difference in the sizes of organs between 
the three genotypes of mice.  
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6.4 Tumour development 
6.4.1 Tumour incidence rate and organ origin 
53bp1-/-Brca1C61G/C61G mice and their littermates were watched to see if they would develop 
tumours at a higher rate if they lacked a wild-type Brca1. Figure 6.5 is a Kaplein Meyer graph 
showing the rate at which mice from each genotype were found to have a tumour upon 
dissection (culled due to signs of morbidity). When an abnormal organ was found (wrong 
shape/size/texture etc) it was photographed and fixed as stated in Chapter 2.5.5. The organs 
that were determined to be cancerous are shown in Appendices figures III and IV, alongside 
the diagnosis (from pathologist at HistoloGix), and genotype and age of relevant mouse. 
Although these results are not significantly different between the genotypes due to low 
numbers (Table 6.6), it is clear that the 53bp1-/-Brca1+/+ mice did not develop tumours in the 
same time frame that the mice with one copy of Brca1 C61G develop half the rate of 
tumours as the mice that are homozygote for Brca1 C61G. These observations need to be 
replicated with larger numbers of mice over a longer period of time, but as preliminary data 
this suggests that the C61G mutation in Brca1 does cause an increased rate of tumour 
incidence in mice lacking 53bp1. It also could suggest that one copy of Brca1 C61G is enough 
to increase risk of tumourigenesis in mice in a similar manner to BRCA1 mutation carriers 





Figure 6.5 – Tumour incidence in 53bp1-/-Brca1C61G/C61G mice 
This figure shows the fraction of mice from each genotype that were found to have 
developed a tumour within all the dissected mice that were culled across 60 weeks. Tumours 
were determined from H&E staining and diagnosed by the pathologist at HistoloGix (Section 
2.5.6).  
Table 6.6 – Incidence of tumours in dissected mice  
n= Incidence 
53bp1-/-Brca1+/+ 25 0 
53bp1-/-Brca1+/C61G 29 3 
53bp1-/-Brca1C61G/C61G 34 6 
Table 6.7 – Tumour incidence in tissue/organ from each genotype  
Spleen Intestine Liver Thymus 
53bp1-/-Brca1+/+ 0 0 0 0 
53bp1-/-Brca1+/C61G 1 1 1 1 
53bp1-/-Brca1C61G/C61G 3 1 0 3 
Although the 53bp1-/- mice are known to have an increased rate of lymphoma development 
(Ward et al., 2003b), it is likely that the outbreeding or the short time span (60 weeks) is the 
reason behind the lack of tumour incidence in the 53bp1-/-Brca1+/+ mice.  
The tissue in which the tumours develop is also of interest as it is still not completely clear 
why BRCA1 mutations cause predominantly breast and ovarian cancer in humans. Previous 
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mouse models have shown a range of tissue types to develop tumours due to a Brca1 
mutation, and a substantial number of these mice tumours are lymphomas (Bachelier et al., 
2003; Cao et al., 2003; Cressman et al., 1999a; Ludwig et al., 2001) or mammary tumours 
(Cao et al., 2003; Cao et al., 2006; Kim et al., 2004; Xu et al., 1999a; Xu et al., 2001c). Table 
6.7 lists the tissues in which tumours were found in the mice in table 6.6 and in which 
different genotypes they occurred (some mice had tumours in multiple organs). Of the 11 
tumours that were found, 4 were from 53bp1-/-Brca1+/C61G mice; the spleen and liver 
tumours were found in one mouse, and the thymus and intestine tumours were found in 
different mice. The 7 tumours from 53bp1-/-Brca1C61G/C61G mice were found in 6 mice; they 
consisted of three spleen tumours, 3 thymus tumours and an intestinal tumour (one spleen 
and one thymus tumour was found in the same mouse). There was one incidence of a mouse 
with suspected mammary tumours on both left and right side inguinal mammary glands but 
these tumours have not been assessed further to confirm cancer as of this time (data not 
included).  
6.4.2 Tumour histology 
To confirm the presence of cancer in the suspected tumours that were isolated from all 
mice, the tumours mentioned in table 6.6 and other organs that were abnormal (ovaries 
with cysts) were sent to HistoloGix Ltd, for blocking, sectioning and H&E stained (Section 
2.5.6). The results confirmed which of the specimens were cancerous through the density of 
cells and types of cell that were found (Figure 6.6i and ii). The histology confirmed that all 
but two tumours are malignant lymphomas. The 53bp1-/-Brca1+/C61G mouse with both a 
spleen and liver tumours were diagnosed to be a histocytic sarcoma and haemangiosarcoma, 








Figure 6.6ii – Histological images of tumours from Appendices figures III and IV continued 
 
Figure 6.6i and ii – Histological images of tumours from Appendices figures III and IV 
This figure shows the histological staining using H&E (Methods section 2.5.6) of tumours 
from Appendices figures I and II. Mice are identified using their cage number and gender 
number. Genotypes and tumour diagnosis is indicated on the left. The diagnosis was 
determined by the pathologist, David Fairley, at HistoloGix from original slides and images. 
Magnification of images by HistoloGix Ltd is as above column (x1.25, x20 or x40).  
212 
 
cells showing signs of enlarged nuclei, reduced cytoplasmic fractions, malformed nuclei and 
some samples showed Reed-Sternberg cells (large cells with multiple nuclei) that are 
associated with lymphoma. Although the abnormal cells are enough to diagnose that these 
tumours are lymphomas, without further histological staining, the particular type of 
lymphoma cannot be diagnosed.  
The origin of the lymphomas could be tested by staining with either CD4 to mark T cell-
lineage and B220 to mark B cell-lineage. Other markers could be used to find the point in T 
or B-cell development the tumour originated; such as IgM and IgD for correctly matured B 
cells and CD3 and CD45R for correctly matured T cells. This could help to show if the tumour 
is produced from the genomic instability created by the DSBs formed in V(D)J recombination. 
6.5 Discussion 
This chapter has shown that the removal of 53bp1 from the Brca1C61G/C61G mice does rescue 
the developmental defect caused by the Brca1 mutation because 53bp1-/-Brca1C61G/C61G mice 
are born at expected Mendelian ratio. The lack of developmental defects suggests that the 
53bp1-Brca1 interplay is the cause behind the defect in development. Figure 6.1b shows that 
the Brca1 genotype does not influence the general survival of 53bp1-/- mice suggesting that 
the Brca1 C61G mutation does not affect the immune deficiency that causes spontaneous 
mouse death from unknown reasons.  
The 53bp1-/-Brca1C61G/C61G mice provide new evidence for two Brca1 roles that are disrupted 
by the C61G mutation; male fertility and tumour suppression. 
53bp1-/-Brca1C61G/C61G mice have male-specific infertility, and this is not a trait associated 
with 53bp1 deficiency (Ward et al., 2003b) but with mice lacking wild-type Brca1. Other 
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Brca1 mutated mice that show male-specific infertility carry either a truncating Brca1 
mutation (Ludwig et al., 2001), the N-terminal missense mutation I26A (Shakya et al., 2011), 
the amino acid deletions Δ223-763 (Cressman et al., 1999a), the removal of exon 11 
(alongside removal of a wild-type p53 allele) (Cao et al., 2006; Xu et al., 2003) or a Exon 2 
deletion (stated to be a protein null-mutation, and alongside the removal of 53bp1) in Brca1 
(Bunting et al., 2012; Ludwig et al., 1997). Not all Brca1 mutations cause male sterility; 
Brca1S1152A/S1152A (Kim et al., 2009b), Brca1S971A/S971A (Kim et al., 2004) or mice with only full-
length Brca1 (no Δ11 isoform) (Kim et al., 2006) do not confer any sterility in male or female 
mice. These results alongside our findings, could suggest that the N-terminal RING domain 
and the C-terminal BRCT domains of Brca1 are required for male fertility. The ubiquitin ligase 
function of Brca1 may also be required since the Δ223-763 mutation does remove some of 
the N-terminal region known to be needed for BRCA1 autoubiquitination (Chen et al., 2002), 
and the I26A mutant is a Brca1 E3 ubiquitin ligase activity-targeting mutation (Brzovic et al., 
2003). The Brca1 C61G mutation protein levels are reduced compared to wild-type Brca1 
protein (Figure 4.5) so the male infertility seen in these mice may be due to the reduced 
levels of the entire Brca1 protein and therefore may not provide evidence for N-terminal 
function of Brca1 in meiosis. But since there is remaining C61G mutated protein, which lacks 
ubiquitin ligase activity (Figure 3.6), it is possible that this may contribute to the male 
sterility, however levels of Brca1 in meiotic cells would need to be investigated. Whether the 
53bp1-/-Brca1C61G/C61G male infertility is due to Brca1’s role in the crossover regulation, or sex 
chromosome inactivation, would require further investigation. The male sterility in 53bp1-/-
Brca1C61G/C61G mice which is not seen in littermates suggests this is an example of a 53bp1-
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independent role for Brca1 and a role in which one wild-type allele of Brca1 is sufficient for 
normal function.  
The increase in tumour development in 53bp1-/- mice with one or two copies of Brca1 C61G 
suggests that the removal of 53bp1 does not rescue the Brca1 tumour suppressing function 
that is disrupted by this mutation. It is interesting that the 53bp1-/-Brca1Δ11/Δ11 mice do not 
show any increased tumour development over 53bp1-null mice (Bunting et al., 2010), 
suggesting that there is a difference in the tumour suppressing properties of the Brca1 C61G 
and Δ11 mutated protein. The fact that heterozygotes do produce tumours at a higher rate 
than 53bp1-/-Brca1+/+ mice is suggestive of a 53bp1-independent tumour suppressing role for 
Brca1 with the Brca1 C61G mutation causing haploinsufficiency. The reduced protein seen in 
mice with one or two copies of Brca1 C61G (Section 4.5) suggest that the C61G mutation 
reduced the amount of Brca1 protein, therefore it is not possible to say that the N-terminus 
of Brca1 is important for tumour suppression. It would be interesting to look at the Brca1 
allele status and protein status in the tumours from the 53bp1-/-Brca1+/C61G mice to see if 
LOH has occurred, or if the protein is reduced compared to normal tissues in that mouse. 
This would give more idea of the influence of Brca1 protein levels and the role of LOH in 
tumour development in these mice.  
The majority of tumours found in the mice with a Brca1 C61G mutation were lymphomas, 
which is similar to other Brca1 mutated mice (Bachelier et al., 2003; Cao et al., 2007; 
Cressman et al., 1999a; Jeng et al., 2007; Ludwig et al., 2001), and 53bp1-/- mice (Ward et al., 
2003b). It would be interesting to stain the lymphomas to see if they are B or T-cell in origin 
since the Brca1 mutant mice are known to produce a mix of B and T cell lymphomas 
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(Bachelier et al., 2003; Jeng et al., 2007; Ludwig et al., 2001), but the 53bp1-/- mice produce 
exclusively T cell lymphomas (Ward et al., 2003b). This information would be able to shed 
light on whether the Brca1 C61G mutation was important for a Brca1 role in lymphocyte 
genome maintenance or if the 53bp1-/- phenotype is exacerbated by a Brca1 mutation.  
One avenue would be to see which lymphocyte development stage that the tumour 
originated from as, if it is the dysregulation of the TCR, CSR and V(D)J recombination which 
happens in maturing B and T-cells, this may give more insight into the role that 53bp1 and 
Brca1 play in DNA repair in these processes.  
In a recent paper, Vasanthakumar et al created mice that possessed two copies of Brca1 Δ11 
allele conditionally expressed in haematopoietic cells (Vasanthakumar et al., 2016). These 
mice developed bone marrow failure from 1 month and 6 had developed haematopoietic 
malignancies by 190 days (4 lymphomas, 1 acute myeloid leukaemia and 1 erythroleukemia) 
and cells from these malignancies showed chromosomal instability and a sensitivity to 
mitomycin C, a DNA crosslinking-agent (Vasanthakumar et al., 2016). They also presented 
evidence that suggested that cells in the peripheral blood originated from the bone marrow 
malignancies and they infiltrated organs (Vasanthakumar et al., 2016). This could suggest 
that lymphoma development in the organs may originate from a bone marrow malignancy. 
Brca1 has been shown to be important in the maintenance of haematopoietic stem cells 
populations (Bai et al., 2013) and some myeloid leukaemias show a reduced expression of 
Brca1 (Deutsch et al., 2003; Scardocci et al., 2006). This data may suggest that Brca1 has a 
role in haematopoietic cell genome stability and therefore, it may be interesting to 
216 
 
investigate bone marrow changes in the 53bp1-/-Brca1C61G/C61G mice to look for a mechanism 
behind the development of lymphomas in these mice.  
It is interesting that the same level of lymphoma development is not seen in human patients 
carrying a BRCA1 mutation (Chen et al., 2013; Friedenson, 2007; Kadouri et al., 2007; Kim et 
al., 2014; Shen et al., 2006; Shih et al., 2000; Yossepowitch et al., 2003), although there are 
two cases, each of an individual BRCA1 mutation carrier patient that developed a B-cell 
lymphoma (Kim et al., 2015; Shen et al., 2000). This may highlight the unknown and 
unexplained differences between human diseases and the mouse model of the 
corresponding disease.  
The rescue of developmental defects seen in Brca1 C61G homozygote mice by the removal 
of 53bp1 suggests that any other phenotypes in the mice are indicative of Brca1 roles that 
are affected by the C61G mutation but roles in which 53bp1 does not play a part, i.e tumour 





Chapter 7 – Discussion 
7.1 Evaluation of data 
7.1.1 Novel data 
This thesis has discussed the gap in the literature for investigation into N-terminal BRCA1 
patient mutations expressed at endogenous levels in cells created by genome editing (not in 
genomically unstable tumour cells), and this gap is largely due to the embryonic lethality of 
Brca1 homozygote mutations. The research described here shows the creation of a MEF cell 
line and starts to investigate Brca1 C61G protein and its effects.  
The novel findings in this thesis are:- 
 A comparison of in vitro E3 ubiquitin ligase activity using mouse and human 
Brca1:Bard1 RING domain heterodimer showing that they are equivalent in their 
ability to make polyubiquitin chains (Chapter 3.5). 
 There is a role for Bard1 in Brca1:Bard1 heterodimer E3 ubiquitin ligase activity in 
mouse that is not associated with the stability of the heterodimer and that the 
arginine residue 93 is important for this Bard1 function (Chapter 3.7). This confirms 
the role of the corresponding human BARD1 R99 residue that have been described 
Ruth Densham from the Morris lab, but not yet published. 
 The removal of 53bp1 from homozygote Brca1 C61G mice does rescue embryonic 
lethality but 53bp1-/-Brca1C61G/C61G cells are still significantly more sensitive to IR than 
cells with only wild-type Brca1, despite HR being functional to the point of normal 
Rad51 foci levels (Chapter 5 and 6) (previous papers suggest the lack of HR DSB repair 
may be the cause of embryonic lethality (Bouwman et al., 2010; Bunting et al., 
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2010)). This is different from the literature as the 53bp1-/-Brca1Δ11/Δ11 cells show a 
wild-type level of cell survival after IR-treatment (Figure S1 in Bunting et al, 2010) 
compared to the reduced cell survival seen in p53-/-Brca1Δ11/Δ11 cells (Bunting et al., 
2010).  
 Two copies of Brca1 C61G causes an increase in FANCD2 foci and a reduction of 
Rad51 foci after MMC treatment (Chapter 5.5) compared cell with wild-type Brca1. 
The literature has previously shown that a reduction in wild-type Brca1 has led to a 
decrease in FANCD2 foci (Bunting et al., 2012; Garcia-Higuera et al., 2001; 
Vandenberg et al., 2003; Zhang et al., 2010) and a decrease in cells with Rad51 foci 
after MMC (Bunting et al., 2012).  
 53bp1-/- mice with one or two copies of Brca1 C61G do have an increased rate of 
tumour development (Chapter 6.4). This is not the case with 53bp1-/-Brca1Δ11/Δ11 mice 
that do not show an increase incidence of tumours compared to mice with a wild-
type copy of Brca1 (Bunting et al., 2010).  
7.1.2 Caveats of the data 
Data presented here has various caveats which need to be taken into consideration before 
making firm conclusions and adding the data here to the literature. Firstly, there are control 
cells which would have made this data stronger, such as cells with wild-type 53bp1 and 
homozygote Brca1 C61G mutation. These cells would have provided a control to look at the 
effects of the Brca1 C61G mutation without any background phenotypes from the lack of 
53bp1. However, Brca1 C61G mice are embryonic lethal and attempts to produce a cell line 




The Brca1 Δ11 cell lines do not replicate the published data despite using the stated 
protocols (Bunting et al., 2010; Bunting et al., 2012). This was particularly evident in looking 
at FANCD2 foci and the cells reactions to DNA-damaging drugs and IR (Chapter 5). The 
NIH3T3 cells line was also used as a wild-type control cell line, but also has caveats as it is 
designed to be a senescent mono-layer cell line for the growth of primary cells. When using 
NIH3T3 cells as a control for the comparison of 53bp1 and Brca1 protein, it became evident 
that they produced a higher amount of 53bp1 protein than expected and very little Brca1 
protein, despite being ‘wild-type’ cells. This makes NIH3T3 unreliable as the protein status 
(perhaps genomic status) for these important proteins is not clear and is likely not to 
replicate wild-type conditions. If the Brca1 Δ11 cells and the NIH3T3 cells are not 
reproducing expected conditions, then comparisons using these cells need to be confirmed 
using alternative controls.  
53bp1+/-Brca1+/C61G cells are used throughout this these as control for comparison but it is 
important to consider that they are heterozygote for both Brca1 and 53bp1. Ward et al 
reported that one copy of 53bp1 is sufficient for normal 53bp1 roles, and therefore they 
should behave as wild-type cells in respect to 53bp1 phenotypes (Ward et al., 2003b). This is 
not the same with Brca1 mutations as a single mutated allele gives increased risk in cancer 
development in human and mice (Clark et al., 2012; Cressman et al., 1999b), and cellular 
functions are altered with a single mutated Brca1 allele which has been shown in the 
literature (Barwell et al., 2007; Buchholz et al., 2002; Ernestos et al., 2010; Febrer et al., 
2008; Foray et al., 1999; Kote-Jarai et al., 2006; Rothfuss et al., 2000; Speit et al., 2000; Speit 
and Trenz, 2004) and in this thesis (Chapter 7.2.4). This thesis does compare 53bp1-null 
background cells with wild-type Brca1 and heterozygote and homozygote Brca1 C61G cells 
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to look the effect of a single Brca1 C61G mutation. This data could be repeated with a wild-
type control MEF line, however, since a Brca1C61G/C61G cell would not be produced (Drost et 
al., 2011), the data would still have the caveat of a 53bp1-null background. It would be 
interesting to use a Brca1+/C61G and wild-type cell line to look further at the roles of a 
heterozygote Brca1 C61G mutation.  
The whole-cell protein extract (WCE) western blots in this thesis produced variable data 
when using the GH118 anti-Brca1 antibody. However when the cytoplasm and nuclear 
fractions of MEFs were used as separate western blot samples or this antibody (GH118) was 
used for IRIF, the results were consistent between repeats. This data does allow more 
information on the localisation of Brca1 protein than the measurement of Brca1 protein in a 
WCE. Before publishing or taking firm conclusions from the WCE western blots, other Brca1-
specific antibodies should be used to repeat this experiment.  
Finally, the tumour data here is preliminary and could not be statistically analysed due to the 
small sample size. There were delays in acquiring home office licences for this tumour watch 
which reduced the number of results available for analysis at this time. This delay also 
caused a reduction in the length of time mice were part of the tumour watch which I believe 
has not allowed enough time for these outbred 53bp1-null mice to produce tumours (like 
previous papers have shown (Ward et al., 2003b)). Despite this, the data in this thesis does 
shown more tumour incidence in mice with one or two copies of Brca1 C61G allele than 
those with only wild-type Brca1. 
The cell cycle can greatly influence the way cells respond to DNA-damaging agents, and 
although the Brca1 C61G MEF cells divide at a similar rate (tissue culture passaging), further 
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experiments into the presence of cell cycle checkpoint should be investigated. An attempt to 
look at the G2/M checkpoint was made using PI stain across time points after IR, but the 
control cells (53bp1+/-Brca1+/C61G) showed abnormalities (an unidentified population of cells) 
which made incomparable to the experimental MEFs. Therefore other controls, such as wild-
type cells, and an alternative 53bp1+/-Brca1+/C61G MEF cell line should be used to assess the 
cell cycle checkpoints in 53bp1-/-Brca1C61G/C61G MEFs.  
7.2 Discussion of the results 
7.2.1 Brca1 C61G protein 
As discussed in the introduction, the literature suggests that further investigation is needed 
into the structural consequences of N-terminal pathogenic mutations, particularly into the 
whether the BRCA1 C61G protein is stable or instable as the literature is divided (Chapter 
1.3.3). The Brca1 C61G missense mutation has been shown here to affect the entire Brca1 
protein levels in cells, its degradation potential and its localisation to IRIF (Chapter 5). This 
suggests that a missense mutation can cause protein-wide defects and that individual 
mutations should be studied to be able to predict which residues would produce this effect. 
Unfortunately the tumour incidence and cell-based data in this thesis does not provide 
information about the N-terminal function of Brca1 because the C61G mutation affect is not 
specific to the N-terminal region of Brca1 as it affects the stability of the whole protein. 
Although the Brca1 C61G mutation does affect the E3 ubiquitin ligase activity of the 
Brca1:Bard1 heterodimer in vitro (Chapter 3), it cannot be said that the phenotypes 
described here are specifically due to a defect in Brca1 ubiquitin ligase activity due to the 
reduction in Brca1 C61G protein.  
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7.2.2 Brca1 C61G in DNA repair and genome stability 
The embryonic lethality of Brca1 mutant homozygote mice is suggested to be due to 
overwhelming DNA damage and errors, that makes normal embryonic develop 
unsustainable. The removal of 53bp1 from Brca1 mutant cells has previously been shown to 
rescue Brca1 mutant phenotypes, specifically Brca1 Δ11 phenotypes (Chapter 1.5.5) 
(Bouwman et al., 2010; Bunting et al., 2010; Cao et al., 2009) and this is due to DSB repair 
being functional in Brca1 mutated cells that lack 53bp1. The presence of 53bp1-/-
Brca1C61G/C61G mice and MEFs shows that the absence of 53bp1 does rescue the embryonic 
lethality of a homozygote Brca1 C61G mutation. This agrees with the literature that the 
53bp1 and Brca1 are antagonistic in their roles of promoting either DSB repair pathway and 
the mutation of both 53bp1 and Brca1 alleles leads to normal development of mice through 
the same alleviation of DNA damage (Bouwman et al., 2010; Bunting et al., 2010).  
According to their research, 53bp1-/-Brca1Δ11/Δ11 cells show normal cell survival after IR-
treatment and similar levels of cells with Rad51 foci formation comparable to wild-type cells 
(Bunting et al., 2010). Here, it is shown that 53bp1-/-Brca1C61G/C61G cells have a similar 
number of cells with Rad51 foci formation after IR compared to cells with a wild-type copy of 
Brca1. But, we have also shown 53bp1-/-Brca1C61G/C61G cells have a significantly reduced cell 
survival after IR treatment compared to cells with a wild-type copy of Brca1 (Chapter 5). 
Since it appears that HR is functional beyond the DSB repair pathway choice, there are two 
possible theories as to why these cells are sensitive to IR. Firstly, HR is functional and the 
sensitivity is caused by Brca1 being defective for its role in NHEJ, or secondly, there are 
defects in HR after the presence of Rad51 foci that are affected by the Brca1 C61G mutation, 
but not the Brca1 Δ11 mutation (Bunting et al., 2010). BRCA1’s role in NHEJ appears to be in 
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aiding Ku80 stability at DSB DNA ends providing an error-free method of DSB repair in G1 
phase of the cell cycle (Dohrn et al., 2012; Jiang et al., 2013a; Wei et al., 2008). Since IR-
induced breaks throughout the cell cycle, it could be that BRCA1 C61G protein causes 
erroneous repair in G1 and this leads to the reduced survival of 53bp1-/-Brca1C61G/C61G MEFs 
after IR. It is also interesting to note that the reported Ku80 binding site is competitive with 
BARD1, the RING domain, and this is mutated in the 53bp1-/-Brca1C61G/C61G MEFs but the 
Brca1 Δ11 isoform that is present in 53bp1-/-Brca1Δ11/Δ11 cells would have a wild-type RING 
domain (Jiang et al., 2013a; Wei et al., 2008). This could be further investigated by looking at 
the DNA sequences of DNA repaired in these cells through HR and NHEJ in G1 and G2 phase 
of the cell cycle, to see if these are being repaired by these repair pathways and if the repair 
is error-free.  
The literature describes BRCA1’s role in DNA crosslink repair to be 53bp1-independent role 
(Bunting et al., 2012) and therefore is would be predicted that 53bp1-/-Brca1C61G/C61G MEFs 
would be sensitive to DNA crosslinking agents, such as Cisplatin and MMC. Long et al report 
that BRCA1 is essential for the removal of the CMG helicase from DNA crosslinks to allow 
FANCD2 and nuclease localisation (Long et al., 2014). The 53bp1-/-Brca1C61G/C61G MEFs are 
Cisplatin sensitive as were the 53bp1-/-Brca1Δ11/Δ11 cells (Bunting et al., 2012). However, 
53bp1-/-Brca1C61G/C61G MEFs have an increased level of FANCD2 foci after MMC which is the 
opposite of what has been reported in 53bp1-/-Brca1Δ11/Δ11 cells (Bunting et al., 2012) and 
other Brca1-depleted cells (Bouwman et al., 2010; Garcia-Higuera et al., 2001; Vandenberg 
et al., 2003; Zhang et al., 2010). Since the Brca1 C61G protein appears to reduce protein 
levels but not eradicate the protein, it could be that the increase in FANCD2 foci after MMC 
in 53bp1-/-Brca1C61G/C61G MEFs is the dominant effect of C61G mutated Brca1 that stops the 
224 
 
removal of FANCD2 from DNA crosslink sites, and different Brca1 mutations may not 
produce this effect. However, it is also possible that BRCA1 C61G is functional for FANCD2 
recruitment but it cannot remove CMG which is a step needed for FANCD2 foci removal 
(Long et al., 2014). Long et al, blocked the DNA polymerase (using Aphidicolin) which 
delayed CMG unloading from ICL replication forks, and this did not disrupt the localisation of 
BRCA1, FANCD2 and Rad51 (Long et al., 2014), suggesting that BRCA1’s recruitment of 
FANCD2 and Rad51 to site of ICL repair is independent of BRCA1’s role in CMG unloading. 
FANCD2 recruitment was also shown to be prior to CMG removal (Long et al., 2014) despite 
its role in creating DNA incisions which is downstream of CMG unloading (Knipscheer et al., 
2009), suggesting CMG unloading may delay the role of FANCD2 in incision formation and, 
consequently, its dispersion from sites of ICL as we have seen in 53bp1-/-Brca1C61G/C61G MEFs. 
Long et al, also reported that the BRCT domains were required for BRCA1 recruitment to 
ICL’s and that the BRCA1:BARD1 heterodimer was essential for CMG unloading (Long et al., 
2014). This suggests that BRCA1 RING domain is needed for the CMG unloading, but may be 
independent of the BRCT domains roles in localisation and recruitment of FANCD2, and 
therefore Brca1 C61G can be functional for FANCD recruitment but not be able to unload the 
CMG helicase causing defects in DNA crosslink repair. 
This does agree with the literature in that Brca1 has a 53bp1-independent role in DNA 
crosslink repair (Bunting et al., 2012), but is novel in its effect on FANCD2 foci. Further 
investigation could identify if CMG or BRCA1 also have prolonged localisation to DNA 
crosslinks to help unpick the mechanism behind this phenotype.  
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CPT and HU both produce DNA/protein lesions as part of the DNA damage they exert and HR 
is used as part of the method of repairing these lesions. The 53bp1-/-Brca1C61G/C61G cells 
showed significant sensitivity to CPT compared to 53bp1-/-Brca1+/+ MEFs, however, the 
53bp1+/-Brca1+/C61G cells were similar in sensitivity to cells with 53bp1-/-Brca1C61G/C61G cells 
suggesting another control (a fully wild-type control) is needed to confirm this finding. The 
53bp1-/-Brca1C61G/C61G cells did show some sensitivity (only one data point is significant due 
to large standard errors) to HU compared to 53bp1-/-Brca1+/+ MEFs. However, 53bp1-/-
Brca1+/C61G cells showed a significantly greater sensitivity on all data point compared to 
53bp1-/-Brca1+/+ MEFs and the control 53bp1+/-Brca1+/C61G cells were variable in their 
sensitivity. If the sensitivity of 53bp1-/-Brca1+/+ MEFs to CPT and HU were to be confirmed 
through further experiments, then this would merit further investigation into whether Brca1 
C61G influences the repair of DNA/protein lesions. Especially as a recent paper described a 
role for BRCA1 in DNA adducts created after Topoisomerase II inhibitors (Aparicio et al., 
2016).  
Defects in DNA repair lead to the accumulation of DNA errors and unresolved DNA damage, 
continuing to cells that are genomically unstable. Despite the normal development of 53bp1-
/-Brca1C61G/C61G mice, 53bp1-/-Brca1C61G/C61G cells are sensitive to multiple DNA-damaging 
agents suggesting that DNA repair is erroneous. 53bp1-/-Brca1C61G/C61G mice also show a 
higher incidence of tumour development (Chapter 6) which is an indicator of genome 
instability and typical of mice with a genetic DNA repair defect. 
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7.2.3 Brca1 C61G and male-specific Infertility 
The male-specific infertility in 53bp1-/-Brca1C61G/C61G mice (Chapter 6) does agree with other 
Brca1 mutant mouse models that show a similar phenotype (Introduction section 1.5.4), that 
Brca1 is specifically important for male spermatogenesis. This role is not seen in mice with 
53bp1 mutations (Ward et al., 2003b), but is also seen in male 53bp1-/-Brca1-/- mice (Bunting 
et al., 2012). Brca1 has been shown to have roles in meiosis that include DSB repair enabling 
chromatid crossover events (Cressman et al., 1999a; Shakya et al., 2011; Xu et al., 2003) and 
a role in inactivating unsynapsed chromosomes and the XY body (Adamo et al., 2008; 
Ganesan et al., 2002; Turner et al., 2004; Turner et al., 2005; Xu et al., 2003). Collectively this 
suggests that it is a 53bp1-independent Brca1 role that causes male-specific infertility in the 
53bp1-/-Brca1C61G/C61G mice.  
7.2.4 Brca1 C61G heterozygote effects 
Several of the results in this thesis suggests that a heterozygote Brca1 C61G mutation is 
adequate to produce cellular defects. 53bp1-/-Brca1+/C61G MEFs show the following 
heterozygote phenotypes: decrease in Brca1 C61G protein levels, reduced Brca1 IRIF in 
Brca1 heterozygote cells and the tumour incidence in 53bp1-/-Brca1+/C61G mice. The decrease 
in Brca1 protein levels in the cell and in the nucleus and cytoplasm in heterozygote Brca1 
C61G cells (with or without 53bp1) (Chapter 4) has the potential to produce haploinsufficient 
phenotypes. There are less Brca1 IRIF in 53bp1+/-Brca1+/C61G cells compared to 53bp1-/-
Brca1+/+ cells (Chapter 4) and this is likely to be due to the reduction of Brca1 C61G protein 
compared to cells with two wild-type Brca1 alleles. This reduction in Brca1 IRIF also has the 
potential to produce haploinsufficient phenotype due to a lack of Brca1 localising for its roles 
in DNA repair. This thesis has also shown that mice with one or more copy of Brca1 C61G in 
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a 53bp1-null background do have an increased rate of tumour development (Chapter 6). 
This, again, is likely to be due to the Brca1 C61G mutation causes a reduction in Brca1 
protein (Chapter 4) and the C61G mutated Brca1 protein that is present in the cells altering 
genome stability in the 53bp1-null background. This thesis does not investigate whether the 
tumours that arose in the 53bp1-/-Brca1+/C61G mice have lost the wild-type allele of Brca1 or 
whether the Brca1 C61G allele causes haploinsufficiency or a dominant-negative phenotype 
in maintaining genome instability in a 53bp1-null background. It would be interesting to add 
53bp1+/+Brca1+/C61G and 53bp1+/-Brca1+/C61G mice to the tumour watch programme to assess 
whether they also show a higher rate of tumour development and to look at whether these 
tumours show loss of heterozygosity of Brca1.  
7.2.5 Brca1 Δ11 and Brca1 C61G phenotypes 
The Brca1 C61G mutation causes a reduction in Brca1 protein suggesting the defect is 
protein-wide (Chapter 4) and not a specific defect to the N-terminus of the Brca1 protein. 
Brca1 Δ11 mimics a known BRCA1 isoform that lacks exon 11 and therefore Brca1 Δ11 
protein does produce a protein product and it has been shown that it can localise to IRIF 
(Huber et al., 2001). This thesis shows that these two Brca1 mutations (Brca1 C61G and 
Brca1 Δ11) display different phenotypes in a 53bp1-null background. 53bp1-null homozygote 
Brca1 Δ11 cells are not sensitive to IR or CPT (Chapter 5), and show reduced a normal level 
of FANCD2 foci after MMC (Chapter 5), unlike 53bp1-null homozygote Brca1 C61G cells 
which are sensitive to IR and CPT and show an increase in FANCD2 levels after MMC 
(Chapter 5). 53bp1-/-Brca1C61G/C61G cells also show a decrease in Rad51 foci after MMC and 
increased tumour development in mice, unlike 53bp1-/-Brca1Δ11/Δ11 counterparts (Chapter 5 
and 6). Bunting et al showed that the 53bp1-/-Brca1Δ11/Δ11 mice were fertile, but 53bp1-/-
228 
 
Brca1φ/φ male mice (φ – Exon 2 is deleted) were infertile like the 53bp1-/-Brca1C61G/C61G mice 
presented in this thesis (Bunting et al., 2012).  
It is possible to speculate from these results that the Brca1 Δ11 mutation does not affect the 
role that Brca1 has in IR and CPT sensitivity that is altered by the Brca1 C61G mutation, and 
perhaps this is due to Brca1 Δ11 having intact RING and BRCT domains. The remaining Brca1 
C61G protein could have a dominant-negative phenotype on DNA damage which cannot be 
rescued by the removal of 53bp1 protein, and the Brca1 Δ11 protein may behave as the Δ11 
isoform and the protein does not cause defects from its presence. The fact that the Brca1 Δ2 
deletion (Bunting et al., 2012), which removes all Brca1 protein, causes male sterility like the 
Brca1 C61G protein suggests that it is the inability of Brca1 to function that causes the male-
specific infertility. The Brca1 Δ11 does not cause infertility (Bunting et al., 2012) and 
therefore it is likely that the Brca1 Δ11 does have some ability to function. Other Brca1 
mouse models that have either a BRCT or RING domain disrupting mutation show male 
sterility suggesting both the C-terminus and N-terminus is important for Brca1’s role in male 
meiosis (Figure 1.11).  
Considering this, the attributed phenotypes in the literature using Brca1 Δ11 alleles may not 
reflect a truly defective Brca1. The Brca1 C61G mutation investigated here is not a clearly 
defective Brca1 as there is remaining Brca1 C61G protein and it may cause dominant-
negative phenotypes. Therefore it is important to clarify what a mutation does to the 
protein in an in vitro and in vivo manner since the effects may be diverse. Using a patient 
mutation, such as C61G, does create clinically relevant research, and highlight the need for 
more basic research to understand pathogenic human BRCA1 mutations. 
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7.2.6 Clinical implications 
Since BRCA1 C61G is a patient mutation, the data here has the potential to provide 
information that aids how BRCA1 C61G carriers are seen clinically. Firstly, this thesis shows 
that reduction of Brca1 C61G protein compare to wild-type Brca1 protein therefore the cells 
may show phenotypes that relate to the entire protein not just N-terminus-involving 
functions. It is also important that these MEFs have been genomically manipulated and 
Brca1 C61G is expressed at endogenous levels, making the phenotypes clinically relevant in 
comparison to data from overexpressed BRCA1 C61G cDNA. Data from this thesis could also 
provide information for cancers that have reduced BRCA1 expression or sporadic N-terminal 
BRCA1 gene mutations.  
The MEFs and mice were only possible to study due to the absence of 53bp1 rescuing the 
embryonic lethality of Brca1 C61G homozygote mice. This means the majority of data in this 
thesis is in a 53bp1-null background which is not replicative of human patients. However, 
Bouwman et al show that reduced 53BP1 expression has a correlation to poorer survival 
outcome of patients with breast cancer (and triple-negative breast cancer) (Bouwman et al., 
2010), suggesting 53bp1 reduction could be used as a biomarker for harder-to-treat breast 
cancers. Therefore the data from the 53bp1-/-Brca1C61G/C61G cells may provide insight into 
these tumours.  
This thesis shows 53bp1-/-Brca1C61G/C61G cells are sensitive to IR, CPT, HU and Cisplatin 
(Chapter 5). The sensitivity to these agents suggests Brca1 C61G influences Brca1’s role in 
DNA crosslink repair and, potentially, NHEJ or DSB repair involving DNA lesions. Therefore 
53BP1-negative, BRCA1-mutated cancer cells should be sensitive to chemotherapies that 
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cause DNA damage similar to these agents. However, it is likely that these cells are highly 
genomically unstable and may become resistant to therapies.  
The Brca1 heterozygote phenotypes described in this thesis could show that Brca1 does not 
need to be fully absent to cause phenotypes that promote genome instability. A single Brca1 
C61G allele causes a reduction in Brca1 protein (Chapter 4) and the remaining mutated 
protein could potentially cause dominant-negative effects on Brca1 roles, such as in 
collapsed replication fork repair (Chapter 5). This is more acutely seen in the development of 
tumours in mice with one copy of Brca1 C61G that are 53bp1-null (Chapter 6). If these 
tumours are produced due to a single Brca1 allele mutation in a genomically unstable 
(53bp1-null) background, then it brings into question whether loss of BRCA1 heterozygosity 
is needed for cancer development in BRCA1 mutation carrier. It may be that mutations in 
other genes that lead to genomic instability, such as 53bp1 or p53, could be the first step to 
tumour development in heterozygote BRCA1 C61G cells. This is supported by the presence 
of BRCA1 mutation carrier tumour cells maintaining their wild-type BRCA1 allele (Clark et al., 
2012; Neuhausen and Marshall, 1994; Smith et al., 1992; Wei et al., 2005). 
7.3 Future experiments 
Experiments that could be done to further this experiment can be broadly characterised into 
three groups: those that strengthen the current data explored in this thesis, those that 
explore the effects of Brca1 C61G in DNA repair and further mouse experiments to provide 
more information on tumour development. 
Red writing indicates the potential methods that could be used to for each experiment. 
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7.3.1 Key experiments 
- Addition controls are needed to strengthen current data: 53bp1-/-Brca1-/- control 
would investigate any haploinsufficiency and possible dominant-negative phenotypes 
from Brca1 C61G (genome editing), 53bp1+/+Brca1C61G/C61G cells would provide 
evidence of the phenotype Brca1 C61G causes without the 53bp1-null background or 
cancer cell line disadvantages (lentivirus/retrovirus insertion of conditional 53bp1 
expression vector), p53+/-Brca1C61G/C61G would aid in determining what Brca1 C61G 
phenotypes are compounded by the removal of 53bp1, and wild-type MEFs would 
provide a strong control for all experiments (MEF immortalisation from mouse 
breeding). 
- An alternative antibody to GH118 is needed to confirm and strength current data 
that suggests Brca1 C61G causes protein-wide defects; suggested experiments to 
compliment are the whole cell extract repeats, degradation and localisation studies 
(western blotting, drug treatments). 
- In vivo protein analysis would allow confirmation of the predicted effects on the 
Brca1:Bard1 heterodimer due to the Brca1 C61G mutation: immunoprecipitations 
using tagged Bard1 to look at binding with Brca1 C61G (IP and western blot, Bard 
DNA vector expression). 
- Cell cycle is essential for assessing how a cell controls the method and timing of DNA 
repair and this would eliminate any compounding defects, such as genomic 
instability, that could be caused by cell cycle defects: cell cycle profiling of untreated 
and irradiated MEFs (PI stain, phosphorylation Histone 3 stain, FACs) and mitosis for 
chromosome errors and mitotic catastrophe (metaphase spreads, Nocodazole 
treatment, immunofluorescent microscopy during mitosis). 
7.3.2 Exploring Brca1 C61G in DNA repair 
- NHEJ/HR levels could reveal the DSB repair pathway balance in cells that lack 53bp1 
and wild-type Brca1, and this could be used to assess the level of errors in DNA 
repair: look at the DSB repair pathway balance in 53bp1-/-Brca1C61G/C61G MEFs (traffic 
light system) and investigate whether repair is erroneous (DNA repair assay and 
breakpoint sequence analysis). 
- Investigation into DNA crosslink repair in cells with Brca1 C61G could help to 
decipher the mechanisms in which Brca1 is involved into ICL repair: look at 
Brca1/FANCD2 foci to establish co-localisation (immunofluorescent labelling and 
microscopy), look for other proteins (e.g. associated nucleases) to look for other 
defects in the DNA crosslink pathway (immunofluorescent labelling and microscopy), 
and use timecourse experiments to look at the outcomes of DNA crosslink repair 
(immunofluorescent labelling and microscopy). 
- The specific effects of Brca1 C61G reduced ubiquitin ligase activity in DNA repair is 
not fully understood and studying this further will provide information about the 
specific roles of Brca1 ubiquitin ligase activity in maintaining genome stability: 
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ubiquitin levels at sites of DSB repair that are affects by the Brca1 C61G mutation 
such as DNA crosslink repair and HR after IR (immunofluorescent labelling and 
microscopy). 
7.3.3 Further mouse experiments 
- A longer and more comprehensive tumour watch would confirm the increase of 
tumour development in mice with one or two copies of Brca1 C61G and assessing 
mice that are heterozygote for Brca1 C61G would correlate with human BRCA1 
mutation carrier cancer incidence: continue tumour watch adding 53bp1+/-Brca1+/C61G 
mice and 53bp1+/+Brca1+/C61G mice, analyse tumours for the type of lymphoma and 
other tumours (e.g. breast cancers) (histopathology of tumours), look at the Brca1 
allele status in the tumours from 53bp1-/-Brca1+/C61G mice for loss of heterozygosity 
(DNA sequencing and/or chromosome analysis). 
- Adding p53/Brca1 mutant mice to the genotypes in the tumour watch is likely to 
accelerate the tumour development caused by Brca1 C61G and would provide more 
information into whether the tissues we see the tumours in are driven by Brca1, 
53bp1 or p53 mutation: created p53+/- and p53-/- Brca1 C61G homozygote mice to 
look at the development of tumours and the specific tissues that they develop in 







Figure 1 – BRCA1 gene gain and loss tree 
  
This ENSEMBL orthologue tree shows the gains and losses of BRCA1 orthologues in species 
and estimate time of divergence from the most recent ancestors. Grey dots show an absence 
of a BRCA1 orthologue. Green dots show the presence of one BRCA1 orthologue and red dots 
show the presence of two BRCA1 orthologues. Length of branches show estimated length of 
time of divergence. 
http://www.ensembl.org/Homo_sapiens/Gene/SpeciesTree?db=core;g=ENSG00000012048;r




Figure 2 – BARD1 gene gain and loss tree 
  
This ENSEMBL orthologue tree shows the gains and losses of BARD1 genes in species and 
estimate time of divergence from the most recent ancestors. Grey dots show an absence of a 
BARD1 orthologue. Green dots show the presence of one to five BARD1 orthologue and red 
dots show the presence of 6 or more BARD1 orthologues. Length of branches show estimated 
length of time of divergence. 
http://www.ensembl.org/Homo_sapiens/Gene/SpeciesTree?db=core;g=ENSG00000138376;r
















Figures 3 and 4 – Images of tumours/organs from 53bp1-/-Brca1+/C61G and 53bp1-/-
Brca1C61G/C61G mice 
This figure identifies the mice that had developed a tumour upon dissection and shows the 
organ/tumour. Two mice had two tumours; remaining mice had a single tumour. The 
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